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The definition of coeliac disease has been reviewed in
recent years. This thesis refers to the pathological and
immunological abnormalities found in coeliacs and other
patients with similar gastro-intestinal symptoms but a
morphologically normal biopsy. Some of these
abnormalities have been reported in latent coeliac
disease, patients who have had a normal mucosa while
eating a normal diet but have later developed a gluten-
related enteropathy. The concept was first described in
patients with dermatitis herpetiformis (DH), but normal
intestinal mucosa, in which experiments of gluten loading
led to villous atrophy.
In the early stages of the work, Dr O'Mahony showed that
DH patients without enteropathy had an abnormal pattern
of antibodies in jejunal fluid, similar to that found in
untreated and treated coeliacs, after morphological
resolution of the mucosa; and therefore, the coeliac-like
intestinal antibody (CIA) pattern might be a marker of
latent coeliac disease in other situations. I thus
studied prospectively the frequency of this intestinal
antibody pattern amongst non-coeliac patients referred
for diagnostic small bowel investigations, eventually
found to have a normal jejunal biopsy.
There was report of a high tS intra-epithelial lymphocyte
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(IEL) count in a normal biopsy of a patient years before
the development of enteropathy. Thus, I set up the
collection of biopsies suitable for frozen sections, and
the study of IEL bearing the tS form of TCR. I thought
that CIA+ patients, particularly those with a high IEL
count, would also have high tS IEL counts. I assessed the
possibility of relationships between the CIA pattern, a
high tS IEL count and the other putative markers of
latent coeliac disease, the serum anti-gliadin
antibodies and an abnormal permeability test. The term
potential coeliac disease was used to describe patients
positive for any of these indices identified in the
course of our research.
I tested the usefulness of jejunal fluids for the study
of humoral intestinal immunity, as a product of the local
secretion, by measuring possible leakage of plasma-
derived proteins (albumin, a-1 anti-trypsin), and the
proportion of IgA bound to secretory component (SC).
In order to explain the immunopathogenesis of the CIA
pattern, some mechanisms were suggested: a primary
abnormality of B cells, a dysfunction of T cells involved
in B cell switching, or the existence of an immuno-
stimulatory factor in mucosa; and some strategies were
developed for the study of these mechanisms. I counted
lamina propria plasma cells in patients positive and
negative for the CIA pattern. CIA positive patients had a
high number of IgM+ cells (thus up-regulation of IgM
responses), and also a high proportion of slgA in jejunal
fluid, suggesting that neither the B cell population, nor
the epithelial transport of these immunoglobulins are
affected, but rather the immuno-regulatory factors
controlling these processes.
The CIA pattern might reflect a low-grade mucosal delayed
-type hypersensitivity (DTH) reaction, and we explored
ways to test this hypothesis, by measuring levels of
soluble IL-2R and TNFa in jejunal fluids; and detecting
the expression of mucosal markers of T cell activation,
HLA-DR, DQ, and CD25. Non-coeliac patients with high
total IEL counts also showed signs of mucosal
inflammation, with HLA-DR expression in crypt epithelium,
but no CD25+ cells in lamina propria.
Gluten sensitivity can only be tested by clinical trials
of GFD and gluten challenge. A group of patients positive
and negative for the CIA pattern were offered a trial of
gluten-free diet, and a clinical response and evidence of
histological changes (eg. decreased IEL counts) were
found in some of them. One woman, clinically gluten
sensitive and positive for three potential markers,
voluntarily added extra gluten to her diet, and an
enteropathy was found in a biopsy taken 5 months later.
Patients with one or more markers have potential coeliac
disease, and if it is confirmed that they represent the
only manifestation of gluten-sensitivity, then the
current definition of coeliac disease should be changed.
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AIMS OF THE STUDY
1. To characterize jejunal fluid aspirate as material for
research in intestinal immunity.
2. To define intestinal immunoglobulins and antibodies in
jejunal fluid from coeliac patients and controls. On the
basis of this, a "CIA" pattern of intestinal antibodies
was defined.
3. To assess the frequency of the CIA pattern amongst
patients with similar symptoms to coeliacs, but normal
histology, and their relative expression by other non-
coeliac diagnostic groups.
4. To identify other putative markers of latent coeliac
disease, their co-expression in patients and possible
relationships with the CIA pattern.
5. To evaluate how the CIA pattern and other markers
relate to the expression of clinical gluten-sensitivity,
by trials of gluten-free diet and gluten loading.
6. To investigate possible immunopathological mechanisms
responsible for the CIA pattern.
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SECTION ONE
REVIEW OF THE LITERATURE
1
CHAPTER I
A. THE HETEROGENEITY OF COELIAC DISEASE
Current definition of coeliac disease
Coeliac disease is currently defined as a permanent
intolerance of the small bowel mucosa to gluten, in
genetically predisposed individuals (Meuwisse 1970).
Since there is great variability of malabsorption and
heterogeneity of clinical presentation, the diagnosis is
based on the presence of an abnormal jejunal biopsy
while the patient is taking a normal diet. These changes
affect the mucosal architecture, with crypt hyperplasia,
and total or partial villus atrophy; but also a very
characteristic increase of different populations of
lymphoid cells in lamina propria, and a high density of
IEL. Treatment with a GFD improves the histological
appearances.
Epidemiology of coeliac disease
Coeliac disease is found preferentially in Europe, but it
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may also affect individuals of European descent in other
continents. The prevalence of the classic disease in
Europe ranges between 1 in 5000 and 1 in 10000, though the
actual figure may be higher (Auricchio 1988).
Epidemiological studies have shown differences in disease
frequency between countries or relatively close areas (eg
Denmark and Sweden, or amongst groups of "European"
genetic background in USA, where the prevalence is low) ,
variation in the age of presentation, increased
heterogeneity in clinical presentation (with milder and
atypical forms), and discordance of monozygotic twins
pairs. The data underline the importance of socio¬
economic or nutritional factors (eg feeding practices,
dietary gluten content) as environmental triggers in
genetically predisposed individuals (Cavell 1992, Greco
1992, Logan 1992, Loft 1993).
In most European countries, the trend in the last two
decades has been towards a decrease in the incidence of
coeliac disease, and a higher age at diagnosis, in late
childhood or adolescence (Logan 1982, 1986; Maki 1988).
However, in Spain, Portugal, and Poland, the cumulative
incidence has increased, perhaps in relationship to an
increased diagnostic awareness. Finland is a good example
of the general trend, with over 60% of diagnoses made at
school age or later, and a milder presentation in adults,
even without abdominal symptoms (Maki 1992a). The
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exception is Sweden, where the current incidence of 1/300
births, has been increasing in the last ten years (Ascher
1991).
Genetics of coeliac disease
Susceptibility to coeliac disease seems to be under
multigenic control, and it has been associated with genes
within the locus of the MHC that code for the human
leukocyte antigens HLA-DR3, DR7 , DQw2, and possibly
others (Kagnoff 1990, 1992). These genes are located on
the short arm of chromosome 6, which also contains genes
for TNFa and B, and heat shock protein-70. In Europe, the
majority of patients possess the extended HLA-DR3
haplotype that includes (Al) B8, DRwl7, DQw2, DPwl (Hall
1990a, Kagnoff 1992). The small minority negative for
this haplotype are DR4, perhaps having a later onset of
the disease, and more often atopic (Verkasalo 1983). The
polymorphism of the HLA-class II proteins (a , S
heterodimers) determines the spectrum of antigen binding
affinities in each individual (Brandtzaeg 1991), and may
modulate the immune responsiveness to gluten, either by
thymic selection of the TCR repertoire or by HLA-
restricted antigen presentation at local level.
Studies of molecular genetics have shown that within the
HLA-D region, susceptibility to the disease is multigenic
4
as defined by analysis of "restriction fragment length
polymorphism" in the DQ and DP subregions (Howell 1986,
Niven 1987); although more than 95% of patients shared a
combination of alleles encoding for the HLA-DQ a6
heterodimer, identified as HLA-DQ Al*0501 and Bl*0201
(Sollid 1989). The pair is located in cis position on the
DR3 haplotype and in trans position in DR5/DR7
heterozygotes (Lundin 1990). Gluten-reactive HLA-DQ
restricted T cells, have been isolated from the small
bowel mucosa of coeliac patients (Lundin 1993). These
alleles are more frequently expressed by healthy first
degree coeliac relatives with high r <S IEL counts (Holm
1992). HLA-DR associated diseases (eg insulin-dependent
diabetes, rheumatoid arthritis) also involve regulatory T
cell abnormalities, increased humoral responses, and
auto-antibodies.
Different forms of expression of coeliac disease
Within the framework of the current definition,
clinical, pathological, epidemiological and immunological
approaches reveal several forms of coeliac disease.
Pathologically it is accepted that there is a degree of
heterogeneity, and descriptive terms such as "flat
mucosa", or "sub-total villus atrophy", are used by some
pathologists for a cluster of features (villus and crypt
sizes, epithelial cell damage, epithelial and lamina
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propria cell infiltrates) which together characterize the
enteropathy of coeliac disease. Quantitative histology
(Ziegler & Ferguson 1984) and computerized image analysis
(Marsh 1988) of biopsies taken during gluten withdrawal
and challenge have shown that all of these features occur
in a continuum with a flat, avillus lesion at one end of
the spectrum and at the other a mucosa with normal villus
and crypt architecture but an abnormally high density or
IEL count (Marsh 1988). The latter would be reported as
normal by many histo-pathologists without a specialist
interest in gastro-intestinal pathology.
Intraepithelial lymphocytes and IEL counts
IEL form one of the largest T cell populations in the
body, but their function is still unknown (Mowat 1990,
Cerf-Bensussan & Guy-Grand 1991). This is a
phenotypically heterogeneous population, though the
majority (70-90%) are CD3+CD4-CD8+ and TCRaB+ (Brandtzaeg
1989b, Jarry 1990). Many IEL lack other T cell-associated
markers, eg CD5 and Thy-1, and they do not express
conventional markers of activation, eg CD25 or HLA-class
II antigens. About 10% of the total IEL population is CD4
positive. There are also double negative cells (CD4-CD8-)
and a proportion of non-T lymphocytes (CD3-CD7+). The
latter do not have markers associated with NK cells
(CD 16 , CD56, CD57) and they do not have NK activity
6
(spontaneous cytolysis of K562 cells)• The CD7 marker has
also been associated with activated T cells (Selby 1983,
Jenkins 1986, Malizia 1985).
Some IEL may migrate directly to gut epithelium at an
early stage of ontogenesis where they remain thereafter.
However, most IEL belong to a recirculating population
which crosses the epithelial basement membrane from the
lamina propria, and a great proportion have the HML-1
marker, perhaps related with the aEB7 integrin involved
in IEL adhesion to enterocytes (Jarry 1990, Cepek 1993).
Functionally, they have low proliferative activity in
vitro with poor response to conventional T cell mitogens
IL-2 and anti-CD3 antibody (Ebert 1990), and there is no
strong evidence of cytotoxic activity in assays in vitro
(Cerf-Bensussan & Guy-Grand 1991). IEL may be involved in
the modulation of epithelial cell growth and marker
expression (eg MHC-class II) by secreting specific
cytokines (Mayer 1991). Almost 50% of IEL are CD45RO, an
antigen-primed T cell population in close proximity to
epithelial cells (Brandtzaeg 1989a, Haltensen 1990, Jarry
1990) .
IEL counts in human jejunal biopsies were first reported
by Ferguson & Murray (1971) in relation to the number of
enterocytes, and were found to be increased in coeliac
disease, cow's milk intolerance, giardiasis and tropical
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sprue (Wright 1973, Ferguson 1977, Phillips 1979). High
IEL counts have been found in crypt epithelium after
gluten challenge in coeliac patients (Leigh 1985, Loft
1989, Marsh 1992) in parallel with an increased mitotic
index, suggesting an increased cell turnover and
activation (Ferguson & Ziegler 1986, 1987a). Intra¬
epithelial lymphocytes are also increased in experimental
enteropathies without enterocyte loss in animals, gut
allograft rejection, intestinal graft-versus-host
reaction, local DTH responses to oral proteins, and
giardiasis (Ferguson 1976, 1977; MacDonald & Ferguson
1976, Mowat & Ferguson 1981).
In untreated coeliac disease, activation markers are
absent from IELs, and there is no change in the CD4/CD8
ratio, although CD8+ cells may have the CD5 marker or the
T2 blast antigen (Selby 1983, Malizia 1985, Spencer
1989a, Jenkins 1986). The proportion of double negative
CD4-CD8- cells increases in both treated and untreated
coeliacs, in parallel with the population of rS IEL
previously described (Spencer 1989a, Verkasalo 1990).
Morphometric studies have shown that IEL infiltration is
an early expression of gluten-sensitivity (Leigh 1985,
Marsh 1988, 1989a, Loft 1989), and it is an early and
common feature of the enteropathy induced by lamina
propria T cell activation in organ culture of human fetal
intestine, before histological damage (Monk 1988,
8
Brandtzaeg 1989a).
Experiments of gluten challenge confirmed the I EL
infiltration (mainly CD3+ TCR aB+ cells), which is
paralleled by an enhanced expression of the adhesion
molecules ELAM-1 and VCAM-1 (Sturgess 1990, 1992; Ensari
1993), and also led to HLA-DR expression, particularly by
crypt epithelium (Ciclitira 1986a). In humans, there is
indirect evidence that IEL can modulate HLA-DR expression
by enterocytes (Scott 1987).
The development of the gluten-sensitive enteropathy
Some theories have suggested that patients with latent
coeliac disease are merely at one end of a spectrum of
the pathology of enteropathy with a minimal lesion of
histologically normal appearance, and/or with a high IEL
count (Marsh 1988, 1992). In studies of gluten challenge
in treated coeliac patients, a pre-infiltrative (type 0)
stage was added to describe DH cases whose unique
abnormality is an abnormal pattern of intestinal
antibodies (O'Mahony 1990a).
It is also possible that coeliac disease develops in a
two-stage process, latent and fully expressed (O'Mahony
1990a). Aberrant immunity to gliadin is a relatively
frequent occurrence (Auricchio 1988, Arnason 1992); it is
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genetically restricted, and may be expressed in gut or
skin. Mucosal immunological sensitization is an
invariable feature of coeliac disease, but is not the
precipitating factor for the expression of the full
intestinal lesion, as it was also shown in an animal
model of gluten-sensitive enteropathy (Troncone &
Ferguson 1991a). A second factor, such as an episode of
hyperpermeability, nutrient deficiency, increased dietary
intake, impaired intraluminal digestion of ingested
gluten, adjuvant effects of intestinal infection, and a
non HLA-associated gene may drive the enteropathy from
minima 1/latent to overt, either by immunological
mechanisms or by direct ancillary effects on enterocytes
(Ferguson 1993) .
The clinical effects of a GFD or gluten challenge may
parallel the effect observed in biopsy, but mucosal
changes may be even more sensitive. Symptomatic patients
with a morphologically normal mucosa and high IEL counts
have been shown to respond to a GFD (Cooper 198 0) . There
is also a report of first-degree relatives of coeliac
patients with normal biopsy where an increased gluten
intake did not lead to mucosal damage (Polanco 1987).
Patients selected by high serum AGA levels but a normal
biopsy did show a high IEL count (O'Farrelly 1987). A
similar group identified by these criteria had abdominal
symptoms and iron deficiency anaemia more often than a
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control group (Arnason 1992).
Latent coeliac disease
Latent coeliac disease refers to those patients who have
normal jejunal biopsy histology while taking a normal
diet, but at some other time, before or since, have been
shown to have typical, severe gluten-sensitive
enteropathy which recovers on a GFD (Ferguson 1992). The
concept was first described in two patients with
dermatitis herpetiformis (DH) who developed a typical
gluten-sensitive enteropathy weeks after starting a
trial of 20 g of gluten added to their already gluten-
containing diet (Weinstein 1974). Nearly all studies have
been performed in DH patients and first-degree relatives
of coeliacs, and these have confirmed the existence of
this condition (Doherty & Barry 1981, Ferguson 1987b,
Chorzelski 1988).
Dermatitis herpetiformis as true latent coeliac disease
DH and coeliac disease are both gluten-sensitive
disorders that share a similar HLA haplotype (Sollid
1989, Hall 1990b). A high percentage of DH patients have
an enteropathy identical to coeliac disease, in some of
them this is only expressed by a high IEL count (Marsh
1989b), and a small proportion have a completely normal
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jejunal morphology and function (Gawkrodger 1991). The
intestinal abnormalities of DH (ie. high IEL counts), and
the skin lesions, even in the cases with normal mucosa,
respond to a GFD (Reunala 1977). Experiments of gluten
loading in patients with normal mucosa led to the
development of enteropathy (Ferguson 1987b). Therefore by
the definition, DH patients with normal jejunal biopsies
are true latent coeliacs. The latter group may also
include first degree relatives of coeliacs (Marsh 1990),
discordant monozygotic twins for the disease (Salazar
1987, Kamath & Dorney 1983), and patients with recurrent
oral ulcers (Wray 1981) or gluten-sensitive diarrhoea
(Cooper 1980).
Cases of latent coeliac disease in the literature
McConnell & Whitwell (1975). A 40-year-old woman with
megaloblastic anaemia due to folic acid deficiency
underwent a jejunal biopsy which was normal. She was
diagnosed as having a nutritional deficiency. Five years
later, she presented with diarrhoea at another hospital,
where a second jejunal biopsy (without knowledge of the
first one) showed a flat mucosa. She had a good response
to a GFD.
Egan-Mitchel (1981). An 8-year-old girl was investigated
because of small stature and iron deficiency, her
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terminal duodenal biopsy was normal (IEL:26%) while
eating 10 g of gluten daily. She was re-investigated 14
months later because of poor growth, persistence of
tiredness, and lack of response to iron supplements. The
second jejunal biopsy showed villous atrophy (IEL:78%),
which resolved on a GFD (IEL:35%), and relapsed 4 months
later after gluten challenge (IEL:51%).
Rolles (1981) . A 4-year- old girl was investigated
because she had loose stools, mild abdominal distension,
slightly abnormal growth ratio, and atopic eczema but her
jejunal biopsy was normal. Her mother had coeliac
disease. Twenty two months later, she was referred with
similar symptoms and challenged with 10 g.b.d. of gluten
for 2 months before being reviewed. The second jejunal
biopsy was flat, and a quick improvement was observed
after treatment with a GFD.
Kamath (1983). One of the monozygotic twins had a
diagnosis of coeliac disease when he was 11 months old.
At that time, the second twin was asymptomatic and had a
normal biopsy. However, at 9 years of age, a jejunal
biopsy performed because of inadequate weight gain for 12
months, showed an atrophic mucosa.
Salazar de Sousa (1987). A discordant monozygotic twin of
a coeliac patient. The first jejunal biopsy was taken at
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3 years/10 months of age because of his brother's
previous diagnosis, but it was normal and he had no
symptoms. Seven years later, he presented with weight
loss, abdominal distension, anorexia, and fatigue, and a
second jejunal biopsy showed a subtotal villous atrophy.
The diagnosis was confirmed with trials of a GFD and
gluten challenge.
Marsh (1989a). The first case was a 59-year-old woman
with 20 years history of malabsorption and macrocytic
anemia, and two previous morphologically normal jejunal
biopsies, in which morphometric analysis showed an IEL
infiltration. Five months later, she presented with an
episode of watery diarrhoea and weight loss, and a third
jejunal biopsy showed a villous atrophy that improved on
a GFD. The second case was a 40 year old woman with a
first (normal) jejunal biopsy performed because of
megaloblastic anemia due to folate deficiency. Five years
later, the biopsy was flat, followed by a good response
to a GFD.
Maki (4 cases in 1990, 1 case in 1991) .
A 0.9-year-old girl was studied because of poor weight
gain, but she had no GI symptoms and no family history of
coeliac disease. Her first jejunal biopsy was normal
(IEL: 34%) and had slightly high serum IgG AGA. After 3.5
years, a second biopsy performed because of high levels
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of IgA and IgG AGA, and IgA of both ARA/AEm, showed STVA
which resolved on a GFD.
The second case was a 2.3-year-old boy, whose brother was
coeliac. He had intermittent loose stools. The first
jejunal biopsy was normal (IEL:31%) and serum antibodies
were negative. At 7.6 years of age, he had no abdominal
symptoms, but a second biopsy performed because of high
ARA-IgA levels showed STVA.
The third case was a 11.4-year-o1d boy without GI
symptoms, suspected of having DH, and a sister with
coeliac disease. His jejunal biopsy was normal (IEL:21%),
and ARA antibodies and skin biopsy for DH were negatives.
As part of a family study, when he was 17.5 years old, a
second biopsy showed STVA, and levels of IgA and IgG
ARA/EMA were positive. A GFD normalized these parameters
after 6 months.
A 32-year-old woman had diarrhoea and was suspected of
having ulcerative colitis. She was involved in a family
study because of a coeliac child, and at that time her
jejunal biopsy was normal. Nine years later she was
asymptomatic, and in a similar study her biopsy showed
PVA (IEL:41%), which was normalized after a GFD.
The last case refers to an asymptomatic 35-year-old man
with a coeliac son and a first normal jejunal biopsy
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(IEL:18%). Two years later, a second biopsy taken because
of high serum IgA AGA and worsening of a preexisting
epilepsy showed villous atrophy and crypt hyperplasia
(IEL:56%). The lesion resolved after 6 months of GFD
(IEL:32%). Counts of epithelial CD3+ cells (81/mm), TCR
aJ3+ (49/mm) and TCR tS+ cells (31/mm) were performed in
frozen sections from the stored first biopsy.
Catassi (1991). A 22-month-old girl diagnosed as having
insulin-dependent diabetes mellitus (IDDM). She had no GI
symptoms or family history of coeliac disease (only HLA-
B8,DR3), and a jejunal biopsy performed because of high
serum IgG AGA showed a normal architecture. She had
persistent high serum AGA levels and occasional abdominal
problems. Two years later, a second biopsy showed a
total villous atrophy, but also serum AGA antibodies were
positive and the sugar permeability test was abnormal.
GFD and gluten challenge confirmed the diagnosis.
Collin (1993) . Seven cases (5 males, 2 females; age
range: 22-66) had a jejunal biopsy taken 1-5 years after
a first normal jejunal biopsy (while on a normal diet)
because of abdominal symptoms in a follow-up study. The
biopsies showed signs compatible with coeliac disease.
The IEL count was high in only one of the first biopsies,
but all were positive for serum IgA-ARA or IgA AGA
titers.
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TABLE 1.1. CASES OF LATENT COELIAC DISEASE IN THE LITERATURE
(first of two pages)
FIRST NORMAL BIOPSY SECOND BIOPSY
SEX AGE REASON IEL IEL REASON AGE HISTOLOGY
COUNT TS+
McConnell f 40 Anaemia ND ND Diarrhoea 45 "Flat"
Egan- f
Mitchell
8/9 Small. 26% ND Poor growth 9/11 TVA
Anaemia
Rolles f 4 Coeliac ND ND Abdominal 5/10 TVA
mother distension
Kamath m •/ll Monozyg. ND ND Poor growth 9 TVA
twin
Salazar m 3/10 Monozyg. ND ND Weight loss 10 TVA
twin Anorexia




FIRST NORMAL BIOPSY SECOND BIOPSY
SEX AGE REASON IEL IEL REASON AGE HISTOLOGY
COUNT TS+
Marsh b f 40 Megalob."high" ND Anaemia 45 TVA
Anaemia Fol.def
Maki a f 0.9 Poor 34% ND High AGA, 3.5 TVA
Maki
wt gain ARA/AEm
m 2.3 Coeliac 31% ND High 7.6 TVA
brother IgA ARA
m 11.4 Coeliac 21% ND Familiar 17.5 TVA
sister study
d f 32 Diarrhoea ND ND Familiar 41 PVA
Coe.child study
m 35 Coeliac 18% 31/mm High 37 TVA
son IgA AGA
catassi f 1/10 IDDM ND ND High AGA 3/10 TVA
High AGA Abn Permb
Collin (5/2f) 22-66 High ARA/AEm ND Follow up l-5ys P/TVA
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B. IMMUNOGLOBULINS AND ANTIBODIES IN JEJUNAL SECRETIONS
Immunoglobulins A and M, and the secretory component
Secretions are characterized by a great proportion of
locally synthesized polymeric immunoglobulins. Jejunal
fluid contains the largest amount of polymeric
immunoglobulins (IgA and IgM), present in the upper small
bowel. Their origin is by local synthesis in lamina
propria and they reach the lumen by an active
transepithe1ia 1 mechanism mediated by secretory
component, involving 98% of plgA, and 99% of plgM
(Brandtzaeg 1981, Mestecky & McGhee 1987), whereas most
plasma proteins may reach the lumen by passive leakage
from lamina propria capillaries (Jonard 1984). Polymeric
IgA represents 92% of jejunal IgA, almost entirely bound
to secretory component (Delacroix 1982). The higher
number of IgA2-containing cells in jejunal lamina
propria, determine that 35% of jejunal fluid IgA is of
IgA2 subclass (Kett 1986). The ratio between IgAl and
IgA2 subtypes may vary according to the area of intestine
and type of antigen.
Secretory IgA (slgA) is a dimer that forms a complex with
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part of the transepithe1ia1 receptor (SC), and a
disulphide-linked polypeptide or J chain, and represents
the main immunoglobulin in secretions (Mestecky 1987).
IgA-producing cells in the intestinal mucosa represent
between 80-90% of all plasma cells (Brandtzaeg 1991), and
there are also specific regulatory mechanisms in mucosal
lymphoid organs that lead to the generation of memory B
cell clones with preferential secretion of IgA. B
lymphocytes express membrane immunoglobulins as antigen
receptors (normally IgM) , they proliferate after
stimulation and some of them (memory cells) will
differentiate to immunoglobulin-secreting cells after
migration to mesenteric nodes and other mucosal areas,
where they undergo terminal differentiation (Strober
1990) .
IgM is the major secretory immunoglobulin not only in the
intestine of children (Savilahti 1972), individuals with
IgA deficiency (Eidelman & Davis 1968), and during the
early local immune response (Girard & Kalbermatten 1970),
but also in young animals (Porter 1977). Pentameric IgM
(plgM), like dimeric IgA, binds to polymeric Ig receptor
(SC) (Weicker & Underdown 1975, Brandtzaeg 1977, Richman
& Brown 1977); and both dlgA and plgM are secreted into
the lumen by a mechanism of epithelial transcytosis
mediated by SC (Brandtzaeg 1985, Conley & Delacroix
1987). This mechanism may be upregulated by interactions
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between epithelium and activated T cells (Scott 1981,
Sollid 1987, Kvale 1988); but it seems not to be affected
by crypt hyperplasia. Polymeric IgM may display
stronger non-covalent interactions with SC, which has a
higher affinity than dimeric IgA (Brandtzaeg 1985, Bouvet
1990), and therefore locally-produced IgM might block,
to some extent, the IgA transepithelial transport by
competing for the receptor.
Functions of secretory immunoglobulins
Secretory IgA functions as a first line of defence,
preventing the adherence and absorption of microorganisms
to the epithelium, by immune exclusion (Svanborg-Eden &
Svennerholm 1978, Taylor & Dimmock 1985). Recently, it
has been suggested that IgA may be active not only in
secretions, but also within the epithelium, by
intracellular neutralization of virus; and in the lamina
propria, by transporting immune-complexes to the lumen
and therefore preventing antigens and toxic products from
reaching the circulation (Mazanec 1993). Because of this
(probable) excretory function, and its known poor
activity in triggering complement (Pfaffenbach 1982), IgA
has non-inflammatory activity, protecting the mucosa
against potentially damaging mechanisms involving
complement activation (Conley & Delacroix 1987, Mestecky
& McGhee 1987, Brandtzaeg 1991).
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Unlike IgA, IgM may opsonize antigens through complement
activation, but this effect may be down-regulated by the
abundance of IgA and its effective competition for
antigen. Subepithelial deposits of C3b and terminal
complement complex have been found in coeliac disease,
and these are particularly increased after gluten
challenge (Haltensen 1992a). The finding of these
deposits was correlated with the number of mucosal IgG+
plasma cells, and with serum IgG antigliadin antibodies.
It may be also related to the increased local synthesis
of IgM found in coeliacs, that would form immune-
complexes after competing for the antigen with IgA.
Measurement of secretory IgA in jejunal fluids
The measurement of secretory IgA, as % of the total IgA
bound to SC in jejunal fluids, may serve as an indirect
indication of local immunoglobulin secretion. Secretory
component is a trans-membrane glycoprotein receptor for
polymeric immunoglobulins, expressed by intestinal
epithelial cells. It has been studied by
immunohistochemistry in frozen sections (Brandtzaeg 1974,
Brown 1976, 1977); and by ELISA, RIA, and other methods
in secretions, either as a free molecule or bound to J
chain positive polymeric immunoglobulins (IgA and IgM)
(Delacroix & Vaerman 1981).
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A non-competitive ELISA method has been used to measure
slgA, slgM, and SC, in serum, but also in culture
supernatants and lysates (Kvale & Brandtzaeg 1986, 1988;
Sollid 1987, Wood 1987). To specifically measure slgA,
slgM can be removed by absorption using small
immunosorbent columns containing specific anti-IgM
antibodies (Bartholomeusz 1989). An alternative method
coats microtiter plates with specific anti-a chain and
uses an anti-SC conjugate as a secondary antibody
(Ishiguro 1981, Hjelt 1988). Low levels of free-SC were
found in most biological fluids (sera, urine, whole
saliva, jejunal fluid) using a sandwich ELISA method with
different specific mAbs for slgA and slgM to measure
free and bound SC (Vincent & Revillard 1988). The
potential advantage of using monoclonal (instead of anti¬
cs chain) antibody, is the lack of interference between SC
and slgA measurements, and also that IgM is not detected.
However, the specificity of monoclonal antibodies and the
results obtained have been criticized (Kvale 1988).
Secretory IgA and IgM specific antibodies to gliadin and
other food proteins have also been tested in serum
(Volta 1985) and jejunal fluid samples (Volta 1990) by
coating microtiter plates with crude antigen and using an
alkaline phosphatase-conjugate anti-SC as secondary
antibody. A similar test has been used by others to
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measure antigliadin and specific slgA antibodies in
serum from coeliac children, but the polyclonal SC
peroxidase-conjugate antiserum was different (Arranz
1986, Blanco 1989).
Regulation of immunoglobulin production in intestine.
Antigen exposure in gut- associated lymphoid tissue
-GALT- induces the generation of secondary or memory B
cells specifically committed to the IgA isotype (Cebra
1984). Most oral antigens are delivered to the Peyer's
patches, where germinal centres contain immature IgM+ B
cells (60%), macrophages and other antigen-presenting
cells. This microenvironment provides the necessary
stimulation for B cell development and the activation of
a particular T helper subset (Weinstein & Cebra 1991,
Biewenga 1993), that, either by direct contact, or by
lymphokine release, together with Peyer's patch stromal
and dendritic cells, will control the first stages of B
cell proliferation and isotype switching to functional
IgA+ B cells (Kawanishi 1983a,b; Spalding & Griffin
1986) .
During primary and secondary responses, distinct subsets
of helper (CD4+) T cells may regulate the antibody
response. Antigen is not directly involved in the
generation of antibody specificity in the course of B-
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cell development (rearrangement and deletion of DNA gene
segments encoding the heavy and light immunoglobulin
chains), however, terminal differentiation requires B
cell activation by antigen, that will determine the
selection and expansion of particular cell clones in
mucosa (Strober 1990). Interactions between antigen,
specific B cells and different subsets of lymphokine-
secreting T cells may determine the isotype and
immunoglobulin subclass produced. In mice, primary
stimulation of spleen cells leads to IL-2 and IFNt
production, whereas priming and subsequent in-vitro
restimulation induces IL-4 and IL-5, the latter
specifically in mucosa (Swain 1988, 1991).
Development of mucosal plasma cells
I. Switch differentiation.
There is a unique population of T cells located in the
Peyer's patch germinal centres which direct the switch of
IgM+ to IgA+ specific isotype B cells. These T cells act
either by direct contact with IgM+ B cells or by cytokine
secretion, and induce DNA-binding proteins to make
accesible the 'switch sites' allowing transcription and
rearrangement of the (Ca) gene for the constant region of
the a chain (McGhee 1989, Strober 1990). In the early
stages of this process T cells and some lymphokines may
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be involved. Transforming growth factor J3 induces IgA
secretion in-vitro, and its effect is enhanced by the
addition of IL-2 or IL-5 to LPS-stimulated B cells in
culture (Sonoda 1989, Coffman 1989). However, TGFB may
not be a primary switch factor, but secondary to other
stimuli (acting on already committed IgA-cells). IL-4 may
also facilitate the switch from IgM+ B cell to IgA+ B
cells.
II. Postswitch differentiation.
Terminal differentiation and clonal expansion of
committed IgA+ B cells probably takes place in mesenteric
nodes and lamina propria. After antigen stimulation in
Peyer's patches, lymphoblasts form a recirculating
reservoir of rapidly switching IgA+ B cells, whose
migration is controlled by interactions of lymphocyte
adhesion molecules with site-specific addressins on high
endothelial venules (Kraal 1983, Picker & Butcher 1992).
These lymphoblastic cells undergo differentiation into
antibody-secreting plasma cells in response to local
factors, eg IL-5, IL-6 and IFNt (Zeitz 1988), which may
be delivered by specific T cells bearing IgA-Fc
receptors. Different lymphokine-secreting T cell subsets
may be prevalent at mucosal sites, but cytokines may also
be isotype-specific in B cell differentiation. IL-5
interacts directly with specific receptors on IgA-
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committed B cells, enhancing IgA (and IgM to a lesser
extent) antibody responses to LPS (Coffman 1987, Harrison
1988). Optimal IgA responses may be provided by their
cooperation with other signals, eg IL-6.
Both human and mouse IL-5 and IL-6 increase the in-vitro
IgA secretion from isolated murine mucosal cells (Beagley
1989). In coeliac disease, the local secretion of IL-5
may explain in part, the increased synthesis of secretory
IgA antibodies. Coeliac patients also have an increased
eosinophil population in the intestinal mucosa (Marsh &
Hinde 1985), and IL-5 is involved in eosinophil
differentiation, though these cells may also be a source
of IL-5 (Desreumaux 1992). It is known that IgA complexes
may trigger human eosinophil degranulation through IgA
receptors, leading to local release of cytotoxic protein
and tissue damage (Colombel 1992).
Circulating antibodies to foods in coeliac disease
IgG antibodies have been found to many food antigens,
whereas IgA antibodies have been little studied, except
for gliadin. A great proportion (80%) of these
antibodies in adults and children are of the IgAl
subclass, probably of bone-marrow origin (Mascart-Lemone
1988, Arranz 1986, Engstrom 1992). In untreated patients,
both subclasses are enhanced, specially IgAl with
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increased IgAl/IgA2 ratio (Elewaut 1989). Sera from
coeliacs and normal individuals contain antibodies with
specificity for a variety of gliadin subunits, and
jejunal fluids seem to have an even broader and different
range (Skerritt 1987). However, there is also a report of
a coeliac patient with hypogammaglobulinemia, absence of
mucosal plasma cells and no serum antigliadin antibodies
(Webster 1981).
Measurement of anti-gliadin antibodies in serum has been
proposed as a non-invasive and reliable test for
screening of patients suitable for biopsy, and a useful
tool for monitoring dietary compliance, especially in
treated children (Volta 1985, Savilahti 1983, Troncone &
Ferguson 1991, McMillan 1991, Maki 1992b); however 20-30%
of patients with active disease may be negative for this
test (Volta 1990, Scott 1992). IgG antibody levels are
more sensitive, but the specificity of IgA is higher and
correlates better with the presence of enteropathy.
Better results can therefore be obtained with a
combination of both antibody titers (Savilahti 1983,
Arranz 1986). Treatment with gluten restriction decreases
IgA antibodies to within a normal range in a short period
of time, whereas IgG antibodies remain high longer, even
after resolution of the mucosal lesion (Savilahti 1983,
Kilander 1987).
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It has been suggested that anti-gliadin antibody
production may be under genetic control (Mearin 1984,
Weiss 1983), and therefore the aberrant humoral response
to gliadin may be explained by an immunoregulatory
defect, eg suppression (Pignata 1985, Corazza 1986). This
hypersensitiveness seems to be independent of the HLA
genotype associated with coeliac disease (DR3, DQ2
haplotype), though HLA-DR2 expression was found mainly in
individuals with high antibody titers. These antibodies
may be associated with gluten sensitivity in the absence
of coeliac disease (Corazza 1992), and they have been
found to be increased (sometimes with abnormal intestinal
permeability and/or high IEL counts) in MHC-related
diseases mediated by immunological mechanisms, such as
DH, IgA nephropathy, rheumatoid arthritis, sarcoidosis
and recurrent oral ulceration. In the latter, high anti-
gliadin antibodies may identify patients who will respond
to GFD (0'Farrelly 1991a,b).
Antibodies in jejunal fluids
Early reports found precipitins to gliadin and other
dietary antigens in duodenal fluid of untreated coeliacs
(Katz 1968, Herscovic 1968, Ferguson & Carswell 1972). It
is generally agreed that the intestinal fluid in
untreated coeliac disease patients contains high levels
both of IgA and IgM anti-gliadin antibody, and that in
29
contrast to serum antibodies, levels of intestinal
antibodies remain high after healing of enteropathy in
treated coeliacs (LaBrooy 1986, Volta 1988, Colombel
1990, O'Mahony 1991a, Lavo 1992). Intestinal antibody
levels do not correlate with those of serum (O'Mahony
1991a, Kelly 1991) , and this independence is also shown
by a different isotype pattern of antibody response to
gliadin. Monomeric IgA (mainly IgAl) and IgG predominate
in serum, while polymeric IgA (higher proportion of IgA2)
and IgM, bound to SC predominate in intestinal fluid
(Jonard 1984, Scott 1992).
High counts of lamina propria plasma cells have been
found in coeliac mucosa of both untreated adults and
children, particularly IgM-containing cells whose density
was similar to IgA+ cells (Douglas 1970, Lancaster-Smith
1974, Baklien 1977, Scott 1984, Dhesi 1984, see results
in Chapter XI). The increased immunoglobulin production
is not limited to food protein antibodies. Treated
patients have fewer plasma cell numbers than untreated
coeliacs, but a greater number than controls (Baklien
1977). In children, however, similar results were found
in treated patients and controls, suggesting that they may
have a higher potential for mucosal normalization (Scott
1980a, Savilahti 1972). In a recent investigation of
intestinal immune responses to an enteric vaccine,
coeliacs generated high levels of intestinal IgM
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antibodies to a bacterial antigen, Cholera toxin B
subunit (O'Mahony 1990b).
These in-vivo results have been confirmed by in-vitro
studies where local secretion of antibodies has been
found in organ culture models of jejunal biopsies (Wood
1987, Fluge & Asknes 1983, Ciclitira 1986b) or studies
with isolated intestinal lymphocytes (Crabtree 1989a).
Using the ELISPOT technigue for the enumeration of class
specific antibody-secreting cells, untreated coeliacs had
a higher number of anti-gliadin spot-forming cells
compared with controls (Lycke 1989), though the anti-
gliadin specificity represents only a small proportion of
Ig-producing cells. It has been reported that almost 50%
of the net increase of IgA and IgM in an in-vitro model
of gluten challenge, is due to synthesis of antigliadin
antibodies (Falchuk & Strober 1974). However, others
have found that specific antibodies account respectively
for the 2.1, 12.1, and 4.1% of the total IgA, IgM and IgG
production by jejunal biopsies (Ciclitira 1986b).
Circulating anti-reticulin and anti-endomysium antibodies
Coeliac and DH patients have serum antibodies against the
connective tissue surrounding the intestinal smooth
muscle. These antibodies are detected by indirect immuno¬
fluorescence on cryostat sections from monkey oesophagus
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(primate-type or anti-endomysium antibodies), or rat
tissues (rodent-type or anti-reticu1in antibodies)
(Chorzelski 1983, Burgin-Wolff 1991; Maki 1991b, 1992a).
Anti-endomysium antibodies of IgA class have a high
specificity in both diseases, where they have been
detected in 90-100% of untreated adults and children with
coeliac disease (Chorzelski 1983, Kumar 1989, Garrote
1992), and in 70% of DH patients. The specificity is
highest in patients with mucosal atrophy (Acetta 1986).
The antibodies have not been found in other skin or gut
diseases (Kumar 1989), and it is known that anti-gliadin
antibodies also bind to endomysial antigenic sites
(Beutner 1986). The detection of ARA/AEm antibodies may
be an useful screening test to identify mild or atypical
forms of the disease, eg amongst relatives of coeliac
patients (Hallstrom 1989, Watson 1992). High antibody
titers have been found in some relatives of coeliac
patients at the time of the first normal biopsy, before
the development of a gluten-sensitive enteropathy (Maki
1990).
Anti-reticulin and anti-endomysium antibodies may have a
similar origin, perhaps as human auto-antibodies triggered
by gluten ingestion in genetically predisposed
individuals. They have different cross-reactivity when
tested in animal tissues, ARA in mice, and AEm in monkey
tissues (Maki 1991b, 1992a). Coeliac sera react with
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human liver, jejunum, lung, spleen, thymus and pancreas;
however, ARA specificities can be removed separately by
absorption with rat liver homogenates (Hallstrom 1989) .
These antibodies of IgA class have also been found in
jejunal juice (Mawhinney & Lowe 1975). Other disease-
specific circulating antibodies have been identified in
children (Karpati 1990), these bind to normal human
jejunum and have similarities with ARA and AEm but not
with anti-gliadin antibodies. The positivity for IgA-
class ARA in patients with normal biopsy histology has a
high predictive value for the development of enteropathy,
and ARA and AEm antibodies may therefore be used as a
marker of genetic predisposition in both silent and
latent coeliac disease, especially amongst first-degree
relatives of coeliacs (Maki 1992b, Collin 1990, 1993;
Holm 1993a).
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C. EXPRESSION OF THE TS T CELL RECEPTOR
The T cell antigen-receptor
Immune cells may recognize and interact with a great
variety of foreign antigens by two polymorphic
structures: immunoglobulins and the T cell receptor. The
TCR is a complex molecular structure consisting of a
clonally variable and MHC restricted antigen binding
subunit, the disulphide-linked a6 heterodimer, and the
five-chain complex of the CD3 molecule, to which the aR
heterodimer is non-covalently bound (Brenner 1985,
Marrack & Kappler 1986). The generation of the functional
repertoire for antigen recognition is the result of
positive and negative selection during intra-thymic
maturation (Fawlker & Pardoll 1989 ) . T cells aR +
recognize antigen "processed" by macrophages and other
antigen-presenting cells and bound to MHC molecules on
their surfaces.
A second isotype of TCR was identified after the finding
of a third gene (located on the short arm of chromosome
7) and its corresponding t glycoprotein which was found to
be expressed with the S chain (Saito 1984, Brenner 1986).
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The TCR a, B, r, and S loci include V (variable), J
(joining) and D (diversity) gene segments similar to
those described for the B lymphocyte receptor, which
undergo somatic rearrangements to generate functional
genes (Tonegawa 1983, Allison & Havran 1991). Both TCR
aB and tS heterodimers are expressed in a mutually
exclusive manner, but have high structural homology and
are associated with the same signal transduction complex
(CD3) (Raulet 1989). They represent two functionally
distinct T cell lineages with a different recognition
structure. The specificity, MHC restriction and function
of TCR tS+ cells are still largely unknown (Tonegawa
1984, Raulet 1989b, Haas 1993).
Differences between TCR aB and tS heterodimers
Most of the human T cells express the aB form of TCR,
whereas tS T cells are less common, representing between
1 and 20% of the total T cell population in peripheral
blood, less than 5% in lymphoid organs, and up to 10% of
T cells in the intestinal epithelium and lamina propria
(Bottino 1988, Faure 1988, Groh 1989, Bucy 1989,
Trejdosiewicz 1989, Spencer 1989a). Flow cytometric
analysis of normal human intestine has revealed that most
tS+ IELs are CD8+ and almost 20% of these have the CD8aa
homodimer (Lynch 1993). Studies in animals showed that,
unlike aB+ T cells, a high number of t6 cells do not
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express CD4 or CD8 molecules, and only a few are CD4 or
CD8 positive (Lanier 1986, Groh 1989, Bucy 1989, Morita
1991, Moretta 1991). In mice, a great proportion of the
IEL tS+ express CD8aa homodimers (Guy-Grand 1991). The
lack of CD4 or CD8 molecules suggest that tS+ cells may
recognize antigen in its native form or presented by
molecules distinct to class I or II, eg class I-like
monomorphic CD1 molecules (Porcelli 1989, Faure 1990).
However, conventional MHC restriction elements, such as
HLA-A2, DR3/7 or HLA-DQA1/DQB1 heterodimers, have also
been reported (Strominger 1989, Ciccone 1989, Spits 1990,
Bosnes 1990).
Phenotypically, tS T cells can be divided into two
subsets, which may follow distinct developmental pathways
(Groh 1989, Falini 1989, Haas 1993). They differ in the
stage of appearance during ontogeny and in the set of r
and S genes used. The VS1/JS1 subset is recognized by
the mAb 5TCS1 specific for the non-disulphide-linked form
of heterodimer. This subset predominates in the thymus
throughout life (foetal thymus express tS T cells early
in ontogeny), and represents approximately 50% of the
peripheral blood lymphocytes in children <1 year, 20% in
adults (Ho & Campana 1991), and 50 to 70% of TCR tS+
cells in intestine. The V52 subset, recognized by the mAb
BB3, becomes predominant in the periphery within the
first month of life, and represents 70 to 80% of the
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peripheral blood lymphocytes. These cells use the
disulphide-linked form of receptor and are absent in the
thymus (Bottino 1988, Spencer 1989a, Brandtzaeg 1989a,
Haas 1990).
Morphologically, TCR t6+ cells are similar to large
granular lymphocytes, showing an extended cytoplasm and
numerous electron-dense granules (primary lysosomes), and
these features have been found in peripheral blood
derived TCR r<S+ clones (Moretta 1991, Arancia 1991). TCR
t8+ cells also have similarities with NK cells as
described in studies with isolated murine IELs, and they
may undergo similar changes to those observed in LAK
cells after IL-2 activation (Lefrancois & Goodman 1988,
Viney 1990).
Function and antigen recognition repertoire of TCR r5+
cells
TCR tS+ cells might represent either the non-essential
evolutionary remains of a primitive T-cell population
that later evolved into aB+ T cells, or a supplementary
subset involved in some aspects of immune defence not
covered by a& T cells (O'Brien 1991). TCR tS+ cells are
freguently localized into various epithelia (Goodman &
Lefrancois 1988, Bonneville 1988, Bucy 1989, Groh 1989,
Itohara 1990) and this characteristic localization
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together with its restricted V gene usage suggests a
separate and specific role in immunological surveillance
that might be mediated by the recognition of stress-
induced self-antigens, rather than foreign antigens
(Janeway 1988, Allison & Havran 1991).
The fact that human TCR r<S+ cells may recognize a
different group of ligands, sometimes localized in areas
susceptible to trauma and pathogen entry, such as the
villus epithelium, and that these subsets have a
restricted V gene usage for each tissue localization,
suggest an heterogeneous function. This suggested
function of TCR tS+ cells is based on their distribution
in vivo and their functional capabilities in vitro (Haas
1990, 1993; Raulet 1989a, Born 1990, Janeway 1988).
Protective role. It has been suggested that TCR tS+
cells might play a special role as a first line of
defence at mucosal sites by the recognition of infected,
transformed or damaged epithelial cells. Recognition of
mycobacteria, autologous shock proteins, and
superantigens such as staphylococcal enterotoxin A, has
been observed (Raulet 1989b, Rust 1990, Born 1991,
Porcelli 1991). These cells also accumulate in human
chronic infectious lesions, such as rheumatoid synovitis
(Modlin 1989, Brennan 1989, Sioud 1991). Early in life,
tS+ cells may provide a non-HLA-restricted local and
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rapid response to common antigen determinants on
pathogens or newly damaged self tissues. Later, when
more elaborate protective responses are developed (by aB+
cells), TCR tS+ cells may help to initiate and localize
specific immune responses, or stimulate the formation of
granulomas (Allison & Havran 1991, Born 1991, Haas 1993).
Effector function. TCR r<5+ cells may be related to non
MHC-restricted cytotoxicity specific for alloantigens and
heat shock proteins (Patel 1989, Brenner 1988, O'Brien
1989), and against tumour cells (Ciccione 1988, Fisch
1990). However, it is not known if they mediate tissue
damage in vivo. TCR tS+ cells may produce high levels of
lymphokines, but this is not related to CD4 or CD8
expression, or to the cytotoxic activity (Patel 1989,
Christmas & Meager 1990 , Morita 1991) . There is an
expansion of TCR tS+ cells in the intestine of patients
with coeliac disease, but this does not affect any
particular T cell clone, nor is it known if they play any
pathologic role in the disease (Spencer 1989a,
Tredjosiewic 1991, Rust 1992, DeLibero 1993).
Regulation of B cell maturation. TCR tS+ cells may be
involved in B cell development and provide help for
immunoglobulin synthesis by production of a particular
pattern of cytokines (Morita 1991). Stimulated murine gut
epithelial TCR tS clones can secrete IL-2, IL-5, IFNr and
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TNFa, though perhaps in lower amounts than aB CD4 cells
(Christmas & Meager 1990, Fujihashi 1989, 1992; Tagushi
1991, Barrett 1992).
Intra-epithelial TCR tS+ cells: differences between mice
and humans
The epithelial predominance of the IEL r«S+ subset in
mice, and the preferential usage of different Vt and V6
gene segments determined by the local epithelial micro-
environment, eg VY6 in gut, V51 in the reproductive tract
(Asarnow 1988, Jarry 1990, Hohara 1990), suggests that
tS+ cells may have a role in maintenance of the epithelial
integrity (Goodman & Lefrancois 1988, Bonneville 1988,
Janeway 1988, Allison & Havran 1991). In normal mice, the
IEL tS+ population represent 30-50%, depending upon the
degree of antigenic stimulation and the age of the
animal. However, differences have been found in other
species, specifically chickens and humans (Bucy 1988,
Groh 1989). There is no evidence for a general epithelial
tropism in man, and these cells are not predominant in
other epithelia such as skin, respiratory tract, or the
reproductive organs where their proportion is similar to
that found in other lymphoid compartments (<5% of the
total T cell number).
In normal human intestine, TCR tS+ cells are segregated
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preferentially in the epithelium, as compared with TCR
t<S+ cells from other localizations, but the majority of
IEL and lamina propria lymphocytes express the TCR aB+
(Groh 1989, Tredjosiewicz 1989, Spencer 1989a, Haltensen
1989, Bucy 1990, Jarry 1990, Vroom 1991). The proportion
of TCR tS+ detected is dependent upon the specificity of
the mAb used. Studies using the mAb 5TCS-1, that
identifies a subset positive for the V51/J51 gene
segments and mucosal-specific, showed that 2% of the
total IEL population are TCR rS+ (Spencer 1989a). Higher
proportions have been found using TCR rS framework
antibodies, up to 15% of the total CD3+ cells in small
and large bowel epithelium (Groh 1989, Bucy 1989,
Haltensen 1989, Fukushima 1991), mainly CD4-CD8- and
CD45RO memory cells (Haltensen 1990). This is
contradicted by the finding of higher numbers in small
bowel and colonic mucosa (Tredjosiewicz 1989, (Ullrich
1991)), and by the finding of a predominant expression of
CD8 antigens by TCR tS+ V61+ IELs (Deusch 1991, Lynch
1993) .
Gut epithelium as a site of T cell maturation
Based on evidence from animal studies, gut epithelium
might have a role in extrathymic T cell development by
promoting the differentiation of immature cells to CD3+
CD8 a+ T cells, without thymus involvement (Rocha 1993).
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Foetal TCR gene rearrangements may occur earlier in some
IEL than in thymic lymphocytes (Carding 1990). In
experiments with athymic mice, it has been observed that
CD3+ CD8aa monodimeric cells repopulate the epithelium
(Guy-Grand 1991); and in animals with severe combined
immuno-deficiency (scid/scid), where Ig and TCR gene
rearrangements should not be possible, the intestinal
epithelium contains immature cells expressing the CD8a
chain (Croitoru 1990 ) . An IEL homodimeric CD8aa
population has been recently identified in single cell
suspensions from human small intestinal biopsies (Lynch
1993), and that may suggest the existence of a thymus-
independent differentiation process in humans (Jarry
1990).
TCR tS+ cells appear during intrathymic development and
represent the CD4-CD8- population in peripheral blood.
Most aB+ IEL are CD4-CD8+; whereas 50-70% of tS+ IEL are
CD3+ CD4-CD8-, and the remainder express only the a chain
of the heterodimer (CD8 a+B-) (Brandtzaeg 1989b, Jarry
1990, Cerf-Bensussan & Guy-grand 1992). The expression of
the second CD8a molecule by tS+ IELs seems to be
secondary to the migration of precursors to the
intestinal mucosa, since the tS+ CD8+ (B-) subset is
absent from peripheral blood. In mice, the co-expression
of TCR rS+ and the CD8aa homodimer characterized cells
undergoing extrathymic development and has only been
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found in epithelium, apparently induced by local factors
(Janeway 1988, Jarry 1990, Fukushima 1991).
In mice, an extra-thymic differentiation of T cells may
explain some of the features of r6 IEL, such as selective
localization in epithelia, preferential usage of a
particular V gene region at different anatomical sites,
and the existence of very limited repertoires in some
epithelia (Bandeira 1991, Rocha 1993). This is also
supported by the finding in murine enterocytes of a class
I-like (CD1) molecule, which is normally expressed by
thymocytes and dendritic cells. Its human equivalent
CDlb, may function as a restriction element in the
enterocyte/IEL interaction by an alternative pathway of T
cell activation (Strominger 1989, Guy-Grand & Vassalli
1993) .
It has been suggested that a preferential localization of
TCR tS+ cells in intestinal epithelium may be explained
by either a developmentally regulated process after
productive rearrangements in bone marrow or elsewhere and
then specific migration to the epithelium, or by a
peripheral antigen-driven expansion where precursors
migrate at random, rearrange in situ, and only undergo
maturation and differentiation in the epithelium (Spencer
1989a, Kluin 1991). There is probably a mixture of both,
a regulated seeding of precursors from thymic and
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extrathymic origins, and a peripheral expansion under the
local microenvironment that shapes the functional IEL tS
repertoire (Kluin 1991).
Possible role of TCR tS+ cells in intestine.
Intestinal TCR tS+ cells may function as
suppressor/cytotoxic cells involved in the control of
inflammatory responses and/or regulation of mucosal
responses to dietary antigens (Barrett 1993, Fujihashi
1992). These cells may produce cytokines in vivo, which
may affect B cell differentiation and immunoglobulin
synthesis, but also other mucosal functions (Brandtzaeg
1988, Morita 1991, Christmas 1991, Tagushi 1991). Of
interest is the unusual finding that both IL-5 and IFNt
can be produced by the same IEL population (Taguchi
1991). These TCR tS+ cells might represent a population
of contra-suppressor cells that restore antibody
responses in mice previously orally tolerized with
specific antigens in vivo (Fujihashi 1989, 1992). This
CD4-CD8- and potentially immature tS+ IEL population may
expand in situations of tissue damage and increased cell
turnover. Precursor double-negative IELs have been
involved in spontaneous LAK activity (Ebert 1989, 1990).
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TCR t<S+ cells in coeliac disease
Coeliac disease and dermatitis herpetiformis (DH) are the
only human diseases in which a consistent TCR tS+ T cell
increase has been observed in the small intestinal mucosa
(Haltensen 1989, Spencer 1989a, 1991; Rust 1992;
Savilahti 1990, 1992; Kluin 1991, Tredjosiewicz 1991,
Vecchi 1992). The increased proportion of CD3+ in
epithelium coincides with the previously reported
increase (2 to 30%) of the CD3+ CD4-CD8- cell population
(Verkasalo 1990). These tS+ IELs express preferentially
the VS1/JS1 phenotype (recognized by the mAb 5TCS-1) and
remain increased in untreated and treated coeliacs with
normal mucosal morphology (Spencer 1989a, Haltensen 1989,
Trejdosiewicz 1989, Savilahti 1990, Kluin 1991, Deusch
1991). However, some of these cells express neither VS1
nor V52 gene products (Spencer 1989a, DeLibero 1993), and
this has also been observed in two suspected coeliac
cases with morphologically normal biopsies (Kluin 1991).
In coeliac disease, it has been suggested that r£+ IELs
may function as cytotoxic cells activated either by
gluten, or indirectly by cytokines released by gluten-
specific TCR aB+ cells, leading to epithelial damage or
the destruction of already damaged cells (Brandtzaeg
1989a, 1991; Viney 1990, Kluin 1991, Russell 1991).
However, TCR rS+ cells are not increased in other
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intestinal diseases associated with villous atrophy and
crypt hyperplasia such as tropical sprue, severe
intestinal food allergy, Crohn's disease or autoimmune
enteropathy (Cuenod 1990, Fukushima 1991, Tredjosiewicz
1991, Cuvelier 1992, MacDonald 1992). An exception may be
cow's milk intolerance in children (Spencer 1991),
though these children may be latent coeliac patients.
The surface epithelium of coeliac mucosa has an enhanced
expression of hsp, and this may represent the association
between rS cells and reactivity to self components.
Constant exposure to autologous hsp-65 presented by
macrophages may lead to continuous lymphokine production
which causes persistence of the lesion, as occurs in
other situations (Soderstrom 1990). However, in coeliac
disease, epithelial damage and release of hsp is not
sufficient to increase IEL t5+ numbers (Harvey 1991,
Kluin 1991). It has been also proposed that in addition
to the presence of hsp, bacterial superantigens might
induce segregation and accumulation of TCR tS cells
within the gut in genetically predisposed individuals
(Kutlu 1993).
High t<5+ iel counts, and dietary and mucosal status
The finding of high numbers of tS+ IELs has been found to
be a constant feature in both coeliac disease and
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dermatitis herpetiformis. This is not related to either
the degree of mucosal damage or the time on a GFD
(Spencer 1989a, 1991; Savilahti 1990, Viney 1990, Kutlu
1993) . High counts of tS+ IEL have also been reported in
non-coeliac patients and in HLA-matched relatives of
coeliacs (Groh 1989, Haltensen 1989, Kluin 1991). In
contrast, other morphological, enzymatic and
immunological abnormalities in small bowel intestine are
reversed by diet, this includes the density of a6+ IELs.
The association found between the tS+ IEL expansion and
the coeliac disease related HLA-DQA1/DQB1 haplotype in
healthy first-degree relatives of coeliac patients (Holm
1992, 1993b) suggests the existence of an inherited
immune abnormality related to the expression of this
haplotype (eg a state of hypersensitivity to gliadin),
and manifested by the expansion of TCR r5+ cells in
intestine (Maki 1991b, Savilahti 1992, Holm 1992, 1993b),
though other unknown genetic factors cannot be excluded.
In mice, the expansion of the rfi+ IEL subset may be
related to one MHC-class II haplotype (Lefrancois 1990).
Alternatively, tS+ IELs might undergo polyclonal
expansion controlled by local regulatory factors
triggered by gluten, to which predisposed individuals may
be specially susceptible. Cytokines may be such a factor
which modulate antigen presentation by the induction of
MHC-class II expression (Kluin 1991, Deusch 1991, Marsh
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1992, DeLibero 1993, Kutlu 1993).
TCR r£ + cells have very limited diversity, and thus
limited capacity for antigen recognition (Allison &
Havran 1991, Rust 1992). However, phenotypic and
genotypic analysis of tS T cells in coeliac disease have
also shown also heterogeneity rather than a monoclonal
expansion of a particular subset. It has been suggested
that more than one antigenic determinant and/or stimulus
may be responsible for the expansion of this population
(Tredjosiewicz 1991, Rust 1992, DeLibero 1993). Moreover,
TCR tS+ cells can be found in human foetal intestine,
which suggests that gluten is not necessary for their
expansion (Spencer 1989b, Haltensen 1989). The fact that
a high density of tS IELs was found in a latent coeliac
patient before the development of enteropathy (Savilahti
1992), and in treated patients after years of gluten
restriction (Kutlu 1993), as well as the high t6 IEL
count that I found in several non-coeliac patients, argue
against their involvement in mucosal damage.
After gluten challenge experiments, it is known that TCR
aB+ cells infiltrate the epithelium in a dose-dependent
manner (Marsh 1980, Leigh 1985, Loft 1989), whereas the
TCR tS+ subset does not change significantly. Before this
infiltration is observed, the lamina propria is occupied
by neutrophils and other mononuclear cells, followed
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immediately by an enhanced expression of the adhesion
molecules ELAM-1 and VCAM-1 (Sturgess 1990, Ensari 1993).
The gluten-sensitised population is formed by CD8+ TCR aB+
IELs, which in untreated coeliacs express the heterodimer
CD8 aR, therefore these cells may be dependent on the
thymus and primed in Peyer's patches by antigens (Guy-
Grand 1991, Kutlu 1993).
Based on the differential expression of the nuclear
proliferation marker recognized by the mAb Ki-67 in
epithelium, and the p55 a chain of the IL-2R (CD25) in
the lamina propria, it has been suggested that gluten
induces a non-proliferative activation of lamina propria
CD4+ cells, which may synthesize cytokines, and induces
proliferation of CD8+ IEL of both phenotypes, TCR aR and
tS (Haltensen & Brandtzaeg 1993). These cells undergo a
polyclonal expansion which may be independent of the
antigen but dependent on IL-2 produced by activated
lamina propria CD4+ cells, and it may also explain the
heterogeneity of the increased IEL population, in
relationship to gluten specificity.
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D. T CELL-MEDIATED IMMUNE RESPONSES IN HUMAN INTESTINE
Delayed type hypersensitivity reactions and mucosal
morphology
The coeliac lesion reflects a T cell-mediated delayed
type hypersensitivity (DTH) reaction to gluten mediated
by lymphokines and other cells involved in non-specific
inflammatory processes. There is evidence of T cell
involvement and lymphokine secretion by cultured jejunal
biopsies after gluten stimulation (MacDonald & Ferguson
1976). The lesion is similar to the intestinal graft-vs-
host disease in animal models (Mowat & Ferguson 1982,
Guy-Grand & Vassalli 1986, Mowat 1987), manifested by
villous atrophy, crypt hyperplasia, increased IEL
infiltration, and increased HLA-DR expression by
epithelial cells. Treatment with anti-TNFa or anti-IFNr
antibodies prevents the intestinal infiltrate and the
mucosal damage in these animals (Piguet 1987, Mowat
1989) .
Studies of cell kinetics in flat mucosa of the human
small intestine showed that crypt hyperplasia is a
primary event in the development of the coeliac lesion
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(Wright 1973). Experiments of in-vitro culture of fetal
explants, have also shown that T cell activation is
associated with crypt cell hyperplasia even before any
mucosal damage, and villous atrophy is the subsequent
effect of crypt hyperplasia. The enteropathy can develop
without a cytotoxic response to epithelial cells, and it
is mediated by soluble factors release by activated
lamina propria CD4+ cells that affect the structure and
function of the small intestine (Griffiths 1988,
MacDonald & Spencer 1988, Monk 1988, Ferreira 1990,
MacDonald 1992).
The initial immunopathological event in gluten challenge
studies is a migration of lymphocytes into the small
bowel epithelium (Marsh 1980, Brandtzaeg 1989a). This may
be a manifestation of T cell activation which, together
with the degree of villous atrophy is related to gluten
in a dose-dependent manner (Leigh 1985) . In coeliac
mucosa, gluten challenge leads to the accumulation of
both phenotypes, lamina propria CD3+ CD4+ and epithelial
CD3+ CD8+ CD45RO-memory or primed cells (recognized by
the mAb UCHL-1). UCHL-1 is mainly expressed by TCR a£+
cells, but a higher number of tS+ cells also have this
memory marker (Harvey 1989, Brandtzaeg 1989b, Haltensen
1990, Halstensen & Brandtzaeg 1991).
Current hypothesis of the coeliac lesion
The coeliac lesion is the result of an aberrant HLA-class
II restricted immune response to gluten, and mononuclear
cell infiltration (Sollid 1989, O'Farrelly & Gallagher
1992, Lundin 1993). Lamina propria CD4+ cells seem to
play a central role in the development of the gluten-
sensitive lesion. These cells are activated as confirmed
by the presence of CD25+ cells amongst the CD4+/CD45RO+
cell population, and also CD3- cells (probably
macrophages) , followed by the expression of the Ki-67
proliferative antigen by both CD8+ aR+ and tS+ cells in
epithelium, and other changes in mucosal structure
(Marsh 1992, MacDonald 1992, Haltensen 1992b, Haltensen &
Brandtzaeg 1993). MHC-class II positive macrophages might
present antigen to CD4+ CD45RO+ cells leading to cytokine
production and a cascade of immuno-regulatory effects
(Marsh 1992). However, the phenotype, cytokine profile
and function of the potential gluten-responding T cells,
are not yet known.
Gluten-reactive T cells have been isolated from the
intestine of coeliac patients. Most of these cells seem
to be restricted by the coeliac-associated HLA-DQa/13
heterodimer (Lundin 1993). These HLA-class II region
alleles are associated the susceptibility to coeliac
disease, but it is not yet known whether this association
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operates (Kagnoff 1992), by involvement of HLA-DQ
molecules in the "selection" of the T cell repertoire
(Altmann 1991), or by local events in mucosa, eg HLA-DQ
restricted antigen presentation to T cells (Lundin 1993).
Evidence of immunologically-mediated mucosal damage
Activation of intestinal T lymphocytes is related to the
presence of CD25+ cells and the increased expression of
HLA-DR antigens by epithelial cells. However, early
reports showed lymphoid cell infiltration but failed to
detect other signs of activation, particularly CD25+
cells (Selby 1983, Kelly 1987). More recently, a high
expression of HLA-class II molecules in epithelium, and
CD25 antigens in the lamina propria, has been reported
(MacDonald & Spencer 1988, Haltensen 1992b). There is
evidence that IELs can modulate the HLA-DR expression by
enterocytes, by IFNr production (Cerf-Bensussan 1984,
Scott 1987, Sturgess 1992). Interferon-r may also induce
epithelial SC expression (Sollid 1987, Kvale 1988b),
inhibition of epithelial cell proliferation, and
increased epithelial permeability (Madara & Stafford
1989) .
T cell activation may also
changes in lamina propria,
neutrophils, basophils and MMC
be associated with other
such as infiltration of
(Dhesi 1984, Marsh & Hinde
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1985); activation and degranulation of eosinophils, MMC
and neutrophils (Hallgren 1989, Horvath 1989, Colombel
1992, Desreumaux 1992, Talley 1992); presence of
prostaglandins and other inflammatory mediators (Lavo
1990, Branski 1992), and activation of complement with
subepithelial deposits of the terminal C complex
(Haltensen 1992a, Scott 1992). Lymphocyte activation by
gluten fraction III led to the expression of IL-2R
(Penttila 1990), and soluble IL-2R levels have been found
increased in serum from adults and children with active
coeliac disease (Crabtree 1989b, Blanco 1992), which are
normalized after gluten restriction.
T cells express the CD25 marker soon after activation by
antigen (Reed 1986). In-vitro polyclonal T cell
activation in human mucosa has shown that CD25 is
expressed only by lamina propria T cells and macrophages
(MacDonald & Spencer 1988, MacDonald 1990a). In the
epithelium, there is an IEL infiltration, with increased
epithelial cell kinetics and HLA-DR expression, but these
cells are CD25 negative. In contrast, epithelial CD25+
cells have been reported in chronic rejection of a
jejunal transplant (Cerf-Bensussan 1990). This in-vitro
enteropathy is similar to the active coeliac lesion with
a differential expression of the proliferative Ki-67
antigen by epithelial cells, and the non-proliferative
CD25 marker by lamina propria CD4+ cells, which may be
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associated with lymphokine synthesis (Haltensen &
Brandtzaeg 1993). These events may explain the difficult
isolation of gluten-specific T cells in mucosa, where
IELs may be induced to proliferate in an antigen-
independent (but probably IL-2 dependent) manner, and
secondary to lamina propria CD4+ cell activation.
In a recent study, signs of inflammation detected by HLA-
DR antigen expression and presence of CD25+ cells, have
been shown in morphologically normal biopsies from first
degree relatives of coeliac patients (Holm 1993a,b).
These patients are "potential" coeliacs with a high
number of r5+ IELs, which correlates with the disease-
associated genetic markers. They may eventually develop a
gluten-sensitive enteropathy, and this may be monitored
by the measurement of ARA/AEm serum antibody titers.
Patterns of cytokine production by T cell subsets
Studies in mice have shown that CD4+ cells can be sub¬
divided into two subsets according to the pattern of
cytokine synthesis (Mossman & Coffman 1989), and these
subsets have different helper activity on immunoglobulin
synthesis by B cells, and cytolytic potential. In humans,
similar T cell clones may exist in both healthy
individuals and disease patients, with different non-
overlapping cytokine profiles (Salgame 1991, Del Prete
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1991). These mature T cell clones may be differentially
regulated by different antigen structures, populations of
antigen-presenting cells, and conditions of immunization.
Macrophage stimulation leads to proliferation of Thl
clones, whereas B cells stimulate preferentially Th2
clones (Gajenski 1991).
Thl subsets produce mainly IL-2 and INFr. They are
involved in cell-mediated immune responses, cytotoxicity,
delayed-type hypersensitivity (DTH) reactions. They also
mediate polyclonal Ig synthesis (IFNr induces IgA2 and
IgM. Kett 1990), when stimulated with high amounts of
antigens, and inhibit the Th2 cell function (IFNt blocks
IL-4) under certain conditions.
Th2 subsets produce IL-4,IL-5,IL-6,IL-10; and are
involved in IgM, IgG, IgE and IgA synthesis (specially in
mucosa), and other non-specific inflammatory processes
with MMC and eosinophils. Antigen absorption through
Peyer's patches (eg oral immunization with cholera toxin)
induces proliferation of Th2 clones. IL-10 blocks the in-
vitro cytokine synthesis by Thl clones, acting on the
antigen-presenting function of macrophages (Fiorentino
1991). There is another group (ThO) of probable memory
cells and unrestricted cytokine profile: IL-2, IFN-r, IL-
4 and IL-5. A high number of mucosal lymphocytes in mice
produce IFNr and IL-5 in vitro (Tagushi 1990).
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Oral administration of soluble antigens might induce
tolerance rather than a mucosal immune response, by
preferential epithelial uptake of antigen, activation of
lamina propria CD4+ cells by macrophages, and subsequent
production of inhibitory cytokines (IL-4, TGFJ3, IL-10)
with suppressive effect on the induction of immune
responses.
Cytokines as mediators of mucosal damage
T cell activation leads to morphological and functional
changes in the small bowel mucosa, and it is likely that
cytokines can act as mediators. Cytokines may be involved
in different activities, such as IgA production; clonal
expansion, activation and differentiation of lymphoid
cells; immuno-regulatory mechanisms of oral tolerance;
modulation of the endothelial receptor function;
epithelial cell physiology and stimulation of epithelial
crypt cell growth; and healing mechanisms in mucosa
(MacDonald & Spencer 1988, Vidrich 1991, Wershill 1992).
- Interferon-gamma
IFNt may modulate the epithelial permeability by acting
on epithelial cell tight junctions (Madara & Stafford
1989), antigen presentation, and mucus secretion. IFNt
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up-regulates the epithelial expression of a variety of
cellular receptors, including MHC-class II antigens and
secretory component (Kvale 1988b). Intra-epithelial CD3+
CD8+ a£+ cells, in turn, may produce great amounts of
IFNt (Scott 1987, Brandtzaeg 1989a, Sturgess 1992). It
has also been shown that IFNt produced by activated T
cells may kill colonic epithelial cells (Deem 1991).
Original studies at single cell level (MacDonald 1990b),
and by immunohistochemistry (Al-Darwood 1992) in coeliac
disease failed to detect IFNr-secreting cells. However,
others have found a correlation between the number of
IFN-r producing cells, increased in untreated coeliacs,
and the degree of villous atrophy (Kontakou 1993).
- Interleukin-2 receptor
Antibodies to IL-2R identify a low affinity a chain of
the IL-2 receptor (Tac antigen), which is essential for T
cell activation and proliferation. High serum levels of
IL-2R have been used as a marker of disease activity in
autoimmune and malignant diseases (Rubin 1985,
Manoussakis 1989) though IL-2R seems to be released into
the circulation asynchronously with immune activation.
Interleukin-2 receptor is mainly produced by helper T
cells in direct relationship to IL-2 production, and in
serum it may have an in-vivo immunoregulatory function,
though this is still unknown (Rubin 1985, Mueller 1990).
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Adults and children with active coeliac disease, have
increased levels of soluble IL-2R in serum, which
decrease after treatment (Crabtree 1989b, Blanco 1992).
Serum levels correlate with soluble CD4 antigens, but
not with serum anti-gliadin antibodies (Blanco 1992).
Activation of peripheral blood lymphocytes by gluten
fraction III has been measured by detection of soluble
IL-2R levels in serum (Penttila 1990), however, though
its measurement may be an index of immune activation, its
cellular origin is unknown (MacDonald 1993).
- Tumor necrosis factor-alpha
TNFa is mainly produced by macrophages, but also by NK
cells and T cells. It has a short life in plasma and
other body fluids, and is sometimes undetectable despite
local production by inflamed mucosa. TNFa is regulated
differently in each tissue, and there is no correlation
between compartments, or between cytokine levels and TNF-
secreting cells (MacDonald 1990b, Meager 1990). TNFa
affects epithelial function and causes acute intestinal
injury, probably by a direct effect on the
microcirculation, as observed by intravenous injection of
TNFa in animals, with endothelial and epithelial cell
damage, neutrophil accumulation, and necrosis of villi
(Remick 1987). The effect on microvascular permeability
and blood flow may be mediated by stimulation of nitric
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oxide production (Liew & Cox 1991), which is also
produced by LPS or IFNr activated macrophages (Stuehr &
Marietta 1987). It has been shown that murine Paneth
cells may also express mRNA for TNFa (Keshaw 1990).
Proinflammatory cytokines, specially TNFa and IFNr, but
also IL-1 and IL-6 are not detectable unless stimulation
occurs. In the intestinal mucosa, these cytokines are
involved in T and B cell activation, regulation of the
expression of homing receptors, and synthesis of
components necessary for IgA transport. In coeliac
disease, IL-1 and IL-3 may affect the epithelium by
stimulation of prostaglandin E2 production (Branski
1992). Subepithelial fibroblasts support the villous
architecture but they may also influence the response to
inflammatory mediators and cytokines (Berschneider &
Powell 1992). Locally produced TNFa and IL-1 are involved
in neutrophil migration, by inducing the expression of
adhesion molecules and chemotactic factors (Kishimoto
1991). Enterocytes may express the intra-ce1lu1ar
adhesion molecule-1 (ICAM-1), and lymphocyte function-
associated antigen-3 (LFA-3), but only the first is up-
regulated by IFNt and IL-1B (Kaiselian 1991), and by TNFa
and IL-6 (Kvale 1992).
Activated MMC may produce TNF-a, prostaglandins and
leukotrienes, but they may also play a role in fibrotic
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processes via TGFB production (Pennington 1992). Isolated
eosinophils express mRNA for TGFB (Wong 1991), IL-3 (Kita
1991), and IL-5 in coeliac disease (Desreumaux 1992).
TGFB may be synthesized by lymphocytes, macrophages and
epithelial cells; it regulates the maturation of
intestinal epithelial cells and enhances IL-6 production
in epithelial cell lines (McGee 1992). Both IL-6 and Thr¬
ee producing cells have been found increased in untreated
coeliac patients, but also there is an increase in the
number of lamina propria macrophages that might be
involved in cytokine synthesis (Przemioslo 1993). In
experimental colitis in rats, colonic epithelial cells
express IL-1B mRNA (Radema 1991).
Expression of HLA-class II antigens in intestine
The polymorphism of the HLA-class II proteins (aB
heterodimers) determine a spectrum of antigen binding
affinities in each individual (Brandtzaeg 1991). In
coeliac disease, the immune responsiveness to gluten may
be modulated by selection of the TCR repertoire in thymus
or by HLA-restricted antigen presentation at local level
(eg HLA-DR+ enterocytes, or lamina propria HLA-DQ+
macrophages). HLA-class II antigens are needed for
monocytes, macrophages and B cells to became antigen-
presenting cells (Ziegler & Unanue 1981), and also in
normal intestinal enterocytes, though the latter
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selectively stimulate nonspecific suppressor cells (Bland
& Warren 1986, Mayer & Shlien 1987). It is also known
that HLA molecules neither bind gliadin in a lectin-like
fashion, nor have antigenic cross-reactivity with gliadin
(Gallagher 1988).
HLA-DR is normally expressed by human villous epithelial
cells, particularly at the tip of the villi, and
decreases towards the crypt, where it is undetectable
(Scott 1980b, Kelly 1988, Montgomery 1988). HLA-DR
expression by crypt epithelial cells may be used as a
marker of local DTH reaction (Ferguson 1987a, Fais 1992).
In coeliac and other inflammatory diseases, the HLA-DR
expression by villous and crypt epithelium is gluten
dependent, and may be secondary to the lymphocyte
infiltration, and IFNr synthesis (Scott 1981, 1987; Cerf-
Bensussan 1984, Ciclitira 1986a, Arnaud-Battandier 1986,
Spencer 1986, Marley 1987, Sturgess 1992). Because HLA-
DR+ cells can be found in uninvolved areas, it has been
suggested that these cells may represent an early change
in inflammation, or a group of immunoregulatory cells
inducing secondary inflammatory responses (Mayer 1991).
HLA-DP expression has a similar distribution, but a lower
intensity than DR expression in villous epithelium or
expression in other cells (Marley 1987, Mayer 1991).
HLA-DQ antigens are absent in normal intestine, and
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positive cells can only be found in lamina propria
(Sarles 1987, Schweizer 1991). In active coeliac disease
HLA-DQ expression may be found in the lamina propria, and
gluten specific HLA-DQ restricted T cells have been
isolated from coeliac jejunal biopsies (Lundin 1990,
1993) .
Expression of the CD25 activation marker in intestine
The CD25 marker is expressed soon after antigen
stimulation (Reed 1986). Experiments of polyclonal T cell
activation of human mucosa in vitro, led to the
expression of CD25 markers by lamina propria T cells and
macrophage-1ike cells (MacDonald & Spencer 1988,
MacDonald 1990). In epithelium, this activation was
manifested by IEL infiltration and HLA-DR expression by
enterocytes. The degree of tissue destruction has been
associated with high numbers of large CD3-CD25+ cells,
probably macrophages, in studies of fetal tissue culture
(Lionetti 1993), and this destruction may be secondary to
the T cell activation in lamina propria and IL-2 and IFNt
production, which are potent activating factors for
macrophages (Belosevic 1988 , Cox 1990 ) . In-vivo
similarities are also found in the mucosa of untreated
coeliacs, where a differential expression of activation
markers is observed, the Ki-67 proliferative marker is
expressed by enterocytes, and the CD25 marker by lamina
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propria cells (Haltensen & Brandtzaeg 1993). This might
suggest that the IEL population is induced to proliferate
in an antigen-independent manner, explaining the absence
of gluten-specific T cells, but probably dependent on IL-
2 production, and secondary to LP CD4+ cell activation.
Autoreactive CD5+ B cells
It has been suggested that polyreactive, low affinity IgM
antibodies, produced by CD5+ B cells that recognize self
determinants, may represent a first line of defence
against infectious agents (Casali & Notkins 1989). In
rheumatoid arthritis, there is an expansion of the T-cell
population bearing the t6 TCR, and of B cells expressing
the CD5+ marker in peripheral blood (Plater-Zyberk 1989),
but they are not related to the severity of the disease
activity. It may be hypothesized that a genetically
determined immunoregulatory abnormality may lead to the
development of a "fetal cell type" population (CD5+ B
cells, tS+ T cells) involved in the generation of an
enhanced reactivity to common bacterial antigens which
are antigenically conserved between species (Brennan
1989) . Furthermore, these cells may not respond to local
factors to avoid clonal expansion which would lead to
excessive auto-reactivity and formation of immune-
complexes. Studies in mice have shown that treatment with
anti-IL-10 from birth causes a reduction of serum IgM
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concentration and the elimination of CD5+ B cells, which
have been postulated to be the principal source of
circulating IgM antibodies (Hayakawa 1983).
In fetal life, HLA-DQ antigens might be involved in the
elimination of autoreactive T cells, and some HLA-DQ
phenotypes might allow these clones to survive (Altmann
1991). Moreover, HLA-DQ expression is absent from coeliac
and non-coeliac epithelium, suggesting the existence of
an epithelial defect for these antigens (Kelly 1988,






PATIENTS AND COLLECTION OF SPECIMENS
A. PATIENTS
This Gastro-Intestinal Unit provides a regional service
for the clinical investigation of gastro-intestinal
function. Patients were collected over a period of 30
months but selected by the availability of samples. All
jejunal biopsies were taken for diagnostic purposes and
in the course of a full range of investigations; or in
the follow up of coeliac cases to assess their response
to the dietary treatment.
Coeliac patients and controls (preliminary study)
Jejunal fluid and serum samples were collected on 80
occasions from 69 patients. There were 41 with coeliac
disease (7 studied twice), 23 women and 18 men (age range
of 15-78 years, median 42); and 28 control patients, 14
women and 14 men (age range of 14-75 years, median 35),
referred for diagnostic jejunal biopsy, eventually found
to be normal, with no other significant pathology, and a
final diagnosis of functional bowel disease.
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Of the coeliacs, 26 were untreated and their jejunal
biopsy showed subtotal or severe partial villous atrophy.
Eleven of these, and a further 15 treated coeliacs (all
with previous diagnostic biopsies) were re-biopsied while
on a GFD. Median period on GFD was 3 years (range 3
months-17 years). Eleven had entirely normal jejunal
histology (all of these had been taking a GFD for at
least 2 years), and 11 had minor histological changes, eg
increased IEL counts (most patients in this group had
been taking a GFD for less than one year). Four further
patients whom it had been our intention to study showed
no histological improvement on a GFD. We attributed this
to non-compliance and thus excluded them; thus, data was
collected from 76 studies.
Patient series A, coeliac and non-coeliacs
During a 16-month period, a total of 151 patients
attended for per-oral jejunal biopsy. Adequate samples of
jejunal fluid and small bowel mucosa (not suitable for
frozen sections) were collected at the same time from 140
patients, 91 women and 49 men, with an age range of 13-83
years (median 37) . Serum samples were collected from 137
of these patients. All specimens from this prospective
cohort study were assessed blinded, therefore 22 of the
series were coeliac patients having follow-up biopsies to
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assess their response to a GFD. A decision as to the
final diagnosis for the remaining 118 cases was made 2-3
months after the biopsy procedure, from examination of
the case records, and without knowledge of the results of
secretion or serum antibody tests. Of the 98 patients
with a final diagnosis other than coeliac disease or DH,
93 were reported to have a histologically normal jejunal
biopsy and 5 had minor histological abnormalities (short
villi in two, excess inflammatory cells in three).
Details of the patients, their diets, final diagnoses,
and biopsy histology, are given in Table II.1. Diagnostic
groups of series A:
Coeliac disease (COELIAC) and Dermatitis Herpetiformis
(DH) A total of 36 biopsies were obtained from 33
coeliac patients (3 of them were biopsied twice). There
were 14 new cases of coeliac disease, and 22 biopsies
from treated patients, the majority with less than one
year of GFD, with improved but still unequivocally
abnormal histology. Five of the six DH patients were
newly diagnosed, and one was on a GFD.
Not coeliac (NOT COE) There were three patients in whom
a diagnosis of coeliac disease had previously been made
on inadequate criteria (no biopsy or normal biopsy); in
the final analysis they have all been classified as
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TABLE II.1. FINAL CLASSIFICATION OF PATIENTS BY DIAGNOSIS AND BY







































2/1 1 2 3
IBD 7 29
(18-41)
4/3 7 5 2
IDIO DIA 23 36
(15-67)
11/12 23 23






NUT DEF 8 49
(23-69)
5/3 8 7 1
IBS 13 35
(20-45)
10/3 13 12 1
NAD 15 34
(13-57)
11/4 15 14 1
DH= dermatitis herpetiformis
NOT-COE= previous diagnosis on inadequate criteria
IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
GFD= gluten-free diet
Minor Changes= high IEL counts, inflammatory cell infiltrate
PTVA= severe partial, or total villus atrophy
70
healthy.
Inflammatory bowel disease (IBD) Four patients had
Crohn's disease and three had ulcerative colitis.
Idiopathic diarrhoea (IDIO DIA) These 23 patients had
chronic, watery diarrhoea, and no firm diagnosis was made
even after full investigation by a consultant gastro-
enterologist. One was also IgA deficient.
Oral ulceration (ORAL ULC) These were patients with
severe aphthous ulceration or oral candidiasis (HIV
negative), referred for malabsorption work-up by Dental
surgeons and in whom no evidence of intestinal disease
emerged.
Miscellaneous GI disease (MISC) There were 23 patients
with various significant organic GI diseases, including
diverticular disease, small bowel bacterial colonization,
colonic polyps, giardiasis, colorectal cancers, radiation
entero-colitis, drug-induced diarrhoea, alcoholic
cirrhosis.
Nutritional deficiencies (NUT DEF) Seven patients had
presented with anaemia or weight loss, ultimately
attributed to poor diet.
71
Irritable bowel syndrome (IBS) These were patients with
abdominal pain, bloating and variable bowel habit with no
identifiable organic cause.
No abnormality detected (NAD) There were a few patients
who had trivial symptoms or psychiatric disease, or had
constitutional short stature.
Non-coeliac patients, series B
Similar studies were performed in a further cohort of 119
non-coeliac patients, from whom jejunal biopsy (not
suitable for frozen sections), jejunal fluid, and serum
specimens, were collected in the following 11-month
period. These included 76 women and 43 men, with an age
range of 15-79 years (median 36.5). A normal jejunal
biopsy histology was found in 111 cases, and 8 showed
minor histological changes (eg high IEL counts). Details
of their diets, final diagnosis and jejunal biopsy
histology are given in table II.2.
Non-coeliac patients, series C and D
Material suitable for the full range of immunological
investigations, including frozen biopsy sections, was
obtained from a further 77 non-coeliac patients (series
C), 49 women and 28 men, age range of 17-77 years (median
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TABLE II.2. FINAL CLASSIFICATION OF NON-COELIAC PATIENTS BY
DIAGNOSIS AND BY JEJUNAL BIOPSY HISTOLOGY. SERIES B.
DIAGNOSIS (n) AGE SEX DIET HISTOLOGY



















































NOT-COE= previous diagnosis on inadequate criteria
IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
GFD= gluten-free diet
Minor Changes= minor non-specific histological abnormalities
(ie. high IEL counts, chronic inflammatory cell infiltrate)
PTVA= severe partial, or total villus atrophy
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33) . A decision as to the final diagnosis for these
patients was made 2-3 months after taking the biopsy,
from examination of the case records, and without
knowledge of the results of immunological investigations.
Details of the patients, their diets, final diagnosis,
biopsy histology and sugar permeability test, are given
in Table II.3. There was an additional diagnostic group,
of first degree relatives (FH) of coeliacs, subseguently
shown to be normal.
With the aim of validating the results and establishing
reference values for tS+ IEL counts in frozen sections of
small bowel intestine, duodenal biopsies from the distal
second part of the duodenum were collected from a further
26 patients undergoing upper GI endoscopy (series D),
none of whom had symptoms of small bowel disease. These
included 17 women and 9 men; age range 16-87 (median
69.5); grouped by 6 different diagnoses: duodenal ulcer
(4 cases) , gastric ulcer (4) , hiatus hernia (3) ,
oesophagitis (4), other diseases (gallstones, portal
hypertension, cancer), and no abnormality was detected in
8 cases.
As part of the technical appraisal of CD3+ and tS+ cell
counts, frozen sections of jejunal biopsies from a group
of coeliac patients (predicted to have high r<S+ IEL
counts) was also examined. Fifteen jejunal biopsies were
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TABLE II.3. DEMOGRAPHIC DATA OF PATIENTS CLASSIFIED BY FINAL
DIAGNOSIS AND JEJUNAL BIOPSY HISTOLOGY. SERIES C.
DIET HISTOLOGY PERMEABILITY























































NOT—COE= previous diagnosis on inadequate criteria
FH= relatives of coeliac patients
IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
N= normal
GFD= gluten-free diet
Minor Changes= minor non-specific histological abnormalities
PTVA= severe partial, or total villus atrophy
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collected from 14 coeliac patients, 11 women and 3 men,
with an age range of 16-86 (median 37.5). Thirteen were
already diagnosed, attending for follow-up biopsies (one
of these had two biopsies, on a GFD and during a gluten
challenge); only one was a newly presenting patient.
A total of 84 serum samples including all 77 non-coeliac
patients from series C, and 7 other samples from previous
series (5 women, 2 men; with 5 different diagnostic
groups), were studied for anti-reticulin (ARA) and anti-
endomysium (AEm) antibody titers (Dr Maki, Tampere,
Finland) . Serum samples from 6 coeliac patients (1
untreated, 1 on gluten challenge, 4 treated) were also
included. (See Chapter VII for details).
Patients studied for total IEL counts
Biopsies from 171 patients, all with normal villous
architecture, were assessed for IEL counts, 7 coeliacs on
a GFD, 4 patients with DH, 44 non-coeliacs from series A,
39 non-coeliacs from series B. In total there were 40
CIA positive non-coeliac cases and 43 patients with a
similar range of diagnoses but normal intestinal antibody
patterns. Conventional IEL counts were performed in all
77 non-coeliac biopsies from series C, which have also
CD3 + and epithelial t s + cell counts in cryostat
sections, to allow comparisons between both counting
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methods.
Patients studied for lamina propria plasma cell counts
Jejunal biopsies from patients included in Series A were
studied for lamina propria IgA+ and IgM+ containing
plasma cells, and MMC. From these, 12 were coeliacs, 6
newly diagnosed and 6 on a gluten-free diet (2 of them
had normal biopsy histology), and 29 non-coeliac patients
(26 showed a morphologically normal biopsy, and 4 minor
histological changes, ie, high total I EL counts). See
Chapter VIII for details.
Patients studied for the intestinal expression of HLA-DR,
DQ and CD25 antigens
These included 32 non-coeliac patients, age range of 20-
72 (median age: 31.5) , 10 of these were patients
diagnosed of having a functional disorder, and no
abnormality was detected in 5 cases. These patients were
grouped by their total IEL count, 16 with high counts,
and 16 with normal counts. Sixteen coeliac patients, age
range: 12-62 (median: 37) were also studied, 7 of them
were untreated, one was undergoing a trial of gluten
challenge, and 8 were treated. See Chapter IX for
details.
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Patients studied for TNFa and soluble IL-2R levels in
jejunal fluids
Suitable specimens from 82 patients, 59 women and 23 men,
included in series A and B, were studied for levels of
tumour necrosis factor alpha (TNFa) and soluble IL-2R
levels (Table II.4). These included 24 coeliac patients,
19 treated (8 had a normal biopsy, and 11 had either PVA
or TVA) and 5 untreated; and 58 non-coeliacs, divided
into a control group of 28 patients with a functional
disorder or those in whom no abnormality was detected
after investigation (all with normal biopsy histology),
and a group of 30 patients with other organic GI
diseases (27 with normal biopsy histology, 2 minimal
changes, and 1 partial villous atrophy). Of these 83
patients, 37 had enough material to measure jejunal fluid
IFNr levels, including 9 coeliacs (2 were untreated, 7 on
a GFD), 3 DH patients (1 untreated, 2 on a GFD); and 25
non-coeliac patients (3 IBD, 6 mouth ulcers, colonic
cancer, etc) , 10 of them described as controls (see
above).
The different series of patients, and some of the studies
performed in each group are represented in Figure II.1.
78
TABLE II.4. DEMOGRAPHIC DATA OF PATIENTS STUDIED FOR SOLUBLE
IL-2R AND TNFa LEVELS IN JEJUNAL FLUID.
DIAGNOSIS (n) AGE SEX DIET HISTOLOGY


















































IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
GFD= gluten-free diet
Minor Changes= minor non-specific histological abnormalities
PTVA= severe partial, or total villus atrophy
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Figure II.1: Patients referred to the G.I. Unit because of
possible small bowel disease, or in treated coeliac patients for
follow up studies.
LP-cells= lamina propria plasma cells
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B. COLLECTION OF SPECIMENS
Collection and processing of jejunal fluids
After an overnight fast, patients (referred for per-oral
jejunal biopsy) swallowed a Watson biopsy capsule
together with 15 mg of Metoclopramide. When the capsule
had passed to the first loop of jejunum (assessed by X-
ray screening), 1-2 ml intestinal fluid was drained by
gravity through the tubing. The protease inhibitor
phenylmethyl sulphonyl fluoride (PMSF), 20 ul/ml at a
concentration of 0.1M, was immediately added. The capsule
was then fired to obtain a jejunal mucosal biopsy.
Jejunal fluid was transferred on ice to the laboratory
and stored at -70°C within 10 minutes of collection.
Venous blood samples were also taken, serum separated,
aliquotted and stored at -70°C.
Collection of jejunal biopsies
Jejunal mucosal biopsies were formalin-fixed and sent to
the diagnostic pathology laboratory, where a report was
issued which included a detailed textual description and
a codeable classification, ie. total villus atrophy
(TVA), severe partial villus atrophy with crypt
hyperplasia (PVA), minor non-specific abnormalities
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(these included villus shortening without crypt
hyperplasia, and general increase in inflammatory cell
infiltrate) and morphologically normal.
Collection of biopsies for frozen sections (Series C, D)
Jejunal mucosal biopsies were orientated with the aid of
a dissecting microscope and divided into two pieces. One
was formalin-fixed and sent to the diagnostic pathology
laboratory (see above) for subjective examination by a
consultant pathologist. The other piece was embedded in
OCT compound, frozen, and stored at -70°C within 10




METHODS AND TECHNICAL DEVELOPMENTS
A. JEJUNAL FLUIDS
Immunoglobulin and antibody assays
In specimens of jejunal fluid, concentrations of IgA and
IgM, and levels of IgA and IgM antibodies to gliadin
(GLI) (gift from Dr H. Weiser), ovalbumin (OVA) and beta-
lactoglobulin (BLG) (Sigma Chemical, Poole, Dorset, UK)
were assayed by enzyme-linked immunosorbent assays. To
standardize the ELISA method for immunoglobulin total
concentration, 20 samples (from the preliminary study)
were used to assess the optical density coefficient of
variation intra- and inter-assay, which ranged between 5-
15%.
For assays of immunoglobulins in jejunal fluid specimens,
serial 2-fold dilutions of a reference preparation were
used to produce a standard curve, and serial dilutions of
test samples were also assayed. Plates were read in an
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MR5000 Automatic microplate reader (Dynatech,
Billingshurst, Sussex, UK) set at a wave length of 405um
(OD405). Only when the results of at least two of the
sample dilutions fell within the range of the standard
curve was the assay considered technically satisfactory,
and the immunoglobulin content of the sample determined
as the mean for these two sample dilutions. Standards
used were: for IgA, human colostral IgA (Sigma Chemical
Co. Poole, Dorset, UK); for IgM, human reference serum
(Protein Reference Unit, Sheffield, UK).
In the assays of specific antibodies, prior experiments
were carried out to determine optimum test conditions for
each antigen, isotype and fluid. Serum from an untreated
coeliac patient, previously recognized as having high
levels of antibodies of IgG, IgA and IgM isotypes to GLI,
OVA and BLG, was used as a reference standard. The
reference specimen and test specimens were studied in
duplicate at a predetermined dilution, varying for the
different assays, and the plates read when the OD for the
standard reached 1.0. If the duplicates varied by more
than 10% the result was discarded. Antibody levels were
expressed as percentages of the OD of the standard.
Results are thus obtained and presented as non-parametric
data; antibody levels are not directly proportional to
the antigen-binding capacity of the sample. This is a
feature of all such assays.
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Assay for secretory IgA
Total and secretory IgA were quantified on the same
microtiter plate by adding duplicate standards and fluid
samples to plates coated with anti-human a chain (Sigma
Chemical Co, Poole, Dorset, UK) and two secondary
antibodies were used, an anti-IgA and a highly purified
anti-secretory piece (The Binding Site, Birmingham, UK) ,
both alkaline phosphatase AP-conjugated. Results were
reported as total IgA concentration and the percentage of
total IgA-bound to secretory component. To validate the
test, and considering the possibility that unbound SC, or
SC bound to secretory IgM, might compete for the binding
sites of the ELISA-solid phase; it was made sure that SC
which was unbound, or bound to IgM, was washed thoroughly
away after the first incubation.
ELISA assay for IgM antibodies
Care was taken to ensure that the results were not merely
due to non-specific binding of IgM, a matter of
particular concern in assays of anti-GLI. All plates were
pre-incubated with 1% bovine serum albumin in buffered
saline with 0.5% Tween 20, pH 7.4, before addition of the
samples. In general, the specificity of antibodies was
tested by incubating samples with the appropriate protein
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antigen and showing that the antibody was specifically
absorbed out. To confirm antigen-specificity of the IgM
assay, samples of jejunal fluid were tested for IgM anti-
GLI and IgM anti-OVA, before and after incubation for one
hour in gliadin-coated microtiter wells; there was 50-70%
reduction of the optical density (OD) reading for anti-
GLI but no change in anti-OVA; similar, antigen-specific
reduction in activity was found after incubation in OVA-
coated wells and testing for IgM anti-OVA and IgM anti-
GLI antibodies (Figure 1) .
Classification of antibody data
"Normal" values for the various antibody assays were
based on results in 28 immunologically normal individuals
previously studied (O'Mahony 1991a); as explained above,
units of measurement were the OD for test specimen
expressed as a percentage of the OD of the standard. For
serum, normal values were taken as <20 for IgA anti-GLI,
and <40 for IgG anti-GLI; for all IgA and IgM antibodies
in jejunal fluid values <15, were considered normal.
When jejunal fluid antibody studies showed a high value
for IgM anti-GLI, together with high levels of at least
two other intestinal antibodies characteristic of coeliac
disease, ie. IgA anti-GLI, IgM anti-OVA, IgM anti-BLG,
the specimen was designated as "coeliac-like intestinal
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antibody" (CIA) positive, and all other specimens were
considered CIA negative.
Total protein, albumin and alpha-l anti-trypsin
Total protein concentration was assessed by a
spectrophotometric method, the BCA (Bicinchoninic acid)
Protein Assay (Pierce UK Ltd. , Cambridge, UK) , with
protein standards provided by the kit, in jejunal fluid
samples, diluted in bovine serum albumin. The standard
protocol instructions were followed, a main incubation
set up at 37° C for 30 minutes, and microtiter plates
were read at 562 nm.
Albumin was assessed by an immunoturbidimetric method,
using an anti-human albumin antibody (Scottish Antibody
Production Unit, Carluke, Scotland). A similar method was
used for a-1 anti-trypsin (a-l AT) , with an anti-human
a-1 AT antibody obtained from the Protein Reference Unit
(Royal Hallamshire Hospital, Sheffield, UK). Absorbency
readings were set up at 340 um for both assays.
TNFa and soluble IL-2R levels
I have used two commercial kits, the TNFa-EASIA (Medgenix
Diagnostic, Brussels, Belgium), and the Cellfree IL-2R
ELISA (T Cell Sciences, Cambridge, MA, USA). The TNFa-
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EASIA is a solid phase "Enzyme Amplified Sensitivity
Immuno-assay", which includes several mAbs against
different epitopes of the TNFa molecule to increase
sensitivity in a short incubation period. Standard
control or jejunal fluids were added to microtiter plates
coated with anti-TNFa. Following incubation at room
temperature, anti-TNFa-HRP conjugate was added. After
further incubation, the chromogen was added and the
plates were read within one hour. Concentrations are
extrapolated from the standard curve.
The Cellfree IL-2R ELISA kit is a sandwich enzyme
immunoassay that includes two anti-IL-2R murine
monoclonal antibodies. Standard control and jejunal
fluids were added to microtiter plates coated with an
anti-IL-2R mAb. After a second incubation with an
anti-IL-2R mAb enzyme-HRP conjugate and addition of a
chromogen, the ELISA-plate was read within an hour at 490
nm. Concentrations are extrapolated from the standard
curve.
In the IFNt-ELISA (developed by Louise Handy), plates
were coated overnight at 4° C, with anti-IFNr mAb
(Chromogenix AB, Molndal, Sweden), at dilution 1/50.
Other incubations were done at room temperature.
Duplicate standards and samples were added, and incubated
for 3 hours. The 1st British Standard for human leukocyte
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IFNr (NBSB, NIBSC, Potters Bar, UK) was double diluted
from 20-40 IU/ml. After overnight incubation with a
biotinylated mAb to IFNt (Chromogenix) at concentration
0.36 ug/ml; an ExtrAvidin Phosphatase conjugate (Sigma),
at dilution 1/2000, was added for 1 hour. The reaction
was visualized by adding 1 mg/ml of pnitrophenylphosphate
substrate (Sigma) in 10% buffer diethanolamine, with
plates shaking until standards OD reached 1.0 at 405 nm.
The test was sensitive for levels >4 Ul/ml of sample.
Sugar permeability test
A sample of urine was also collected from some patients,
to perform a 1actu1ose/rhamnose (L/R) jejunal
permeability test (MacDonald 1991). Concentrations of
lactulose and rhamnose in urine were assayed by High
Pressure Liquid Chromatography and the percentage of
lactulose and rhamnose excreted was expressed as the L/R
ratio. Normal values are < 0.040.
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B. JEJUNAL BIOPSIES
Counts of Intra-Epithelial Lymphocytes
A count was performed of lymphocytes within the villus or
surface epithelium in H & E sections with a Leitz
microscope and X100 immersion lens. At least 1000
enterocytes per biopsy were counted and the results were
expressed as numbers of lymphocytes per 100 villus
enterocytes, and normal values were considered to be
between 10-40 IEL per 100 villus enterocytes (Ferguson &
Murray 1971).
Counts of CD3 positive and of TCR tS positive IEL (series
C,D)
Serial 7 um cryostat sections mounted on poly-l-lysine
(Sigma, Poole, Dorset) coated slides, were dried, and
then fixed in fresh acetone for 30 minutes at room
temperature. After being rehydrated in Tris buffered
saline (TBS, pH 7.6) and blocked with rabbit serum
(Scottish antibody production Unit, SAPU, Carluke,
Scotland) in TBS, monoclonal antibodies were then applied
for 60 minutes: TCR-51 (T Cell Sciences, Cambridge, MA)
at dilution 1/80, or CD3 (SAPU) at dilution 1/20;
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followed by a Biotinylated rabbit anti-mouse IgG (DAKO,
High Wycombe, UK) at dilution 1/400, for 60 minutes. The
sections were treated with StrepABComplex (DAKO) for 60
minutes, and the reaction was visualized using
diaminobenzidine as a substrate. Sections were
counterstained with Gills number 1 haematoxylin. Optimal
dilutions were selected following pilot studies using
different antibody dilutions.
A Leitz-TAS plus computerized image analysis system,
with a TASIC software operating system, was used for cell
counts in frozen sections, and the results expressed as
total cell count per mm of villous epithelium. Only those
specimens in which at least 5 mm of epithelium could be
counted were considered technically acceptable. Details
of reference range derivation are presented below.
Counts of lamina propria plasma cells (series A)
An immunoperoxidase technique was used to stain
immunoglobulin-containing cells. Briefly, sections were
pre-treated with trypsin 0.1% in Tris buffered saline (pH
7.6) at 37® C for 20 minutes, and then serially incubated
with a primary antibody, sheep anti-human IgA or IgM
(at 1/250 and 1/200 dilutions, respectively); a secondary
antibody, affinity purified donkey anti-sheep/goat IgG
(at dilution 1/500); and a tertiary antibody, sheep
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peroxidase/anti-peroxidase (at dilution 1/80). All
incubations were carried out in a humid chamber at room
temperature for 60 minutes, and all antisera were
obtained from the Scottish Antibody Production Unit
(SAPU), Carluke, Scotland. Positive and negative controls
were included in each batch. Toluidine blue staining was
used for mucosal mast cells.
Cell counts were performed blinded using a Leitz
microscope with appropriate eyepieces and graticules,
calibrated with a stage micrometer. Only well orientated
sections were used, and fields were examined
systematically, starting with the base of the graticule
at the muscularis mucosae, counting sequential fields of
lamina propria vertically to the luminal surface, then
realigning the graticule on the muscularis mucosae and
continuing the process. Epithelium was excluded, and
where only part of a field comprised lamina propria, the
proportion was estimated by eye. At least 40 lamina
propria graticule fields were counted. The grid area with
a xlOO objective was 0.0132 square mm. The results were
expressed as numbers of positive cells per square mm of
lamina propria tissue (Arranz 1992).
Detection of HLA-DR, HLA-DQ and CD25 antigens in frozen
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sections
According to previous reports, cell activation in gut
mucosa may be manifest by HLA-DR expression by crypt
epithelial cells; and by high numbers of CD25+ T cells and
macrophage-1ike cells in lamina propria (Arnaud-
Battandier 1986, Scott 1987, MacDonald & Spencer 1988,
Haltensen & Brandtzaeg 1993 ) . The intensity and
distribution of HLA-DR+ cells in jejunal epithelium was
assessed in relationship to the finding of a high total
IEL count.
The immunohistochemical method is a three-stage
streptavidin/biotin alkaline phosphatase (AP) technique
with monoclonal antibodies (mAbs) to specific epitopes of
the HLA-DR, HLA-DQ, and CD25 molecules (Immunotech,
Marseille's, France). Sections were incubated with
optimal dilutions of primary mAbs (1/100) for 40 minutes,
then with a secondary antibody Biotinylated rabbit anti-
mouse immunoglobulins Fab2 (DAKO, High Wycombe, UK) at
dilution 1/300; and finally, treated with an
streptavidin/biotin complex AP (StrepABComplex DAKO) for
60 minutes. The reaction was visualized using Fast Red TR
AP-substrate (Sigma Chemical Co, Poole, Dorset, UK)
containing levamisole 1M (Sigma) to block endogenous
alkaline phosphatase, and N-N dimethylformamide. Sections
were counterstained with Gills number 1 haematoxilin.
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Sections were read blind on at least two different
occasions within two months, using a Leitz microscope and
appropriate objective lens, for a subjective evaluation
of the intensity, number and distribution of positive
cells. For every biopsy, sequential cryostat sections
stained for CD3 , HLA-DR, HLA-DQ, and CD25, were
evaluated, as well as two control sections, negative
(sequential section stained with the same protocol,
except the specific antibody) and positive (section from
an untreated coeliac patient). Staining results were
scored as negative (0), positive weak (1), strong (2),
very strong (3); and an estimate of the number of
positive cells was recorded by different areas of
distribution: villus epithelium (VE) , villus lamina
propria (VLP), crypt epithelium (CE), and pericryptal
area (CA).
Disaccharidase levels
If the biopsy specimen was large enough, a separate piece
of tissue was taken for assays of disaccharidases:
lactase, sucrase, maltase and trehalase (Dahlquist 1968) .
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C. STATISTICAL METHODS
The Student t test and the Mann-Whitney U test were used
respectively for comparing immunoglobulin and antibody
levels between groups; and the Spearman's test for
correlations between serum and jejunal fluid anti-GLI
antibody levels. P values of <0.05 were considered
significant. Differences in cell counts between groups
in series C,D, were assessed by the two-tailed Mann-
Whitney U test. Comparisons of frequency tables of







STUDIES IN JEJUNAL FLUIDS
Introduction
Jejunal fluid is an homogeneous secretion obtained under
controlled conditions from a point distal to the
duodenal-jejunal junction. Basically, intestinal fluid is
drained by gravity through the tubing of the Watson
biopsy capsule, and collected during a fixed period of
time (5 minutes) into a recipient tube which contains 20
ul/ml of the protease inhibitor phenylmethyl sulphonyl
fluoride (PMSF) at a concentration of 0.1 mol/1, to
preserve the protein content. Jejunal fluid is
transferred on ice to the laboratory and stored at - 70°
C within 10 minutes.
Many studies have been published on immunoglobulin and
antibody measurements in jejunal fluid aspirates, but
they are uncritical in assuming the validity of this
fluid as a local secretion, and also in the application
of immuno-assays (ELISA) and other tests previously used
in serum to jejunal fluid without adapting them to the
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special characteristics of this secretion. This chapter
brings together several technical and validation
experiments carried out on our samples.
Detection of sugar probes in jejunal fluids
Jejunal fluids are collected at the time of performing
the sugar permeability test (using two sugar probes,
lactulose and rhamnose). The question arose of whether
this procedure was technically correct, because the
probes might also be aspirated with the fluid. The
results, obtained from a group of 10 samples, suggest
that only 2-5% of the calculated amount given is found in
jejunal fluid aspirate. It is important to point out that
our normal values are based on individuals in whom a
sugar test is performed at the same time as jejunal fluid
collection. Therefore, if further work in other
conditions is to be carried out, normal ranges in jejunal
secretions would have to be re-calculated.
Jejunal fluids taken through the tubing of a biopsy
capsule may be different from those obtained in the
endoscopy theatre (fasting state). It is possible that
the latter are less diluted, and therefore they would
have a higher concentration of immunoglobulins or
antibodies. However, this will have to be investigated by
comparing samples from endoscopy and those taken by our
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routine procedure in the course of a diagnostic jejunal
biopsy.
Determination of plasma protein leakage: total protein,
and albumin and a-1 anti-trypsin levels
For a proper interpretation of the studies in jejunal
fluid, it was necessary to assess how much of the jejunal
fluid volume obtained is contibuted by plasma leakage,
and whether this was different in the various diagnostic
groups, such as coeliac disease or inflammatory bowel
disease (IBD). Others in our group (O'Mahony 1991b,
Brydon 1993) have developed assays for plasma derived
proteins, albumin and alpha-1 anti-trypsin, in whole gut
lavage fluid, and they were ready to be applied to
jejunal fluid specimens. Whole gut lavage fluid is a gut
perfusate with a rate of 20 ml/per minute. Normal ranges
for albumin (<1-26 ug/ml) and a-1 AT (<1-19 ug/ml) have
been described for gut lavage samples obtained from a
group of individuals with minor GI symptoms or considered
to be immunologically normal (Brydon 1993).
Intestinal secretions may contain IgG related to certain
diseases, and IgG seems to be a specific index of disease
activity in gut lavage fluid from IBD patients (O'Mahony
1991b, Choudari 1993). The IgG is probably derived from
plasma because of the correlation found between IgG and
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albumin levels. Faecal a-1 AT concentration and
clearance have been previously used as indices of gastro¬
intestinal protein loss.
- Description of cases, results and discussion
Total protein content, expressed as mg per ml of sample,
was tested in jejunal fluid specimens from 14 patients
(10 women, 4 men), 3 of them were treated coeliacs and
one was an untreated coeliac, one patient has DH, and 9
cases had other disorders (description of cases and
results are shown in Table IV.1). Albumin and a-1 AT
levels were tested in 36 patients (27 women, 9 men), of
whom 11 were coeliacs (5 untreated and 6 treated); 15
were non-coeliacs patients with a variety of GI diseases
such as IBD, idiopathic diarrhoea, or mouth ulcers; and
10 were patients who had a functional bowel disorder, or
in whom no diagnosis was reached after full investigation
(description of cases are shown in Table IV.2).
Reference ranges for jejunal fluid specimens were set up
using the group of 10 non-coeliac patients with minor GI
symptoms considered to also be immunologically normal.
This range was calculated using the 95% confidence
interval: 1-65 ug/ml for albumin and 1-21 ug/ml for a-1
AT. Results are shown in Table IV.3. Untreated coeliac
patients had higher albumin levels when compared to non-
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TABLE IV.1. DESCRIPTION OF CASES AND RESULTS OF TOTAL PROTEIN

































TABLE IV.2. DEMOGRAPHIC DATA OF PATIENTS STUDIED FOR ALBUMIN AND
a-1 ANTI-TRYPSIN IN JEJUNAL FLUID.
DIAGNOSIS (n) AGE SEX DIET HISTOLOGY






















MISC 3 30 3/- 3
(26-33)
NUT DEF 2 40 2/- 2
(25-55)
IBS 7 35.6 5/2 7
(20-59)
NAD 2 44.5 2/- 2
(21-55)
IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
GFD= gluten-free diet
Minor Changes= minor non-specific histological abnormalities
PTVA= severe partial, or total villus atrophy
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* Coeliac patients had higher albumin concentrations (p<0.001)
than control and organic disease groups.
Data expressed by mean, standard deviation (range values)
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coeliac patients with either an organic GI disease or
controls (both, p<0.01) This "normal" range for jejunal
fluid albumin is twice the value reported for whole gut
lavage samples, whereas a-l AT levels are similar in both
fluids. Protein concentration in jejunal fluid samples
studied ranged from 0.4 to 5.3 mg/ml (mean value 3.1).
Eleven of the 36 patients studied had albumin levels
above the upper range limit, these include 6 coeliac
patients (all 5 untreated, and one treated patient with
PVA). In coeliac disease, the results may be explained by
the existence of an increased intestinal permeability.
Five non-coeliac patients had high albumin levels (a
description of the non-coeliac cases is shown in Table
12) , 4 were CIA positive: 2 diagnosed as having
idiopathic diarrhoea and an abnormal permeability test;
one of gastritis and a high IEL count; one of recurrent
mouth ulcers; the fifth CIA negative case had ulcerative
colitis. Alpha-1 anti-trypsin levels were high in 4 non-
coeliac patients (Table 12): one patient had idiopathic
diarrhoea, a high level of jejunal fluid albumin, and an
abnormal permeability test; there were 2 IBD patients
(one had high albumin levels); and a woman with minor
symptoms who was convinced that she had multiple food
allergies, though we had no evidence to support this.
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TABLE IV.4. DESCRIPTION OF NON-COELIAC CASES WITH HIGH LEVELS OF
ALBUMIN AND a-1 ANTI-TRYPSIN IN JEJUNAL FLUID
DIAGNOSIS AGE BIOPSY
HISTOLOGY








































Measurement of Secretory IgA
The measurement of secretory IgA in jejunal fluids, as
the percentage of total IgA bound to secretory component
(SC), may serve as an indirect indication of local
immunoglobulin secretion, given that non secretory
component bound IgA, might be derived from serum leakage.
Secretory component is a transmembrane glycoprotein
receptor for polymeric immunoglobulins, synthesized and
expressed by intestinal epithelial cells (Brandtzaeg
1974; Brown 1976, 1977), that can also be found in
secretions as a free molecule or bound to polymeric
immunoglobulins (IgA and IgM) (Delacroix & Vaerman 1981).
Secretory IgA, IgM, and SC are antigenically different
for the specificities of the polyclonal antibodies used
in immunoassays. Human SC epitopes are differently
expressed in slgA, being more inaccessible because of the
covalent properties needed for binding and stabilization
of the molecule (Solari 1985). The presence of free SC
may be a problem in the measurement of secretory
immunoglobulins by immunoassay, because it might block
binding to the solid phase. Circulating free SC is almost
absent from serum (perhaps only detected in cases of
hypogamma-globulinaemia), and the different binding
properties of SC versus SC-IgA-bound, reduce the
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possibility of competition for the coated antisera in
serum estimations.
Free SC may also be a problem in the quantification of
slg in fluids by immunoassay, because this molecule may
compete with slgA for the binding sites on the solid
phase, and therefore it may give a reduced estimation of
the actual slgA concentration. When secretions are
tested, the inhibitory effects between SC-bound pigs may
be overcome by coating the microtiter plates with an
excess of anti-SC antibody, and reducing the level of
slgM and slgA by appropriate dilution; or by using an
anti-a chain as a coating antibody (Chapter VI) . Low
free-SC levels have been reported in most biological
fluids, such as sera, urine, whole saliva, and jejunal
fluid using specific coating mAbs (Vincent & Revillard
1988) .
Secretory IgM can be removed from intestinal secretion
samples by absorption using immunosorbent columns
containing specific anti-IgM antibodies (Bartholomeusz
1989). An alternative method coats microtiter plates with
specific anti-a chain antibody, or different mAbs
specific for slgA and slgM, then after binding uses an
anti-SC conjugate as a secondary antibody (Ishiguro
1981, Hjelt 1988).
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- Description of cases, results and discussion
A group of unselected jejunal fluid samples from 20
patients were tested for slgA as a percentage of the
total IgA concentration. These included 12 women and 8
men, with an age range of 15-67 (mean: 33.7); of whom 3
were coeliac or DH patients, 12 had other GI diseases
(IBD, idiopathic diarrhoea, nutritional deficiencies,
others), and in 5 cases no abnormality was detected after
further investigation. Description of cases and results
are shown in Table IV.5. Secretory IgA levels ranged from
58 to 98% of the total IgA, with a mean value of 74.7%
(SD 11.2). No significant differences were found when
CIA positive (8 cases, mean value of slgA: 75.4%), and
CIA negative patients (12 cases, mean value of slgA:
72.6), were compared.
Previous results using the same specific ELISA in a
population of elderly and control patients (Arranz 1992)
showed that almost all salivary IgA was bound to the SC
(99% of the total IgA concentration), the percentage
decreased to 70-90% in jejunal fluid, and it was even
lower in whole gut lavage samples (65%). Since leak of
plasma-derived proteins, such as albumin and a-1 anti¬
trypsin, was unusual, this 10-30% of unbound IgA detected
in jejunal fluid cannot be 7S-IgA (monomeric) derived
from plasma. However, it might be 10S
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TABLE IV.5. DESCRIPTION OF CASES AND RESULTS OF JEJUNAL FLUID
TOTAL IgA AND SECRETORY IgA AS PERCENTAGE OF THE TOTAL
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61 + Min chan
24 + Min chan
28 - Normal
15 - Normal
19 + Min chan
28 + Normal




















































Min Chan= high total IEL counts
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monomers) or lis (dimeric) IgA.
The results of antibody levels in jejunal fluids (see
Chapters VIII and IX) were broadly similar to those in
other intestinal secretions, eg whole gut lavage fluid;
and a positive correlation was found for IgA anti-gliadin
antibody levels in patients studied by both techniques
(O'Mahony 1991a). Immunoglobulin concentrations, however,
differed markedly in jejunal and gut lavage fluids,
whereas total IgA, IgM and IgG were elevated in jejunal
fluid from untreated coeliacs. Only IgM was significantly
elevated in gut lavage fluid. In this respect, whole gut
lavage samples are a less homogeneous fluid (it is likely
to contain gastric juice, bile, and secretions from
pancreas, small bowel, and colon), as compared to jejunal
fluid, which may reflect more accurately local immune
phenomena in the jejunum only.
Antigen-related terminal differentiation and expansion of
IgM and IgA B cells appear to be normal in non-coeliac
CIA positive patients. Trans-epithelial immunoglobulin
transport is also normal (Baklien 1977), indeed the
production of SC by epithelial cells is increased in
coeliac disease (Scott 1981). An abnormally high capacity
for transport of IgM and IgA across the epithelium might
produce the CIA pattern. However, this is not supported
by the finding of a similar proportion of jejunal fluid
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IgA bound to SC in CIA positive and CIA negative
samples. The pentameric IgM molecule may have a stronger
non-covalent interaction with SC than dimeric IgA
(Brandtzaeg 1985, Bouvet 1990). Thus, over-production of
IgM in the lamina propria may partially block the trans-
epithelial IgA transport, an explanation for the presence




HUMORAL SECRETORY IMMUNITY IN COELIAC DISEASE
Introduction
The initial part of this work, which involved the study
of intestinal humoral immunity in coeliac disease, was
done in collaboration with Dr Seamus O'Mahony, and we
worked together in laboratory testing and evaluation of
data. Previous studies in the literature had focused on
systemic humoral immune responses, whereas information on
local mucosal immunity was scarce. Circumstantial
evidence of the existence of a local cell mediated
response to gluten, had been reported (MacDonald &
Ferguson 1975). Immunohistochemical studies showed that
untreated coeliac patients had increased numbers of IgA
and IgM jejunal plasma cells, but also IgG (Baklien 1977,
Wood 1987) ; and coeliac children had antibodies to
dietary antigens in intestinal secretions (LaBrooy 1986,
Volta 1988).
The aim of the study was to characterize the secretory
antibody responses in vivo, and establish type-specific
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values for total immunoglobulins and antibodies to gliadin
and other common dietary antigens in well characterized
groups of treated and untreated coeliacs and non-coeliac
controls. The results were evaluated to determine if the
changes observed were intrinsic and due to a primary
abnormality in coeliac intestinal immunity (eg found in
treated and untreated patients) or, on the other hand, if
the changes were secondary to the lesion (eg only in
untreated patients). Eventually, systemic and mucosal
immune responses (serum vs jejunal fluid samples) were
compared to test the value of these local secretions in
the study of GI immunity in coeliac disease and other
disorders.
Immunoglobulin concentrations in sera and jejunal fluids
No significant differences were observed in serum samples
when coeliac patients and controls were compared.
However, untreated coeliacs had significantly higher
jejunal fluid concentrations of IgA, IgM and IgG when
compared to controls, and higher IgM when compared to
treated coeliacs (Table V.l). Values for treated
coeliacs were not significantly different from controls.
Of interest is the fact that the IgM content in gut
lavage fluid was also found to be significantly higher
than controls in both untreated and treated coeliacs
(0'Mahony 1991a).
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JEJUNAL IgA *290(25-2285) 140.7(20-1558) 102.5(23-540.6
FLUID
(ug/ml) IgM *+29.8(1.9-358) 9.6(0-174) 4.5(0-39.5)
IgG *23.9(3-261.8) 11.8(0.3-271.4) 7.3(1.2-29.3)
immunoglobulin concentration higher (p<0.05) than in controls
+Immunoglobulin concentration higher (p<0.05) than in treated
coeliacs
Data expressed by median and range values
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Food antibody levels in serum and jejunal fluid samples
High levels of serum IgA anti-gliadin antibody were found
in untreated coeliacs, whereas treated coeliacs have
similar values to controls. Both untreated and treated
coeliacs had high levels of serum IgG anti-gliadin
antibody, with significantly higher levels in the
untreated group. There were no significant differences
between patient groups in levels of serum IgM antibodies.
Patterns of serum antibodies to BLG and OVA were
generally similar to those for anti-gliadin antibody
(Table V.2). Untreated coeliacs had high values for IgA
anti-BLG and anti-OVA and IgG anti-BLG antibody. Serum
IgA anti-BLG and IgG anti-OVA antibody levels were higher
in treated coeliacs than controls.
In jejunal fluids, there was very little antibody
detected in samples from controls, but as detailed in
Table V.3, for all 3 isotypes, and all 3 antigens
studied, levels of antibody were significantly higher in
jejunal fluids from untreated coeliacs than in controls
(p<0.02 for all). For anti-gliadin antibodies, levels in
treated coeliacs were intermediate between untreated
coeliacs and controls and significantly different from
both. When antibody levels in the 11 treated patients
with entirely normal jejunal histology were compared with
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*Antibody values higher (p<0.05) than in controls
+Antibody values higher (p<0.05) than in treated coeliacs
BLG=betalactoglobulin
OVA=ovalbumin
Data expressed by median and range values
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*Antibody values higher (p<0.05) than in controls
+Antibody values higher (p<0.05) than in treated coeliacs
BLG=betalactoglobulin
OVA=ovalbumin
Data expressed by median and range values
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controls, IgA anti-gliadin antibody levels were not
significantly higher. Conversely, levels of IgM anti-
gliadin antibody remained significantly elevated
(p<0.005) in this group. Antibodies to BLG and OVA showed
a greater overlap between levels in coeliacs and
controls, but again high levels of IgM antibodies
persisted in the treated patients. Jejunal fluid IgA and
IgM anti-gliadin antibody levels are shown in Figure V.l.
Serial studies in coeliac patients
Seven coeliac patients who had a clinical and
histological response to a GFD were studied before and
after treatment. Serial changes in serum IgA anti-gliadin
antibody and jejunal fluid IgA and IgM anti-gliadin
antibodies are shown in Figure V.2. Whereas serum
antibody levels fell significantly (p<0.05) with
treatment, there was no significant change in levels of
intestinal antibody despite histological recovery on a
GFD. It should be noted that these 7 patients had been
taking a GFD for 6 months or less; this may account for
the fact that they have different results from other
treated coeliac patients on a GFD for a longer period,
who had significantly lower jejunal fluid antibody levels



































A Treated coctiac patients with minor jejunal histological changes
• Treated coeliac patient with entirely normal jejunal histology
Figure V.l: Jejunal fluid IgA and IgM anti-gliadin antibody
values (mean antibody values shown as horizontal bars).
UCD=untreated coeliacs, TCD=treated coeliacs, C=controls
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Figure V.2: Serial changes in values of serum anti-gliadin
antibody and jejunal fluid IgA and IgM anti-gliadin antibodies in
7 coeliac disease patients before and after treatment with GFD.
ND= normal diet; GFD= gluten-free diet.
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Correlations between antibody levels in serum and jejunal
fluids
IgA anti-gliadin antibody levels were compared in serum
and jejunal fluid samples. In the untreated coeliacs, we
found a positive correlation between antibody levels in
serum and jejunal fluid (r=0.68, p<0.0001) but in the
treated coeliacs, this correlation was not maintained, as
treated coeliacs had high levels of jejunal fluid
antibody, whereas serum antibody levels were low or
absent.
Discussion and implications of these results
Intestinal anti-gliadin antibodies in coeliac patients
are mainly of the IgA and IgM classes, and significant
amounts of IgM antibody persisted in the secretions of
treated coeliacs with entirely normal jejunal histology.
Secreted IgA antibody was detected only in the subgroup
of treated coeliacs with minor histological
abnormalities, most of whom had been less than a year on
treatment. It is possible that the intestinal IgA anti-
gliadin antibody and minor histological changes could
both be due to continued ingestion of small amounts of
gluten. Conversely, intestinal IgM antibody levels
remained higher than controls even in patients with
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completely normal jejunal mucosa who had been taking a
GFD for some years. It is likely that minute amounts of
gluten maintain a local immune response rather than a
systemic one. The finding of a persistent IgM antibody
response parallels the finding of a relatively high
fraction of IgM+ plasma cells in treated coeliacs
(Baklien 1977; Scott 1984, 1992).
Concentrations of IgA, IgM and IgG were all high in
jejunal fluids from untreated coeliacs. Counts of jejunal
plasma cells and in-vitro immunoglobulin production in
coeliac disease are higher than in controls for all
isotypes (Lancaster-Smith 1976, Scott 1984, Wood 1987),
supporting the view that the immunoglobulins (at least
IgA and IgM) in coeliac intestinal secretions are
produced locally. It is likely that most of the jejunal
IgG is plasma-derived, as numbers of IgG-secreting plasma
cells are low even in untreated coeliac disease (Baklien
1977). It should be pointed out that immunoglobulin
measured in jejunal fluid is total immunoglobulin, and
not specific secretory IgA and IgM. It is conceivable
that at least some of the jejunal IgA and IgM is serum-
derived (coeliac disease is a protein-losing disorder).
Other studies have been performed to characterize
jejunal immunoglobulins and antibodies in terms of
molecular weight and percentage of total Ig which
contains SC. Elevation of intestinal fluid immunoglobulin
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content was not accompanied by equivalent changes in
serum immunoglobulins; in fact, serum IgM content was
markedly low in some untreated coeliacs.
In any event, enhanced intestinal antibody production in
coeliac disease is not limited to gluten-derived
proteins. High levels of intestinal antibody to BLG and
OVA in untreated coeliacs were also found, with
persistence of IgM antibody to these proteins in treated
coeliacs. Antibodies to these food proteins were less
specific to coeliac disease than anti-gliadin antibodies.
It has been suggested that high levels of serum antibody
to these proteins in untreated coeliacs are simply the
result of increased intestinal permeability to antigens.
Although ELISA is now accepted as the standard assay
technique for measuring antibodies to food proteins in
coeliac disease, several different ELISA methods have
been described, and different reference preparations are
used by each group of investigators. The method employed
is essentially similar to one previously reported
(Savilahti 1983), and I used crude gliadin (instead of a-
gliadin) as antigen for the ELISA, as others (Skerrit
1987) have shown that sera and intestinal fluid from
coeliac patients contain antibodies which bind to
several different gliadin subunits. Levels of positivity
or negativity have not been ascribed to antibody levels;
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such arbitrary designations are of some value in
screening tests used in clinical practice but not in
prospective research investigations.
It is notable that antibody findings in jejunal fluids
were broadly similar to those in other intestinal
secretions, eg gut lavage fluid; and a positive
correlation was found for IgA anti-gliadin antibody
levels in patients studied by both techniques (O'Mahony
1991a). Immunoglobulin concentrations, however, differed
markedly in jejunal and gut lavage fluids, all 3
immunoglobulin isotypes were elevated in jejunal fluid in
the untreated coeliacs, whereas only IgM was
significantly elevated in gut lavage fluid. Gut lavage
fluid is likely to contain secretions not only from the
small bowel, but also gastric juice, bile, pancreatic
secretions and colonic secretions. In this respect, it is
not a homogeneous fluid, unlike jejunal fluid, which
reflects events in the jejunum only, and is thus more
likely to represent accuratelly local immune phenomena in
coeliac disease. Fluid flow rate is another factor which
may influence immunoglobulin levels in exocrine
secretions; this may partly account for differences in
findings in jejunal and whole gut lavage fluids.
The results of this preliminary study in coeliac patients
lead to the definition of a "coeliac-like intestinal
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antibody" (CIA) pattern, as the presence in jejunal fluid
of IgM anti-gliadin together with at least two of the
three other characteristic antibodies, IgA anti-GLI, IgM
anti-OVA and IgM anti-BLG.
The study also demonstrates the virtual independence of
systemic and intestinal humoral immune responses, and
shows that for the study of immunopathology of intestinal
disease, direct investigation of the gut is mandatory.
This intestinal antibody pattern persists during strict
gluten exclusion in coeliac patients. The finding of a
similar antibody pattern in DH patients without
enteropathy (O'Mahony 1990a), suggests that non-DH latent
coeliacs might also be CIA positive.
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CHAPTER VI
HUMORAL SECRETORY IMMUNITY IN SYMPTOMATIC PATIENTS
REFERRED AT THE G.I. UNIT
Introduction
It has been shown in the previous chapter that treated
coeliacs with healed mucosa have a similar pattern of
intestinal antibodies to untreated coeliacs. A similar
pattern has been described in DH patients without
enteropathy (O'Mahony 1990a). It was thought that this
antibody pattern might recognize latent coeliac disease
amongst non-coeliac patients. Between 200-250 patients
per year are referred to this unit for diagnostic small
bowel investigations, under the suspicion of coeliac
disease. In order to facilitate research on latent
coeliac disease, I organized the collection of specimens
of serum and jejunal fluid at the same time as the
jejunal biopsy was taken. Eventually, the majority of
these patients are found to have a morphologically normal
biopsy, or only an unexplained high IEL count.
I studied the expression of the coeliac-like intestinal
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antibody - CIA - pattern in this prospective cohort of
non-coeliac patients, to assess its frequency in this
total population and also its relative expression by
different non-coeliac diagnostic groups. Of potential
interest was to find out if cases of gluten-sensitivity
in which classical enteropathy was not present, might be
found in this way. However, in this part of my work, I
studied only the presence of the CIA pattern and how it
related to serum anti-gliadin antibodies; studies of
clinical gluten sensitivity were carried out separately.
Characterization of the CIA pattern
The "coeliac-like intestinal antibody" (CIA) pattern was
defined as the presence in jejunal fluid of IgM anti-GLI
together with at least two of the three other
characteristic antibodies, IgA anti-GLI, IgM anti-OVA and
IgM anti-BLG. This antibody pattern does not correlate
with antibody levels in serum, when samples of jejunal
fluid and serum are compared in the same patient.
Anti-gliadin antibody levels in sera, series A
Serum samples, collected at the time of jejunal biopsy,
were available for 137 of the 140 cases studied. Levels
of serum IgA and IgG anti-gliadin antibodies are shown in


















• Patients on normal diet
o Patients on gluten free diet
Diagnostic groups
Figure VI.1: Serum IgA antigliadin antibody levels in patients
grouped by final diagnosis (Normal range is shaded).
128
Diagnostic groups
• Patients on normal diet
o Patients on gluten free diet
Figure VI.2: Serum IgG antigliadin antibody levels in patients
grouped by final diagnosis (Normal range is shaded).
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had high levels of serum IgA anti-gliadin, as did 9 of
the 21 coeliacs on a GFD. Of the 5 new DH cases, two had
high serum IgA anti-gliadin, and one had high serum IgG
anti-gliadin. Fourteen of the 96 non-coeliac, non DH
cases also had IgA anti-gliadin values above 0.20, but,
as illustrated, in only one was the level particularly
high, a man with alcoholic cirrhosis. In contrast,
detectable serum IgG anti-gliadin was present in the
majority of patients and although a high value was found
in 10 of 14 untreated coeliacs, high values were also
present in 24 of 96 non-coeliac, non-DH cases.
Food protein antibodies in jejunal fluids, series A
The CIA pattern was present in 13 of 14 newly-presenting
coeliacs, and in 4 of the 5 new DH patients. Clinical,
biopsy and immunological information on the two CIA
negative cases are presented in Table VI.1; there were
no unusual clinical features but it is of interest that
the coeliac patient, who had classical enteropathy, also
had a classical coeliac HLA phenotype, whereas this was
not the case for the DH patient, whose jejunal mucosa was
normal. Of the 22 coeliacs and one DH patient on GFD, the
frequency of the CIA positive pattern was 69.5%, and 16
of the 98 non-coeliac patients (16.3%) were CIA positive.
Results of assays of intestinal fluid IgA and IgM anti-
gliadin antibodies are shown in Figures VI.3 and 4.
130
TABLE VI.1. CLINICAL, PATHOLOGICAL AND IMMUNOLOGICAL DETAILS OF
TWO PATIENTS (COELIAC AND DH) ON NORMAL DIET, NEGATIVE FOR THE
CIA PATTERN.
























/100 enterocytes) 35 40 32
LACTULOSE/RHAMNOSE
PERMEABILITY TEST 0.14* 0. 034 0.02
SERUM: IgA-AGA 25.8* 8.7 4 . 8
IgG-AGA 51.0* 35.0 23 . 1
JEJUNAL FLUID:
T.IgA(ng/ml) 11.5 19. 1 32.7
T.IgM(ng/ml) 1.4 1.5 0.7
IgA-AGA 2 . 2 3 . 9 6.4
IgM-AGA 6 . 1 7 . 8 8 . 2




























• Patients on normal diet
o Patients on gluten tree diet




Figure VI.3: Jejunal fluid IgA antigliadin antibody levels




• Patients on normal diet
o Patients on gluten free diet
Figure VI.4: Jejunal fluid IgM antigliadin antibody levels in
patients grouped by final diagnosis (Normal range is shaded).
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Classification by intestinal antibody pattern, series A
The 140 patients were also subdivided by intestinal
antibody findings into four groups: COE/CIA+ and COE/CIA-
coeliacs and DH patients, who did (33 cases) or did not
(9 cases) express the CIA pattern; OTH/CIA+ and OTH/CIA-,
patients with other diagnoses who did (16 cases) or did
not (82 cases) express the CIA pattern.
Immunoglobulin concentrations in jejunal fluids, series A
As shown in Table VI.2, concentrations of IgA and IgM in
jejunal fluid were generally higher in coeliac and DH
patients on a normal diet than in other diagnostic
groups. When the patients were subdivided according to
intestinal antibody patterns, it emerged that the two
subsets with positive CIA patterns, COE/CIA+ and
OTH/CIA+, had significantly higher concentrations of IgM
than the CIA negative cases, irrespective of diagnosis.
Total IgA concentrations were higher in the OTH/CIA+
group than in the other subsets.
Serum anti-gliadin antibodies and the intestinal antibody
pattern, series A
There were no differences in the levels of serum
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TABLE VI.2. IMMUNOGLOBULIN CONCENTRATIONS IN JEJUNAL FLUID.













































































































Data expressed as mean value, and standard deviation
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antibodies between the CIA positive and CIA negative
non-coeliac groups. In other words, high levels of serum
anti-gliadin correlated with the presence or absence of
gluten-sensitive enteropathy, but not with intestinal
antibody levels.
Clinical details of CIA positive non-coeliac patients,
series A
Details of diagnosis, reason for the biopsy and other
studies performed in the group of 16 non-coeliac, non-DH
cases in series A, positive for the intestinal antibody
pattern, are presented in Table VI.3. In six cases the
total IEL count was high, whereas in five of these other
features of the biopsies were normal, one man had minor,
non-specific abnormalities with short villi. Minor
abnormalities of the mucosa were also present in two
cases with normal IEL counts. The sugar permeability test
was abnormal in only five cases, including the three with
minor histological abnormalities.
Intestinal antibody pattern in series B
Jejunal fluid antibody levels were measured in a further
119 non-coeliac patients with normal jejunal biopsy
histology. Positive CIA patterns were present in 2 of 8
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idiopathic diarrhoea, 3 of 12 with mouth ulcers, 6 of 34
with various other diagnoses, 3 of 7 with nutrient
deficiencies, one of 18 with irritable bowel syndrome and
3 of 14 with no abnormality detected.
Discussion and implications of these results
It has been shown previously that DH patients without
mucosal involvement are also CIA positive (O'Mahony
1990a), and thus this pattern might provide a diagnostic
test for latent coeliac disease in other situations. In
this prospective study, 40 of 217 non-coeliac patients
(series A + B) have a CIA positive pattern (20-30% of all
referred for diagnostic biopsy); 14 of these also had
other minor mucosal abnormalities (eg high IEL counts)
and thus clearly have intestinal pathology at the mild
end of the spectrum of gluten-sensitive enteropathy
(Marsh 1989a, 1992). However, in contrast to DH latent
coeliacs, most of these patients had symptoms suggestive
of small bowel disease. Thus, quite apart from the
theoretical interest in such patients, there is an
important practical issue as to whether their diagnoses
and management should be revised, and a GFD now
prescribed.
It is now clear that CIA positive specimens also contain
high concentrations of total IgM, in keeping with the
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over-expression of IgM in the intestinal mucosa of
coeliacs (Baklien 1977, Scott 1984, Dhesi 1984, Ciclitira
1986b, Wood 1987, Crabtree 1989a, Lavo 1992). This is not
limited to food protein antibodies. In a recent
investigation of intestinal immune responses to an
enteric vaccine, coeliacs generated high levels of
intestinal IgM antibodies to a bacterial antigen, Cholera
toxin B subunit (O'Mahony 1990b).
From the assessment of the CIA expression by diagnostic
groups, it is also interesting to point out that one of
14 newly-presenting coeliacs was CIA negative. Two of
the eight cases of DH without enteropathy previously
studied by us were also CIA negative (O'Mahony 1990a), as
was one DH case without enteropathy in the present
series. The fact that she lacked the HLA haplotype
characteristic of coeliac disease (and was DR4 positive,
as are other such atypical coeliacs) (Sachs 1986) may be
important, and highlights the possibility that
differences between patients in their intestinal
expression of gluten-sensitivity, or in their mucosal
immune responses, may have a genetic basis. It has been
suggested that there may be separate genetic factors
which regulate the capacity for gluten sensitization on
the one hand, and a susceptibility to develop severe
enteropathy in the expression of mucosal T cell mediated
immunity on the other (Troncone & Ferguson 1991a).
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Since this antibody pattern persists during strict gluten
exclusion, the theory that it reflects a polyclonal
response to lectin-like stimulation by gliadin cannot be
sustained. Mucosal immunity is characterized by an overall
down-regulation of isotypes other than IgA (Brandtzaeg
1991). The general increase in the IgM component of
intestinal immunity which I have described could reflect
a primary disorder of the B cell population (ie an
abundance of "polyreactive" CD5+ B cells); an aberrant
function of the T cell subsets which control the early
stages of B cell development (ie suppressor T cell
dysfunction) (Corazza 1986, Pignata 1985), or over¬
activity of local helper T cells (Troncone & Ferguson
1991a); or the existence of an unusual immunostimulant
operating in mucosa.
The unusual up-regulation of IgM secretory responses may
be an independent factor, perhaps genetically determined,
reflecting a state of immunological hyper-responsiveness
to many local stimuli, and relevant to the induction of a
state of aberrant immunity to gluten. Similar findings
have been obtained in some immuno-deficiencies (Geha
1979) with high serum IgM titres, signs of T cell
activation such as high levels of soluble IL-2R in
plasma, and high number of HLA-DR+ cells; and other
autoimmune phenomena which often have a genetic basis.
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Non-coeliac CIA positive patients seem to have a
dysbalance of lamina propria plasma cells, manifested by
an increased number of IgM-containing cells.
Alternatively, an immunoregulatory T cell-related
disturbance may determine an altered pattern of cytokine
production which might lead to the persistence of some
mucosal abnormalities; eg polyclonal IgM secretion by B
cells without antigen, or terminal differentiation of IgM+
B cells, induced by IL-5 and IL-6.
Antigen-related terminal differentiation and expansion of
IgM and IgA B cells appear to be normal. Trans-
epithelial immunoglobulin transport is also normal
(Baklien 1977), indeed the production of SC by epithelial
cells is increased in coeliac disease (Scott 1981). An
abnormally high capacity for transport of IgM and IgA
across the epithelium might produce the CIA pattern.
However, I have examined the molecular forms of jejunal
fluid IgA (with and without SC) and found no differences
between CIA positive and CIA negative specimens (Chapter
VII) . It has been suggested that the affinity for the SC
of IgM is much higher than dimeric IgA. Thus over¬
production of IgM in the lamina propria may partially
block trans-epithelial IgA transport - an explanation for
the presence of dimeric IgA in the serum in coeliac
disease (Troncone 1991b).
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According to the new putative roles suggested for IgA in
mucosal immunity (Mazanec 1993), this immunoglobulin may
be involved in the excretion of immune-complexes (IC) and
other potentially damaging products from intestinal
mucosa. However, IgM-IC are not so easily removed, and
high titers of secretory IgM antibodies, found in CIA
positive patients, may form large IC with antigen, more
difficult to be excreted into the lumen, contributing to
maintaining the antigen for a longer time in the lamina
propria, and therefore increasing the possibility of
antigen stimulation. Moreover, IgM may activate
complement, leading to a cascade of other inflammatory
reactions, and the immuno-complexes formed may reach the
capillaries and the systemic circulation.
Positivity for the CIA pattern is shown by almost 20% of
patients referred for diagnostic biopsy, and its
frequency is similar amongst different diagnostic groups.
Some of these patients had gut symptoms, but there is a
proportion in whom no abnormality was detected. Screening
for jejunal fluid antibodies is a simple procedure that
may identify patients susceptible of being followed up




JEJUNAL MUCOSA STUDIES IN SYMPTOMATIC PATIENTS REFERRED
AT THE G.I. UNIT
Introduction
In the course of the study of secretory antibody patterns
in non-coeliac patients referred for diagnostic jejunal
biopsy, a report was published which showed a high tS IEL
count in an histologically normal stored biopsy of an
individual who later developed an enteropathy (Maki
1991a). Looking for other putative markers of latent
coeliac disease in the same non-coeliac population, I
thus set up arrangements to obtain material suitable for
frozen sections from jejunal biopsies collected at the
time of fluid sampling, in order to address the question
of whether non-coeliac CIA positive patients also had a
high density of tS+ IELs.
Given that the reason for investigating these patients
was the existence of small bowel symptoms and therefore
the suspicion of coeliac disease; the question arose of
whether the expression of these mucosal abnormalities (eg
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high tS+ IEL counts) might occur in the non-coeliac
population as a whole. To address this, I also collected
duodenal biopsies from an unselected group of patients
attending for upper endoscopy, to study tS+ cells in
epithelium.
It was of practical interest was to compare two
techniques for counting IELs, the conventional count
expressed as a total IEL number per 100 enterocytes,
using formalin-fixed, H & E paraffin sections of jejunal
mucosa; and CD3+ and tS+ IEL analysis of frozen sections
of jejunal mucosa stained by appropriate monoclonal
antibodies.
I assessed other possible relationships with the CIA
pattern, and the co-expression of potential markers in
particular cases, eg abnormal intestinal permeability
test, serum antibodies, etc. Positive ARA/AEm antibodies
of IgA class have been reported in latent coeliac
patients (Maki 1990), and in collaboration with this
author, all patients in series C and other cases with
different patterns of expression of potential markers,
have been assessed for these serum antibodies.
Intraepithelial lymphocyte counts, series A and B
With the technique used the normal range is 10-40 IEL per
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100 villus enterocytes, and virtually all untreated
coeliacs have abnormally high counts within the flat
surface epithelium (eg results in our studies of four
separate groups of patients have ranged from 44-180 IEL
per 100 enterocytes) (Ferguson & Murray 1971, 1976;
Ziegler & Ferguson 1984, Ferguson & Ziegler 1986).
Results for biopsies from patients in series A and B are
shown in Figure VII.1. Abnormally high counts were
present in one (CIA positive) of 7 treated coeliacs, in 3
of the 4 DH patients (all three were CIA positive), and
in 15 patients with other diagnoses. Fourteen of these
were CIA positive cases; IEL count was high in only one
CIA negative non-coeliac patient, a woman with colonic
Crohn's disease.
Reference values for t<S+ IEL counts, series C and D
A subset of 34 jejunal biopsy patients, immunologically
normal, was used to establish reference ranges for
jejunal CD3+ IEL cells and tS+ IEL counts per mm
epithelium. There were 16 with IBS, 14 with trivial or
transient disorders and 4 in whom no abnormality had been
detected. Reference values for the upper limit of normal
(mean + 2SD) thus obtained were 67.5 CD3+ IEL per mm
epithelium and 5.5 t6+ IEL per mm epithelium,
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Figure VII.1: Intraepithelial lymphocyte counts in jejunal
biopsies from 94 patients, reported as normal or with minor
histological changes (Normal range 10-40 lymphocytes per 100
villus enterocytes).
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Figure VII.2: Serial cryostat sections of jejunum from a non-
coeliac patient with high total IEL count. Immunoperoxidase
staining of intra-epithelial lymphocytes with antibodies to CD3
(Figure 9a) and to TCR 51 (Figure 9b).
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CD3+ and tS+ IEL is shown in Figure VII.2. The results
for tS+ IEL counts are presented as the unmodified count
per unit length of surface villus epithelium, taking
counts >5.5 tS+ cells per mm of epithelium as abnormally
high (Table VII.1). Fourteen of the biopsies from
coeliacs had abnormally high tS+ IEL counts. The
remaining patient (normal mucosa, on a GFD, with no
unusual clinical features) had a normal count; his data
is presented separately from the other cases.
There were significant differences between the reference
values obtained for CD3+ cells in duodenal and jejunal
specimens (Table VII.1), with values for duodenum (mean
19.4 CD 3 + per mm epithelium) significantly lower
(p<0.001) than for jejunum. However, tS+ cell counts per
mm of epithelium were similar in the two sites. There was
one endoscopy patient (a woman with an uncomplicated
gastric ulcer) who had a strikingly high tS+ cell count
at 24 per mm of epithelium; in other respects her
duodenal biopsy was normal.
Comparison of CD3+ and Total IEL counts, series C and D
The material examined from the 77 non-coeliac patients
in the present series allows a comparison of the two
techniques of IEL counts: in H & E stained sections,
using a conventional light microscope, and with results
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TABLE VII.1. VALUES FOR CD3+ and TCR tS+ CELL COUNTS IN VILLOUS
EPITHELIUM
CD3+ CELLS TCR t/S CELLS
PER MM PER MM
Coeliac patients +69.2 ,32.9 +21.5 , 16.7
(n=15) (31.9-120) (5.5-66)
Atypical case 42.2 0.2
Control group
Jejunal biopsy patients *33.7 , 16.9 1.5 , 2
(n=77) (6-68.7) (0-7.4)
Duodenal biopsy patients 19.4 , 11.4 1.5 , 4.7
(n=26) (2.3-45.9) (0-24.4)
Excluding
atypical case 18.4 , 10.3 0.6 , 0.6
(2.3-44.1) (0-2.5)
* CD3+ cell counts were higher in the control group (p<0.001)
than in duodenal biopsy patients.
+ Coeliac patients had higher CD3+ and TCR tS+ counts (p<0.001)
than both controls and duodenal biopsy patients.
Data expressed as the mean, standard deviation (range values)
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expressed as number of IEL per 100 enterocytes; and in
frozen sections and image analysis where counts are
expressed as CD3+ cells per mm of epithelium. As shown
in Figure VII.3, there was a highly significant
correlation between IEL counts in paraffin sections and
CD3 + cell counts in frozen sections (r=0.771, p<0.001).
All cases with high CD3+ cell counts had high IELs, but
there were 7 cases with high IEL count, normal CD3+ cell
count, suggesting that an non-T subset of lymphocytes may
be present in the epithelium of these patients.
Positive markers of potential coeliac disease, series C
Results for these 77 non-coeliac patients subdivided into
diagnostic groups, are summarized in Table VII.2. The CIA
pattern of jejunal fluid antibodies was present in 21
patients. There were 9 patients with high counts of tS+
IEL in the villus epithelium, and conventional IEL counts
were high in 13 cases. High titers of serum IgA anti-
gliadin antibodies were present in 12 patients, with no
obvious relationship with diagnostic groups or the other
markers, except for the sugar permeability test (p<0.05),
which was abnormal in 9 cases, mainly those with mild
abnormalities of jejunal pathology or with IBD.
Associations between the CIA pattern, high tS+ cell









































Figure VII.3: Intra-epithelial lymphocyte counts in 77 pairs of
jejunal biopsy specimens. Total IEL counts in paraffin sections
are expressed as IEL per 100 villus enterocytes; CD3+ cell counts
in frozen sections are expressed as cells per mm length of villus
epithelium.
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TABLE VII.2. DIAGNOSTIC GROUPS: NUMBERS OF CASES POSITIVE FOR
CANDIDATE MARKERS OF LATENT COELIAC DISEASE.
FINAL (n) CIA+ HIGH T/S HIGH IEL ABN.L/R HIGH SERUM
DIAGNOSIS CASES COUNTS COUNTS TEST AGA LEVELS
NOT COE 4 2 1 1
FH 4 1 1
IBD 6 2 1 4 2
DIA IDIO 14 4 3 4 1 2
ORAL ULC 4 2 1 2 1 1
MISC 19 4 2 2 3
NUT DEF 4 2 1 1
IBS 16 3 2 1 2
NAD 6 1 3 1
COE. N diet 1 1 1 not done 1 1
Glu ch 1 1 1 not done 1 1
GFD 13 8 12 not done 6 4
ABN.L/R=abnormal lactulose/rhamnose permeability test
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diagrammatically in Figure VII.4. High tS+ IEL counts
were found in 6 of the 21 CIA positive patients, but only
in 2 of 56 CIA negative (p<0.001) ; there were no
significant associations in any other marker
combinations. A high total IEL count was more frequent in
CIA positive patients (5 of 21), than in patients
negative for the CIA pattern (8 of 56) , but the
difference was not significant.
There were 31 patients with one or more positive result,
but in 19 only a single test was abnormal. Of particular
interest are patients with three parameters positive: CIA
pattern, tS+ IEL count and total IEL count. Two of the
three have been shown to be gluten-sensitive after a
trial of a GFD (see Chapter X) . In one case, the
diarrhoea resolved within 2 weeks of gluten restriction
and a normal IEL count was found in a biopsy taken 2
months later. In the second case, she noticed some
improvement of her recurrent aphthous ulceration but took
the diet for only five weeks. Several months later, when
a high count of tS+ IEL was found in a stored biopsy
specimen, she agreed to take an extra 10 g of gluten
daily for a month and had another jejunal biopsy.
Pathological examination revealed STVA.
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Anti-reticulin and anti-endomysium antibodies
A description of the patients studied is shown in Table
VII.3. Serum antibody levels were positive in 2 of the 6
coeliacs studied (both on a gluten-containing diet, and
showing PVA). Amongst non-coeliac patients, there were 6
positive cases: two had very low levels (eczema, and
Crohn's disease) and both were negative for other
putative markers. A third case had only high ARA levels,
and borderline counts for both total IEL and tS+ IELs (39
per 100 enterocytes, and 6.5 cells per mm of epithelium).
Of the other 3 cases, two (idiopathic diarrhoea,
recurrent mouth ulcers) were positive for the full set of
markers of potential coeliac disease, CIA pattern, high
counts of total and tS+ IELs. Both responded clinically
to a trial of GFD, and one is the case who developed an
enteropathy after adding extra gluten to her already
normal diet. The third non-coeliac positive case was
previously incorrectly diagnosed as having coeliac
disease (without a positive biopsy), and had low tS+ IEL
counts.
Discussion and implications of these results
I have presented the results of a potential way of
identifying patients who may have latent coeliac disease,
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by the expression of a characteristic CIA pattern in
jejunal fluid (see Chapter VI). It was shown that 14 of
the 40 non-coeliac CIA positive patients also had a high
IEL count, and therefore they have intestinal pathology
at the mild end of the spectrum of gluten-sensitive
enteropathy (Marsh 1989a, 1992). Latent (or low-grade)
coeliac disease may also be recognized by studies of TCR
tS expression by IEL, which have been found to be
increased in DH patients and in a case of latent coeliac
disease detected during a family study (Savilahti 1990,
1992; Maki 1991a). Up to 30% of coeliac relatives with
normal biopsy histology had high tS IEL counts, and the
number of positive tS cells is associated with the HLA-
DQa/B gene markers in a dose dependent manner (Holm 1992,
1993b). Healthy first degree relatives of coeliac
patients may have ARA and AEm antibodies (Maki 1990); and
also changes in intestinal permeability (Bjarnason 1983).
These results, together with in-vivo gluten challenge
studies in coeliac patients (see Chapter X), indicate
that the expression of gluten hypersensitivity as
enteropathy may be minimal, measurable only if a count of
IEL is performed. An accepted name for this type of
pathology is needed, such as "high IEL mild enteropathy"
(Ferguson 1993). This must be clearly differentiated from
low-grade or other forms of non-coeliac enteropathy.
However, the presence of the CIA pattern seem to be an
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TABLE VII.3. DEMOGRAPHIC DATA OF PATIENTS STUDIED FOR SERUM ANTI—
RETICULIN (ARA) AND ANTI-ENDOMYSIUM ANTIBODIES (AEm).
DIAGNOSIS (n) AGE SEX DIET HISTOLOGY
























































NOT-COE= previous diagnosis on inadequate criteria
POT COE= potential coeliacs on follow up studies
IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
GFD= gluten-free diet
Minor Changes= minor non-specific histological abnormalities
PTVA= severe partial, or total villus atrophy
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even more sensitive index of mucosal DTH expression than
is IEL count.
Some of the cases in the literature, conforming to the
present definition of latent coeliac disease, will, on
review of biopsy pathology, be found to demonstrate high
IEL mild enteropathy, thus falling within the "continuum"
concept of gluten-sensitive enteropathy (Marsh 1992).
However, there are already published and unpublished
cases in which the total IEL count in the original biopsy
was normal. Not all such patients are asymptomatic, so
the word "latent" may in any event be inappropriate in
relation to the full clinical expression of gluten
sensitivity.
In humans, the finding of a high IEL count in an
otherwise morphologically normal mucosa may reflect a
state of T cell activation, probably antigen-driven.
Morphometric studies have shown that this is an early
expression of gluten-sensitivity (Marsh 1980, Leigh
1985) , that may follow lamina propria T cell activation
(Monk 1988). In some cases, this minimal lesion may
progress to a fully-expressed enteropathy. In first-
degree relatives, a correlation has been found between
IEL counts and the positivity for HLA-DR3, but this does
not occur amongst coeliac patients (Holm 1993a).
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The expression of the TCR tS by IELs in coeliac disease
may be genetically determined (Savilahti 1992; Holm 1992,
1993b), but local factors might also be involved, perhaps
after being triggered by gluten (Kluin 1991, Deusch
1991). These cells have a limited capacity for antigen
recognition, and no gluten specificity has yet been
reported (Haltensen 1989, Rust 1992, De Libero 1993). It
is very unlikely that rS cells play a role in mucosal
damage, because high tS+ IEL counts have been found in
non-coeliac patients with a normal biopsy histology, and
in a case of latent coeliac disease before the
development of enteropathy (Maki 1991a).
In much of the published work on latent coeliac disease,
and on the spectrum of pathological expression of gluten
sensitivity, IEL counts have been performed in H&E
stained sections, using a conventional light microscope.
In the future, if frozen sections and image analysis are
necessary to count r5+ IEL, it may be preferable to count
CD3+ cells per mm as an alternative to total IEL per 100
enterocytes. A direct comparison of these two techniques
presented in this chapter (Figure VII.3), shows a highly
significant correlation between IEL counts in paraffin
sections and CD3+ cell counts in frozen sections. All
cases with high CD3+ cell counts had high IELs, but there
were 7 cases with high IEL counts and a normal CD3+ cell
count, suggesting that a non-T cell subset may be present
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in the epithelium of these patients.
A high total IEL count, in an H&E stained section, may be
due to expansion of one or more of the three main subsets
of lymphocytes within the villus epithelium of the small
intestine: (i) CD3+ IEL (T cells) which utilize the aG
TCR; numbers of these rise and fall in coeliac patients
with gluten ingestion and exclusion; (ii) CD3+ IEL (T
cells) which utilize the r <5 TCR; generally, counts of
these cells are high in coeliac patients, irrespective of
diet; (iii) a small proportion of IEL are CD3- cells,
with no T cell receptors; their nature, in man, is
uncertain. This non-T/non-B IEL (atypical) subset may
occasionally be expanded, as shown above. Further
patients will need to be studied in order to establish
the clinical significance of this finding.
It has been shown that a CIA positive pattern is
significantly associated with high r<5+ IEL counts, and
also (though not statistically significant) with high
total IEL count. I have also confirmed the previous
finding that patients with subtle immune changes in gut
humoral immunity have entirely normal levels of serum IgA
anti-gliadin antibody (O'Mahony 1991a, Arranz & Ferguson
1993). A positive sugar permeability test is independent
of the other features, and it is mainly abnormal in
patients with inflammatory bowel disease and alcohol or
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NSAID-related problems.
The CIA pattern and a high t 5 + IEL count occur
independently in some non-coeliacs, but also co-exist
more frequently than expected by chance. These phenomena
may be due to separate, intrinsic, genetically determined
aberration of the constituent lymphocyte populations of
the mucosal immune system. They may be expressed in all
phases of intestinal immune activation, but it is equally
possible that aberrations occur only as part of the
expression of immune responses and inflammation in the
gut. Whatever the underlying mechanism, the repertoire
selected from the full range of potential immune cells
and molecules includes intestinal IgM antibodies and r<S+
IEL in coeliacs, whereas these are not utilized in most
non-coeliacs.
Other groups have reported the results for tS+ IEL counts
in frozen sections as a percentage of the total number of
CD3+ IEL (Spencer 1989a, 1991; Tredjosiewicz 1989, 1991;
Kluin 1991) . However, I found that method produced
spuriously high, abnormal values in a few cases with very
low total CD3+ cell counts (presumable with deficiency of
aR IEL rather than excess of tS cells); and therefore the
results are presented as the unmodified count of tS+ IEL
per unit length of surface villus epithelium.
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The differences in the reference values obtained for CD3+
cells in duodenal and jejunal specimens (r5+ IEL counts
per mm of tissue were similar in the two sites), may
reflect a true difference between these tissues, but
alternatively may be explained by the fact that duodenal
biopsy patients were significantly older than the
reference jejunal biopsy group (I have previously
reported low IEL counts as a feature of human
immunosenescence (Arranz 1992).
With the currently available range of tests, studies of a
single putative marker cannot be expected to identify all
cases of latent coeliac disease. The two best indices
are a positive CIA pattern and high tS count. However
these are not present even in all classical coeliacs. I
found one of 14 untreated coeliacs and one of 6 DH
patients in series A were CIA negative (Arranz & Ferguson
1993), and one otherwise completely typical coeliac man
in series C (who also has insulin-dependent diabetes) had
tS+ IELs undetected. Although logistically difficult, the
identification of potential coeliacs still requires
studies of several candidate markers, using jejunal fluid
for ELISA studies, and frozen sections of a mucosal
biopsy for T cell receptor staining.
For prospective studies of candidate latent coeliacs,
such as those with high IEL count, positive CIA pattern,
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high TCR tS expression of IEL, relatives of coeliacs, IgA
deficiency, a more generally applicable expression is
needed, for instance the term potential coeliac disease
(Ferguson 1992).
The combined assessment of the CIA pattern and several
other immunological and functional tests shows that these
markers will only identify potential coeliac cases, and
gluten sensitivity still requires clinical monitoring on
a GFD and after a gluten challenge. It is important to
emphasize that a high density of villus IEL (as assessed
by differential counts in the present study) may be the
only pathological expression of gluten sensitivity in
coeliac patients (Marsh 1989a), defining a mild but
significant enteropathy, rather than a truly latent
condition. Thus a positive result for total IEL count
may have different implications than positive findings
for the other parameters examined.
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CHAPTER VIII
STUDIES OF LAMINA PROPRIA PLASMA CELLS
Introduction
Markers of potential coeliac disease may be integrated in
the spectrum of gluten-sensitivity in two ways,
representing either the primary mucosal abnormality,
which predisposes to the existence of gluten sensitivity
when other predisposing factors occur; or alternatively
they may be subtle evidence of the existence of an on¬
going hypersensitivity reaction activated by local
immuno-stimulating factors, or by other mechanisms.
Though I pursued the latter hypothesis, the first
possibility was also explored by counting lamina propria
IgA+ and IgM+ containing plasma cells in jejunal biopsy
sections. The aim was to assess whether total IgA and IgM
concentrations, or specific class antibodies, found in
jejunal fluid specimens, were due to differences in the
total mucosal B cell population, or to differential
transport across the epithelium.
I compared two groups of "probably normal" non-coeliac
patients with minor GI symptoms and a variety of
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disorders, who were distinguished by the expression of
the CIA pattern in their jejunal fluid. These comprised
15 CIA positive patients, 10 of whom had a normal biopsy
histology and 5 had a high IEL count; and 14 CIA negative
patients, all with a morphologically normal biopsy
including a normal IEL count. I also included a group of
12 coeliac patients as an abnormal group, known to have a
high number of lamina propria IgM+ plasma cells as well
as a CIA positive pattern. All sections studied here
correspond to patient included in series A, and they are
described in Table VIII.1.
Lamina propria cell counts in jejunal biopsies
Non-coeliac CIA positive patients had a higher number of
lamina propria IgM+ plasma cells (p<0.05) when compared
to patients negative for the CIA pattern. Untreated
coeliac patients had significantly higher counts of IgM+
plasma cells compared with both non-coeliac patient
groups, either positive or negative for the CIA pattern
(p<0.01). However, when these non-coeliac groups were
compared with treated coeliacs, the difference was not
statistically significant (Figure VIII.1).
Untreated coeliacs had a higher number of IgA plasma
cells when compared with non-coeliac patients positive
and negative for the CIA pattern (p<0.01). No
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TABLE VIII.1. DEMOGRAPHIC DATA OF PATIENTS STUDIED FOR LAMINA
PROPRIA PLASMA CELL COUNTS IN JEJUNAL BIOPSIES.
DIAGNOSIS (n) AGE SEX DIET HISTOLOGY














































NOT—COE= previous diagnosis on inadequate criteria
POT COE= potential coeliacs on follow up studies
IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
GFD= gluten-free diet
Minor Changes= minor non-specific histological abnormalities
PTVA= severe partial, or total villus atrophy
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Figure VIII.1: Lamina propria
mm of tissue in treated (n=6)
non-coeliac patients positive
CIA pattern.
IgM+ plasma cell counts per square
and untreated (n-6) coeliacs, and
(n=14) and negative (n=13) for the
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statistically significant differences were found between
non-coeliac patient groups, or when these groups were
compared to treated coeliacs (Figure VIII.2). Results for
the different Ig+ class plasma cell counts and patient
groups are shown in Table VIII.2.
Lamina propria IgM+ and IgA+ plasma cell counts do not
correlate with concentrations of IgA and IgM-class
specific immuno-globulins in jejunal fluid specimens.
Discussion and implications of these results
An over-expression of IgM generally in the intestinal
mucosa has been reported in coeliacs (Baklien 1977, Scott
1984, Dhesi 1984, Ciclitira 1986b, Wood 1987, Crabtree
1989a, Lavo 1992), and also in non-coeliac CIA positive
patients, as shown by the study of jejunal fluid
immunoglobulins and antibodies (see Chapter VI), and
counts of lamina propria plasma cells described in this
chapter. Antibody responses are not restricted to
gliadin, and high levels of intestinal IgM antibodies to
Cholera toxin B subunit have been also found in coeliacs
(O'Mahony 1990b).
In the present chapter, I have assessed the hypothesis
that the general increase in the IgM component of
intestinal immunity might reflect a primary disorder of B
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Figure VIII.2: Lamina propria
mm of tissue in treated (n=5)
non-coeliac patients positive
CIA pattern.
IgA+ plasma cell counts per square
and untreated (n=6) coeliacs, and
(n=14) and negative (n=13) for the
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TABLE VIII.2. NUMBER OF LAMINA PROPRIA PLASMA CELLS PER SQUARE
MILLIMETER OF JEJUNAL BIOPSY TISSUE
IgA+ IgM+
PLASMA CELLS PLASMA CELLS
(n) (/mm2 LP tissue) (/mm2 LP tissue)
NON—COELIAC PATIENTS
CIA positive (15) 267 , 174 #157 , 65
CIA negative (14) 250 , 85 106 , 36
COELIAC PATIENTS
Normal diet (6) *682 , 118 +*419 , 239
GFD (6) *330 , 137 *145 , 88
* Coeliac patients, both on a normal diet and on GFD, had higher
number of IgA+ and IgM+ plasma cells (p<0.001) than non-coeliac
patients positive and negative for the CIA pattern.
+ Coeliac patients on a normal diet had higher number of IgM+
plasma cells (p<0.05) than coeliacs on GFD.
# Non-coeliac patients positive for the CIA pattern had higher
IgM+ plasma cells (p<0.05) than non-coeliacs CIA negative.
Data expressed as the mean value and standard deviation
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cells in the lamina propria (eg an abundance of poly-
reactive CD5+ B cells). This population of "abnormal"
cells might determine the production of polyclonal low-
affinity IgM antibodies. If the increased proportion of
IgM produced cannot compete successfully with dimeric IgA
for the SC, the molecules are susceptible to rapid
cleavage by proteolytic enzymes, and this susceptibility
is increased by the lack of stability of the molecule
lacking SC.
An alternative explanation for the increased up-
regulation of IgM responses, namely that the
"abnormality" may be due to the existence of an aberrant
function of T cell subsets which control the early stages
of B cell development, and probably manifested by an
abnormal pattern of mucosal activation or cytokine
production, is assessed in Chapter IX.
The unusual up-regulation of IgM secretory responses in
CIA positive patients may be genetically determined,
reflecting a state of immunological hyper-responsiveness
to many local stimuli, and relevant to the induction of a
state of aberrant immunity to gluten. In addition, an
immunoregulatory T cell disturbance may also determine an
altered pattern of cytokine synthesis that might lead to
the persistence of some mucosal abnormalities, eg
polyclonal IgM secretion by B cells without antigen, or
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terminal differentiation of IgM+ B cells.
However, antigen-related terminal differentiation and
expansion of IgM and IgA B cells appear to be normal, as
does the trans-epithelial immunoglobulin transport
(Baklien 1977). The finding of a similar proportion of
IgA bound to SC in jejunal fluid samples from CIA
positive and CIA negative patients (see Chapter V) does
not support the hypothesis that an abnormally high
capacity for transport of IgM and IgA across the
epithelium might produce the CIA pattern. If the affinity
for the SC for IgM is much higher than for dimeric IgA,
then over-production of IgM in the lamina propria may
partially block trans-epithelial IgA transport, which
gives an explanation for the presence of dimeric IgA in
the serum in coeliac disease (Troncone 1991b).
The higher number of IgM+ plasma cells found in non-
coeliac CIA positive patients as compared to CIA
negative, is evidence of an apparent imbalance of lamina
propria plasma cells in the first group of patients.
These results confirm data shown in Chapter VI, validate
the finding of the CIA pattern, and support the view that
this antibody pattern is locally produced. Moreover, this
finding, together with the high proportion of jejunal
fluid slgA found in the CIA positive group, suggests that
neither the B cell population, nor the transepithelial
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immunoglobulin transport, are affected, but rather that
it is the immuno-regulatory factors that control these
processes.
The lack of correlation between lamina propria IgM+
plasma cell counts and IgM concentrations may suggest
that they are unrelated. CIA positive patients have a
high concentration of IgM and a polyclonal IgM antibody
response. The intra-cellular form of IgM (mainly
monomeric) detected by immuno-histochemical studies may
be different to the secreted form (polymeric) detected in
jejunal fluid by ELISA, as occurs for IgA (Moldoveanu
1984). It is also possible that in CIA positive patients,
the secreted low-affinity and polyclonal IgM molecule is
rapidly cleaved or is not functional, and its levels are
not paralleled by the number of specific plasma cells at
a given time. Only a small proportion of the IgA and IgM-
producing plasma cells are involved in anti-gliadin
antibody production, as shown by in vitro culture of
untreated biopsies (Ciclitira 1986b, Lycke 1989).
The number of IgM+ B cells may also be secondary to
gluten ingestion in sensitized individuals, and as in
other mucosal changes observed in coeliac patients,
adults maintain these abnormalities even after long
periods of GFD, as compared with children who have a
higher potential for mucosal normalization (Baklien
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1977, Scott 1980a, Savilahti 1972)
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CHAPTER IX
OTHER STUDIES IN NON-COELIAC PATIENTS
Introduction
Markers of potential coeliac disease may be integrated in
the spectrum of g1uten-sensitivity in two ways,
representing either the primary mucosal abnormality (see
Chapter VIII); or as subtle evidence of the existence of
an ongoing hypersensitivity reaction activated either by
a local immuno-stimulating factor or by other mechanisms.
I pursued the latter hypothesis and carried out various
studies, described in this chapter.
Within the spectrum of expression of a low-grade mucosal
DTH reaction, the CIA pattern may be positive even before
the IEL count is raised. Intestinal immune activation is
manifested by IEL infiltration and HLA-DR expression by
crypt epithelium (Marsh 1980, Leigh 1985). Within the
lamina propria there is a polyclonal activation of CD4+
cells and expression of the CD25 marker (Griffiths 1988,
Haltensen & Brandtzaeg 1993); local production of
prostaglandins and soluble factors (Lavo 1990, Branski
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1992); increased number of plasma cells (Scott 1980a,
Dhesi 1984); infiltration of basophils, neutrophils,
eosinophils, MMC and goblet cells (Dhesi 1984, Marsh &
Hinde 1985), evidence of cellular activation and
degranulation (Hallgren 1989, Norvath 1989, Colombel
1992, Desreumaux 1992, Scott 1992) and complement
activation (Haltensen 1992a).
Cultured coeliac biopsies release cytokines into the
supernatant after gluten challenge (Ferguson 1975). These
products may mediate morphological and functional changes
induced by gluten- specific T cells. It is known that
gluten challenge induces a dose-dependent IEL
infiltration, followed by activation of lamina propria
cells (Marsh 1980, Leigh 1985, Monk 1988) and expression
of HLA-DR antigens predominantly by crypt epithelium
(Ciclitira 1986a). Activated IELs produce IFNr which
modulates the epithelial HLA-DR expression (Scott 1981,
Cerf-Bensussan 1984), and this may be related to the
induction of a secondary inflammatory reaction (Mayer
1991). Expression of HLA-DQ molecules on the lamina
propria may also be involved in antigen presentation.
There is an exciting new report where gluten-specific
cells, characterized as HLA-DQ restricted T cells, have
been cloned (Lundin 1993).
It was thought that patients positive for markers of
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potential coeliac disease, eg CIA positive, high total IEL
and tS+ IEL counts, might have an active low-grade DTH
reaction in an otherwise morphologically normal mucosa.
This might be manifested by the presence of high numbers
of MMC in lamina propria, HLA-class II antigen expression
by jejunal epithelial cells (particularly HLA-DR in crypt
epithelium), and/or by the cell activation marker CD25
(which identifies the IL-2R a chain). Eventually, I
wanted to establish whether the existence of these
markers correlated with the expression of other indices
of potential coeliac disease.
During the study to characterize jejunal fluids as
material for the study of mucosal immunity, a colleague
(Dr Obedy Mwantembe) found detectable levels of soluble
IL-2R and TNFa in whole gut lavage fluid samples. This
finding encouraged me to measure these cytokines in
jejunal fluid specimens using the same tests. In
addition, an ELISA test for IFN-r was developed in the
laboratory (by Louise Handy), and this was added to the
battery of cytokine assays performed in jejunal fluids.
I also studied a group of treated coeliac patients. This
group was subdivided either by dietary status or by
mucosal histology when compared with the group of non-
coeliac patients, to evaluate differences in cytokine
levels.
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A. Evidence of "DTH" effect on crypt epithelial cells
Though the study was carried out to assess the expression
in general of HLA-DR and DQ antigens by the intestinal
mucosa, I was looking in particular at the significance
of the IEL population in the epithelial compartment.
Demographic data of patients studied are shown in Table
IX.1. Coeliac patients were grouped according to biopsy
histology and dietary status; and non-coeliac patients
were categorized by the total IEL count and the
expression of the CIA pattern.
HLA-DR antigen expression was observed in the villus
epithelium of almost all specimens studied, showing a
general staining pattern with maximum expression at the
tip of the villi affecting the basolateral membrane of
enterocytes, and decreasing towards the crypt epithelium,
where the staining was almost absent. This pattern was
particularly expressed by untreated coeliacs with PVA or
STVA, where positivity for HLA-DR in crypt epithelium and
the presence of lamina propria CD25+ cells seem to be the
most specific markers of T cell activation.
No differences were found in the HLA-DR expression by the
villous epithelium when coeliac patients with a
morphologically normal biopsy and non-coeliac patients
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TABLE IX.1. DEMOGRAPHIC DATA OF PATIENTS STUDIED FOR THE
EXPRESSION OF HLA-CLASS II ANTIGENS AND THE CD25 MARKER IN
JEJUNAL BIOPSIES.
DIAGNOSIS (n) AGE SEX DIET HISTOLOGY




































































NOT-COE= previous diagnosis on inadequate criteria
POT COE= potential coeliacs on follow up studies
IBD= inflammatory bowel disease
IDIO DIA= idiopathic diarrhoea
ORAL ULC= recurrent mouth ulcers
MISC= significant organic GI disorders
NUT DEF= nutritional deficiencies due to poor diet
IBS= irritable bowel syndrome
NAD= trivial symptoms, psychiatric disease
GFD= gluten-free diet
Minor Changes= minor non-specific histological abnormalities
PTVA= severe partial, or total villus atrophy
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with or without high IEL counts were compared (Table
IX.2). The intensity of staining was, in general, higher
in the villous epithelium than in the crypts.
In crypt epithelium, 14 of the 16 coeliac patients were
positive, as were 12 of the 16 non-coeliac cases with
high total IEL counts (frequencies not statistically
different). By contrast, only 3 of the 16 non-coeliac
cases with normal IEL counts had positive HLA-DR staining
in crypt epithelium, and the frequency was significantly
lower when compared to coeliacs (p<0.001) and non-coeliac
patients with high IEL counts (p<0.01) (Table 23).
When coeliacs were subdivided by diet, no differences
were found between either the group on a normal diet or
on a GFD or non-coeliac patients with high IEL counts.
However, both coeliac groups had higher HLA-DR expression
in crypt epithelium (p<0.01) when compared with non-
coeliacs with normal IEL counts. On the other hand, only
non-coeliac CIA negative patients had a significantly
lower HLA-DR expression in the crypt epithelium when
compared to coeliac patients either as a whole (p<0.001)
or on a normal diet (p<0.05).
HLA-DQ expression was absent in villus and crypt
epithelium from all the sections. However, positive cells
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TABLE IX.2. POSITIVE EXPRESSION OF HLA—CLASS II ANTIGENS IN
JEJUNAL BIOPSIES FROM COELIAC AND NON-COELIAC PATIENTS
HISTOLOGY HLA-DR HLA-DQ CD25+











































PTVA=severe partial or total villus atrophy





with an heterogeneous morphology, were found in the
lamina propria of most specimens. No significant
differences were found when groups were compared.
Positive cells may be numerically similar between coeliac
and non-coeliac groups: however, the staining pattern is
stronger in the coeliac group, and in some of these cases
these cells had a subepithelial localization (Table
IX.2).
B. Evidence of lamina propria cell activation
Counts of lamina propria MMC were performed in biopsy
sections from the same group of patients studied for
lamina propria plasma cell counts (see Chapter VIII). A
description of patients is shown in Table VIII.1. Mucosal
mast cell counts were not significantly different when
both treated and untreated coeliac patients were compared
to non-coeliac patients either positive or negative for
the expression of the CIA pattern (Figure IX.1).
Studies of expression of the CD25 cell marker were
performed in the same cases as for HLA-DR and DQ
expression and they are shown in Table 7 (see Chapter V).
Positive cells for the CD25 marker were only found in the
lamina propria of coeliac patients in 13 of the 16 cases
studied, and this was particularly related to the co¬
existence of PVA or STVA, but not with the dietary
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Figure IX.1:Lamina propria MMC counts per square mm of tissue in
treated (n=5) and untreated (n=7) coeliacs, and non-coeliac
patients positive (n=15) and negative (n=14) for the CIA pattern.
182
status. When compared with non-coeliac patients, coeliacs
had a higher lamina propria CD25+ cell expression
(p<0.001).
Amongst non-coeliacs, only two patients had any lamina
propria CD25+ cells: a woman with recurrent mouth ulcers
and positive for all three markers of potential coeliac
disease, who later developed a gluten-sensitive
enteropathy (see Chapter X); and a man with idiopathic
diarrhoea, high total IEL and tS IEL counts, but CIA
negative. Both also had positive HLA-DR expression in
crypt epithelium.
Cytokines in jejunal fluid samples
I. Measurement of soluble IL-2R levels.
Jejunal fluid samples were studied from patients
described in Table II.4. Results of soluble IL-2R levels
are shown in Figure IX.2. Mean values and comparison
between groups are also shown in Table IX.3. The upper
reference range for IL-2R (138 IU/ml) was calculated
using the 95% confidence interval of the values obtained
by the mainly normal or control group. Samples had high
soluble IL-2R levels when above this value. The control
group includes patients with a diagnosis of a functional







































D IS OR D E R S
Figure IX.2: Jejunal fluid soluble IL-2R levels expressed as
IU/ml, in coeliac patients (n=24), non-coeliac patients with
organic GI disorders (n=28), and controls (n=28).
Normal= morphologically normal mucosa, PTVA= severe partial or
total villus atrophy
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PTVA= severe partial, or total villus atrophy
GFD= gluten-free diet
* Patients with organic disorders, and coeliacs with either
normal and PTVA (p<0.05) or on GFD (p<0.001) had higher levels of
soluble IL-2R than controls.
+ Coeliac patients either with PTVA or on normal and gluten-free
diets had higher levels of TNFa (p<0.05) than controls.
Data expressed as the mean, standard deviation (range values)
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after investigation.
In the control group, two of the 28 patients had high IL-
2R levels (Table IX.3), a woman with a positive CIA and a
high total IEL count; and a second case with a high rS
IEL count, but no other abnormalities, who was finally
diagnosed as having a functional bowel disorder. Control
group patients had significantly lower IL-2R levels when
compared with both non-coeliac patients with a
significant GI disease (p<0.05), and coeliac patients
whether treated or untreated (p<0.05).
Coeliac patients were subdivided using the dietary status
and the jejunal biopsy histology. High soluble IL-2R
levels were found in 3 of the 8 coeliac patients with
normal histology, and 2 of the 16 patients with either
PVA or STVA. Both treated and untreated coeliac patients
had similar IL-2R levels when compared to non-coeliac
patients with other organic GI diseases (Table IX.3).
Three of the patients with other organic GI disorders
also had high levels of soluble IL-2R, a man with
diarrhoea due to high alcohol intake, and two women, one
with a diagnosis of collagenous colitis, the second with
idiopathic diarrhoea, and positive for the 3 markers of
potential coeliac disease. Positive control cases and
non-coeliac patients with other organic diseases are
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described in Table IX. 4.
II. Measurement of TNFa levels.
Jejunal fluid samples were studied in the same cases as
for soluble IL-2R (see Table II.4) . Results of TNFa
levels are shown in Figure IX.3. Mean values and
comparison between groups are also shown in Table IX.3.
The upper reference range for TNFa (40 pg/ml) was
calculated using the 95% confidence interval of the
values obtained from the control group. Samples had high
TNFa levels when above this value. One of the patients
from the control group had high TNFa levels, this was a
woman in whom no diagnosis was reached after full
investigation.
Three coeliac patients with an atrophic-villous mucosa,
but none of the cases with a normal histology had high
TNFa levels. Compared to the control group, coeliac
patients with PVA or STVA had higher TNFa levels
(p<0.05), and these levels were also higher than those
for non-coeliac patients with an organic GI disease and
normal biopsy histology, though this difference was not
statistically significant (Table IX.3).
TNFa levels were high in 4 of the patients with organic
GI disorders, two men with a diagnosis of pancreatic
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TABLE IX.4. DESCRIPTION OF NON-COELIAC CASES WITH HIGH LEVELS OF
SOLUBLE IL-2R IN JEJUNAL FLUID
DIAGNOSIS CIA HIGH TOTAL HIGH T8+ COMMENT














COLITIS Trial of GFD
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JEJUNAL FLU ID TNF-alpha LEVELS
GROUP NORMAL DIET ONGFD DISORDERS
Figure IX.3: Jejunal fluid TNFa levels expressed as pg/ml, in
coeliac patients (n=24), non-coeliac patients with organic GI
disorders (n=28), and controls (n=28).
Normal= morphologically normal mucosa, PTVA= severe partial or
total villus atrophy
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cancer and recurrent mouth ulcers, respectively, but no
other abnormalities; and two women, both with idiopathic
diarrhoea, one the case positive for 3 markers of
potential coeliac disease and high levels of soluble IL-
2R in jejunal fluid. A description of the control case
and the 4 non-coeliac patients with high TNFa levels are
shown in Table IX.5.
III. Measurement of IFNt levels.
Suitable jejunal fluid to measure IFNt levels was
available from 37 of the 82 patients studied for soluble
IL-2R and TNFa (see Chapter II). Results of IFNr are
shown in Figure IX.4, and reference values obtained by
the study groups are given in Table IX.6. The sensitivity
of the ELISA test for jejunal fluid IFNt was >4 IU/ml.
None of the control group patients had detectable levels
above this value.
Two coeliac patients: one treated and one on a normal
diet (both with P/TVA) , and two DH patients, one treated
and one on a normal diet (both with minimal histological
changes in their biopsies), had detectable INFt levels in
jejunal fluid.
Four of 15 patients with organic GI disorders also had
detectable IFNt levels: three women, one with idiopathic
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TABLE IX.5. DESCRIPTION OF NON-COELIAC CASES WITH HIGH LEVELS OF


















ORAL ULCERS not done
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D IS OR D E R S
Figure IX.4: Jejunal fluid IFNr levels expressed as IU/ml, in
coeliac/DH patients (n=12), non-coeliac patients with organic GI
disorders (n=15), and controls (n=10).
Normal= morphologically normal mucosa, PTVA= severe partial or
total villus atrophy
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CONTROL GROUP" 10 0.13 , 0.4
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PTVA=severe partial, or total villus atrophy
Data expressed as the mean, standard deviation (range values)
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diarrhoea who was CIA positive and had a high total IEL
count; and two with recurrent mouth ulcers, one of whom
was CIA positive and had a high total IEL count; as well
as a man with a diagnosis of ulcerative colitis.
Descriptions of positive cases are shown in Table IX.7.
Differences between groups were not significant: the
group of untreated coeliacs was very small, however. No
positive correlations were found when cytokine levels
were compared within the group of 37 patients in whom
samples were available for measurements of soluble IL-2R,
TNFa, and IFNt.
Conclusions and implications of these results
Evidence of mucosal T cell activation can be found in the
intestine of non-coeliac patients positive for some
markers of potential coeliac disease, without any major
change in villous architecture. These include polyclonal
expansion of cells in mucosa (eg IgM+ plasma cells),
production of cytokines, and expression of cell
activation markers in jejunum. This suggests the
existence of an inflammatory process in the intestine.
HLA-DR expression by crypt epithelium is more frequent
amongst patients with high IEL counts; whereas lamina
propria CD25+ cells are only found in patients with
villous atrophy, or minor histological abnormalities.
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TABLE IX.7. DESCRIPTION OF NON-COELIAC CASES WITH HIGH LEVELS
IFNt IN JEJUNAL FLUID
DIAGNOSIS CIA HIGH TOTAL HIGH TS+ COMMENT
PATTERN IEL COUNT IEL COUNT
UC + not done
IDIO DIA + - not done
ORAL ULCERS - - not done
ORAL ULCERS - - not done
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Similar results have been obtained in a proportion of
healthy first degree coeliac relatives with a normal
biopsy, and HLA-DR expression was found to be correlated
with the coeliac-associated DQ gene markers. These
patients are potential coeliacs with high tS+ IEL counts,
and may be monitored for the development of histological
changes by screening for positive (seroconversion) ARA
and AEm antibodies (Holm 1993b). In coeliac patients,
activation markers (HLA-DR, CD25) are expressed in
parallel with the aB+ cell infiltration of the epithelium
(not by tS+ cells) , which is related to the stage of the
disease (Kutlu 1993).
The coeliac lesion is due to an aberrant mucosal immune
response to gluten that seems to be mediated by HLA-class
II restricted lamina propria cells (O'Farrelly &
Gallagher 1992). MHC products may determine the immune
responsiveness to gluten, whether by repertoire selection
in thymus or by antigen presentation at local level, by
HLA-DR+ enterocytes or more likely by HLA-DQ+ antigen-
presenting cells. HLA molecules do not bind gliadin as
lectins, and there is no cross-reactivity with gliadin
(Gallagher 1988). However, gluten specific HLA-DQ
restricted T cells have been isolated from jejunal
coeliac biopsies (Lundin 1990, 1993).
Experiments of polyclonal T cell activation of human
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mucosa in vitro induce crypt cell hyperplasia, expression
of CD25 markers by T cells and macrophages, lymphokine
release, IEL infiltration, and increased HLA-DR
expression by enterocytes and crypt epithelial cells
(MacDonald & Spencer 1988, MacDonald 1990; Fais 1992).
These features are also found in untreated coeliacs, with
lamina propria expressing the CD25+ marker, whereas the
epithelium expresses the proliferative antigen identified
by the mAb Ki-67 (Haltensen & Brandtzaeg 1993). This
suggests that IELs are induced to proliferate
independently of the antigen (thus the absence of gluten-
specific T cells), but probably dependent on IL-2
production secondary to lamina propria CD4+ cell
activation.
In agreement with others, these results show that villous
epithelial cells normally express HLA-DR antigens.
However, HLA-DR expression by crypt epithelium is more
frequently associated with a high IEL count, without any
other histological change. The frequency of positive
cases was similar in coeliacs and non-coeliacs with high
IEL counts, though the intensity of staining was stronger
in the first group, suggesting that it may represent an
early inflammatory change in non-coeliacs. CIA positive
patients had a similar frequency of cases with positive
cells in crypt epithelium to coeliacs. HLA-DQ antigens
are less numerous, but positive cells are found in lamina
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propria, some of them big, macrophage-like cells.
I am aware that the jejunal fluid samples I have used to
measure cytokine levels had been previously thawed and
frozen at least once (for total immunoglobulins and
specific antibodies levels), therefore the results have
to be evaluated with caution. However, in order to give a
complete report of the work carried out on these
patients, cytokine data has been included. It is clear
that if a definitive study on cytokine levels in jejunal
secretions is to be compiled it will be necessary to use
"fresh" aliquoted jejunal fluid samples.
The lack of correlation between jejunal fluid IL-2R and
TNFa levels and markers of potential coeliac disease may
be due to the short lifetime and rapid clearance of
cytokines from fluids. As the reliability of the assay
depends on rapid treatment and storage of samples, the
samples in this study were not ideal. Independently of
the mucosal status, non-coeliac patients with organic GI
disorders had similar IL-2R levels to coeliacs, whereas
only the latter have high TNFa levels in association with
the presence of an atrophic-villous mucosa. IFNt was
found to be positive only in patients with organic
disease, including one who later developed a gluten-
sensitive enteropathy and was positive for the two other
cytokines and 3 markers of potential coeliac disease.
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IFNt modulates the epithelial function and expression of
surface markers HLA-DR and SC (Cerf-Bensussan 1984,
Madara & Stafford 1989, Scott 1987, Sollid 1987). In
coeliac disease, IFNr-secreting cells are increased in
relation to the degree of villous atrophy (Kontakou
1993). Serum soluble IL-2R levels may be an indirect
index of immune activation by dietary gluten in coeliacs,
perhaps related to CD4+ cell stimulation (Crabtree
1986b, Blanco 1992) . Lamina propria TNFa producing cells
and macrophages are also increased in active coeliac
disease (Przemioslo 1993) . However, TNFa has a short life
and, though it may be produced by activated macrophages
and Paneth cells it is normally undetectable in
secretions. A great proportion of IELs, with memory
phenotype, may synthesize IL-2, IL-5, and/or IFNr.
Further elucidation of the relationships between the
immunological phenomena described and the clinical entity
of coeliac disease will require extension of the studies
described in this chapter, together with direct, "in-
vivo" investigations of gluten sensitivity in potential
coeliac patients, as well as characterization of the
genetic make-up of both coeliac and non-coeliac patients,




CLINICAL EFFECTS OF GLUTEN-FREE DIET AND GLUTEN LOADING
Introduction
One of the implications of the study of the expression of
candidate markers of latent coeliac disease in
symptomatic non-coeliac patients, some of them found to
be positive for one or more, is the need for a complete
re-think of the basis for selecting patients who need to
undergo a GFD trial, and consequently the revision of
diagnostic criteria of the disease. There has been a
previous report of gluten-sensitive diarrhoea, describing
benefit from a GFD in 9 of 17 patients suffering from
chronic diarrhoea, but their jejunal biopsies were not
normal (Cooper 1980).
In this laboratory, Kathleen Kingstone is currently
working on the characterization of coeliac and non-
coeliac patients using genetic markers associated with
the HLA-DQ locus, and their relationship to different
patterns of expression of candidate markers of latent
coeliac disease. Patients positive for at least 2
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indices, who may express the HLA-DQ a/6 heterodimer,
should be followed up. However, the diagnosis of latent
coeliac disease may be confirmed earlier by a clinical
trial of gluten sensitivity, and if confirmed, a GFD can
be recommended in these patients.
Although clinical effects of treatment are important to
the patient, objective measures of the effects of GFD in
coeliac disease are mandatory for clinicians and
investigators. Thus histopathological improvement
currently forms part of the definition of the disease.
Objective assessment of a response to a GFD in the
present series of patients will only be possible in
patients who have a functional disorder (eg abnormal
permeability), or those with minor biopsy abnormalities
within the classical spectrum of enteropathy (eg high IEL
counts). This is independent of the remission of
symptoms.
Trials of gluten-free diet in non-coeliac patients
This study was carried out in an opportunistic, non
systematic way, selecting patients on the basis of the
presence of symptoms or the finding of a high total IEL
count. The 14 patients studied were offered a clinical
trial of gluten restriction. These were non-coeliac non-
DH patients, 8 were CIA positive at the time of the first
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biopsy on a gluten-containing diet, and 6 were CIA
negative. Details are presented in Table X.l: 8 cases
had high IEL counts (5 CIA positive), one had villus
shortening and a normal IEL count, and 5 had a
morphologically normal biopsy. At the time of completion
of this thesis (03.12.93) two of these patients are on
the list for a second biopsy.
Five CIA positive and 2 CIA negative patients with
chronic high-volume watery diarrhoea had complete and
rapid resolution of diarrhoea within 1-2 weeks of
starting a gluten-free (or, in one case, low gluten)
diet; in four of the CIA positive cases, the IEL count
in the initial biopsy was high, and in the three cases in
which repeat biopsy has been performed, the IEL count has
fallen to normal. There are two CIA negative patients
(JS, AS) who showed a good clinical response, and a
reduction in the IEL count (though in the first one, the
count was still high).
After 6 months of GFD a partial improvement was observed
in the severe watery diarrhoea of a woman with
collagenous colitis (CS) whose identical twin is a
coeliac. She was CIA negative, her jejunal biopsy was
morphologically normal with an IEL count of 31% and no
r5+ IELs. She is currently on a GFD. The trial of GFD had
no effect in a CIA positive patient (CR), with ulcerative
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colitis and sclerosing cholangitis (on 10 mg/day of
prednisolone), who had a high-volume watery diarrhoea
after colectomy and formation of a pelvic ileal pouch.
Development of a mucosal lesion in a case of potential
coeliac disease after gluten loading
There were three patients of particular interest,
positive for 3 markers of potential coeliac disease. One
of these patients defaulted from follow-up. The other two
have been shown to be gluten-sensitive (see above). One
of the cases (PK) had resolved her chronic high volume
diarrhoea within 2 weeks of starting the trial, and IEL
count was normal in a biopsy taken 2 months later.
The second case (JP) was a 41 year old, CIA positive
woman with recurrent severe oral ulceration when eating a
diet with 24 g gluten daily, despite a reportedly
morphologically normal jejunal biopsy, but the presence
of an abnormal permeability test. She was prescribed a
GFD and she noticed some improvement but found the diet
inconvenient and kept to it for only five weeks. Several
months later, when studies of TCR t5+ IEL in a stored
biopsy specimen were performed and counts were found to
be high, she agreed to take 10 g additional gluten daily
for a month and had another jejunal biopsy. Pathological
examination revealed STVA (classical coeliac-like
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enteropathy). This patient was one of the two non-coeliac
cases with CD25+ cells in jejunum.
Gluten sensitivity and potential coeliac disease
Around 40% of patients referred for diagnostic jejunal
biopsy, and in whom routine biopsy pathology was normal,
had positive results for one or more of the tests that
have been proposed as indices of latent coeliac disease.
Although evidence of clinical and mucosal gluten
sensitivity has been obtained in a few of these patients
(Arranz 1993), this was done on an opportunistic basis,
unsystematic and uncontrolled, and further careful
studies are now essential.
Of the 31 patients with a positive result for one or more
indices of potential coeliac disease, there were 19 with
a single abnormal test. Of particular interest are the
three patients with 3 parameters positive: cia pattern,
t<S+ iel count and total iel count. Two of the three,
both women, were shown to be gluten-sensitive after a
trial of GFD; and one of them (JP) was the patient who
underwent a trial of gluten loading, and developed a
gluten-sensitive enteropathy (see above).
Induction of severe enteropathy by extra dietary gluten
would be unequivocal proof of gluten sensitivity, but
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this raises ethical issues and may be clinically
unacceptable to these patients. Acute enteral or rectal
gluten challenge, monitored by multiple biopsies, should
be practicable. However, since the histopathological
effects of dietary gluten in clinically gluten-sensitive
patients with normal jejunal biopsy are strikingly
different from those in classical coeliacs, it is
entirely possible that the pathological changes produced
by acute gluten challenge in the jejunum or rectum will
be different in latent or potential coeliacs as compared
with classical coeliacs, so a range of pathological and
molecular indices will still require measurement in
future work.
Clinical details of patients and investigations
(Note: when biopsy is referred to, this is a jejunal
biopsy unless otherwise stated.)
Mrs CR. A 24-year-old woman diagnosed as having
ulcerative colitis and sclerosing cholangitis, on 10 mg
of prednisolone daily. She developed a high-volume watery
diarrhoea after colectomy and formation of a pelvic ileal
pouch. Her first biopsy showed minor villus shortening
and a total IEL count of 15%, she had a CIA positive
pattern in her jejunal fluid, and the sugar permeability
test was grossly abnormal (0.240). Serum anti-gliadin
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antibodies were negative. No effect was found after 6
months on a GFD, her second biopsy showed similar
histological changes (IEL count of 16%), and the sugar
test was abnormal (0.104).
Mrs DM. This 19-year-old woman was investigated because
of a 6 month history of watery diarrhoea with some weight
loss. Her daily gluten intake was 37 g. Her first jejunal
biopsy was morphologically normal, but the total IEL
count was very high (80%). The diagnosis was made of
idiopathic diarrhoea. She had a CIA positive jejunal
fluid, high levels of IgG anti-gliadin antibodies in
serum, and the sugar permeability test was normal (0.012).
Her diarrhoea resolved within 2 weeks of starting a low
gluten diet (5 g daily), and a reduction of the IEL
count to 23% was observed in her second jejunal biopsy.
She has been advised to maintained an strict GFD
indefinitely.
Mrs DP. This 54-year-old woman presented with watery
diarrhoea. She was investigated by a colonoscopy, and a
colonic biopsy taken showed microscopic colitis. She had
no response to trials of prednisolone and sulphasalazine.
The study of her jejunal biopsy and fluid also revealed a
morphologically normal mucosa with a high IEL count
(46%), and a CIA positive pattern, respectively. The
serum AGA test was negative, and the sugar permeability
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test was within the normal range (0.032). Her diarrhoea
resolved after one week of GFD. The second biopsy showed
an IEL count of 36%. She is currently on a GFD.
Mrs PK. A 23-year-old woman investigated by jejunal
biopsy because of chronic diarrhoea and fatigue. Her
jejunal biopsy had a normal villous architecture but the
IEL count was increased (61%), with an high proportion
of epithelial tS+ cells (80/mm). Only the serum IgG anti-
gliadin antibody titer was slightly high, but IgA
ARA/AEm antibodies and the jejunal fluid CIA pattern,
were positive. The sugar permeability test was normal
(0.020). She had a good clinical response to a GFD, with
remission of diarrhoea within two weeks. Her second
biopsy showed a reduction in the IEL count to 38%.
Mrs KW. This 26-year-old woman presented with
intermittent watery diarrhoea, colicky abdominal pain,
lethargy, and iron deficiency anaemia. Her jejunal biopsy
showed a normal villous architecture but a high IEL count
of 44%, and an increased chronic inflammatory cell
infiltrate in the lamina propria. Serum antigliadin
antibodies were not detected, and the sugar permeability
test was abnormal (0.065). She had a CIA positive jejunal
fluid. Diarrhoea resolved within a week of starting a
GFD, but she defaulted from further appointments.
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Mrs HS. This 52-year-old woman was investigated by
jejunal biopsy because of iron deficiency anaemia and
idiopathic diarrhoea. Her biopsy was normal with an IEL
count of 21%. She had a CIA positive jejunal fluid, serum
anti-gliadin antibodies were negative, and an abnormal
sugar permeability test (0.062). Her second biopsy was
normal with a total IEL count of 23%, but the sugar test
was still abnormal (0.074). She is currently on a GFD.
Mrs JP. This 41-year-old woman had a history of recurrent
severe mouth ulcers related to her menstrual period. Her
diet contained 24 g of gluten daily. A diagnosis of iron
deficiency anaemia was made in 1989, but she had
irrelevant symptoms or family history. Her first jejunal
biopsy was morphologically normal, with an IEL count of
50% and a high number of tS+ cells (51 cells per mm of
epithelium). The sugar permeability test was abnormal
(0.079), she had 12 g/dl of haemoglobin and a low level
of ferritin (<5 ug/ml). She had a CIA positive jejunal
fluid, and high titers of serum IgG and IgA anti-gliadin
and IgA ARA/AEm antibodies. Her mouth ulcers improved
clinically after 2-3 weeks on a GFD, but she decided to
recommence a normal diet, and a trial of gluten loading
was then performed. The jejunal biopsy taken at that time
showed STVA, but no changes in her mouth ulcers. The
symptoms disappeared after gluten restriction, with iron
and folate supplements. She is currently being treated
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with a GFD and has been recommended to remain on this
diet indefinitely.
Mrs HS. This 45-year-old woman was previously diagnosed
as having Crohn's disease, which has been clinically
inactive. However, she developed a severe diarrhoea after
undergoing a limited ileal resection for active disease,
and the diarrhoea was unresponsive to Cholestyramine. Her
first jejunal biopsy was normal with an IEL count of 36%,
but a high epithelial tS+ cell count (8.2 cells per mm)
was found in frozen sections. She had a CIA positive
jejunal fluid, serum anti-gliadin antibodies were not
detected, and the sugar permeability test was abnormal
(0.052). There was no clinical effect after two months of
a GFD, no further investigations were done, and she
returned to a normal gluten-containing diet.
Mrs CS. This is a 68-year-old woman with a diagnosis of
collagenous colitis, whose identical twin is a coeliac
patient. She was investigated because of severe
exacerbation of her diarrhoea, and had a poor response to
trials of prednisolone and sulphasalazine. Her first
jejunal biopsy was normal with a total IEL count of 31%.
She had a CIA negative jejunal fluid, the serum IgA anti-
gliadin antibody titer was slightly increased, and the
sugar permeability test was within a normal range
(0.035) . After 6 months on a GFD, she had a partial
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clinical improvement, with reduction by half in her
faecal frequency. She was recommended to stay on her GFD
indefinitely.
Mrs HJ. This 22-year-old very thin woman had a long
history of fatigue, constipation, lower abdominal pain
and tenesmus. Coeliac disease was suspected because of a
duodenal biopsy performed in another hospital, showing a
mild PVA, inflammatory cell infiltrate and increased
IELs. A rectal biopsy also showed a solitary ulcer. A
jejunal biopsy performed at this hospital was
morphologically normal, an IEL count of 38%, no r<S+ cells
in epithelium, and no significant inflammation. She had a
CIA negative jejunal fluid, serum anti-gliadin antibodies
were not detected, and the sugar test was slightly
abnormal (0.040). The clinical response to GFD was
equivocal, though she felt better. A second jejunal
biopsy was normal with an IEL count of 28%, a repeated
sigmoidoscopy showed no evidence of ulceration, and the
rectal biopsy was normal. Her sugar permeability test
(0.020) and other bowel functions were normal. She has
been recommended to maintain her GFD indefinitely.
Mrs JS. This 22-year-old woman presented with a 4-month
history of recurrent mouth ulcers and angular stomatitis,
intermittent diarrhoea and abdominal bloating. She has
had bowel complaints all her life, with a tendency to
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constipation, and she had recently lost some weight and
felt tired. Her first jejunal biopsy was morphologically
normal with a high IEL count (73%), and had no epithelial
tS+ cells. The sugar permeability test was normal
(0.021). She had a CIA negative jejunal fluid, and serum
anti-gliadin antibodies were low. She responded
clinically to a GFD, though the jejunal biopsy was still
slightly abnormal with an IEL count of 56%, and her sugar
test was normal (0.014) . She has defaulted twice to
follow up appointments.
Mrs AS. This 62-year-old woman had a several year history
of watery diarrhoea. She had old rickets, faecal
incontinence, and had had a previous cholecystectomy and
hysterectomy. The first duodenal endoscopic biopsy was
normal with an IEL count of 29%, and a jejunal biopsy
showed a normal morphology with an IEL count of 35%, but
a lamina propria cell infiltrate. Her jejunal fluid was
CIA negative, serum anti-gliadin antibodies were not
detected, but the sugar permeability test was abnormal
(0.046). She had a good response to a GFD, with remission
of diarrhoea within one week. Three months later, a
second jejunal biopsy showed a normal histology and an IEL
count of 15%. This time, frozen sections were available
for tS+ cells in epithelium, which were absent. The sugar
permeability test was slightly abnormal (0.042). She
remains on a GFD, with good appetite and weight
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increased.
Mrs JF. This 49-year-old woman presented with diarrhoea
for 3 weeks, lower abdominal pain and weight loss. Her
sister has coeliac disease. She had a diagnosis of
coeliac disease based on jejunal biopsy with mild chronic
inflammation, an IEL count of 42% but no tS+ IELs. Her
sugar permeability test was abnormal (0.052). She
responded clinically to a GFD. One year later, she was
re-admitted because of the recurrence of the original
symptoms. Further investigations revealed a normal rectal
biopsy, an active chronic gastritis in stomach, minimal
changes in jejunum (IEL count of 28%, no tS+ IELs), and a
colonic chronic inflammatory infiltrate compatible with
microscopic colitis. Her sugar test was borderline
(0.042), and she had a CIA negative jejunal fluid on both
occasions. Within 2 weeks of re-introducing gluten in her
diet, she had an episode of watery diarrhoea, which
confirmed her clinical sensitivity. She was recommended
to continued a strict GFD for the rest of her life. At
the time of completion of this thesis this patient is on
the list for biopsy.
Mr AB. This 27-year-old man had a 10 year history of
lower abdominal pain and watery diarrhoea, which
alternated with episodes of constipation. His jejunal
biopsy showed minimal changes, with a high IEL count
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(75%) and an increased number of rS IELs (7.1/mm). The
sugar permeability test was grossly abnormal (0.173). The
ileal function (SeHCAT test) was also abnormal,
suggesting a moderately severe bile acid malabsorption.
He has been found to be a-1 anti-trypsin deficient
(phenotype PiSZ). He had a CIA negative jejunal fluid and
serum antigliadin antibodies were not detected. The
provisional diagnosis was idiopathic diarrhoea. When he
was reviewed one year later, the symptoms persisted, and
a trial of GFD was recommended. At the time of completion
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CHAPTER XI. GENERAL DISCUSSION AND CONCLUSIONS
Inappropriate immunity to gliadin without mucosal
histological changes may be more common than previously
realized. Between 15 and 20% of the non-coeliac patients
we studied were CIA positive, and some of them had a high
IEL count. Almost 40% of patients had one or more
immunological indices of potential coeliac disease. CIA
positive patients are certainly gluten sensitized in one
sense, because they produced high titers of specific
anti-gliadin antibodies. A high IEL count suggests the
existence of an enteropathy, which is restored to normal
after gluten restriction. They are, by definition,
gluten-sensitive. High tS IEL counts have a positive
correlation with the CIA pattern, but these cells are
related to the genetic markers of the disease (Holm
1993), rather than the dietary status.
Studies of jejunal fluid antibodies, and counts of total
and tS IELs, may be a useful screening test to determine
patients suitable for follow-up to determine latent
coeliac disease. These may also include cases with
biopsies unsuitable for histological assessment, patients
with late relapse after gluten challenge, or those in
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whom a proper biopsy was not taken before treatment. An
abnormal immune activity in mucosa may affect the
intestinal function even before morphological changes are
observed. Most patients for diagnostic jejunal biopsy are
referred because of small bowel symptoms, but some also
have nutritional deficiencies, sometimes increased by
poor intake, blood loss or metabolic stress (eg
infection, pregnancy). Previous work on latent coeliac
disease has not considered the possibility of latent
coeliac disease in asymptomatic patients.
Diagnostic criteria of latent coeliac disease are
stringent, and the diagnosis is usually made in
restrospect or by chance. Thus we have suggested that the
term potential coeliac disease may be more appropiate in
clinical practice, to be used while dietary manipulations
are undertaken in patients suspected to be latent
coeliacs (Ferguson 1993). If the findings are positive,
the diagnosis of low-grade coeliac disease is confirmed.
Coeliac and DH patients whose intestinal lesions have
resolved on a GFD and whose jejunal biopsies are
classified as "normal" for diagnostic purposes may still
express subtle pathological or immunological
abnormalities similar to those of untreated coeliacs.
These include a high count of villous IEL (Ferguson &
Murray 1971), an increased expression of the rS T cell
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receptor by IELs (Savilahti 1990), abnormal intestinal
permeability (Bjarnason 1983), and high levels of IgM
anti-gliadin antibody, other class antibodies, and IgA
anti-gliadin antibody in specimens of jejunal fluid and
whole gut lavage fluid (O'Mahony 1991a).
All of these features can be used as putative markers of
latent coeliac disease. TCR tS+ IELs have been found
increased in DH patients and in a case of latent coeliac
disease detected during a family study (Savilahti 1990,
1992; Maki 1991a; Holm 1993a-b) . High ARA and AEM titres
are present in some healthy coeliac relatives (Maki
1990). Intestinal permeability changes have also been
reported in first-degree relatives of coeliacs (Bjarnason
1983) . Up to 30% of coeliac relatives with normal biopsy
histology had high tS+ IEL counts, and this is associated
with the HLA-DQa/B coeliac associated gene markers.
A new method of identifying potential cases is presented
in this thesis, based on the observation that the
intestinal antibody pattern of coeliac disease - CIA -
also occurs in DH patients with normal biopsy histology
on a gluten-containing diet (O'Mahony 1990a), and it may
provide a diagnostic index of latent coeliac disease in
other situations. The CIA pattern may only identify
potential coeliac cases, because gluten sensitivity still
requires clinical monitoring on a GFD and after a gluten
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challenge. It is important to emphasize that a high
density of villus IELs may be the only pathological
expression of gluten sensitivity in coeliac patients
(Marsh 1989a), defining a mild but significant
enteropathy, rather than a truly latent condition. Thus
a positive result for total IEL count may have different
implications compared with positive findings for the other
parameters examined.
The approach to the recognition of latent coeliac disease
in this thesis differs from other similar studies in the
group of patients concerned. Other reports have targeted
specific groups, particularly first-degree relatives of
coeliacs, which have an expected high incidence of
positivity for the coeliac HLA-associated haplotypes.
However, the scope of this study has been much wider,
since the only selective criteria used is referral for
diagnostic small bowel investigations.
Coeliac disease is a life-long condition, and latent
coeliac disease refers to those patients with a genetic
predisposition, in which the disease is not manifested by
enteropathy at the time of the study. The best example is
DH patients with normal jejunal biopsies, and they
provide the only well defined group of patients in whom
in-vivo dietary manipulations (the current gold standard)
lead to the development of a gluten-sensitive enteropathy
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in many cases. The existence of latent coeliac disease
implies that the finding of a normal jejunal biopsy does
not completely exclude gluten sensitivity, and patients
may be identified by the expression of immunological
abnormalities, similar to those which persist in treated
coeliac and DH patients after healing of the enteropathy.
There was a positive correlation between high counts of
IELs and the expression of HLA-DR antigens by crypt
enterocytes in patients with morphologically normal
mucosa. This suggests that amongst the range of
immunological abnormalities described in these patients,
a high total IEL count may identify cases more likely to
have a mild DTH reaction in the intestine, whereas other
abnormalities (ie. CIA pattern, high tS+ IEL counts) are
not related with an active process in the intestine.
Two interesting angles emerge from this study, and both
affect the management of patients referred for diagnostic
jejunal biopsy. First, there is the need to investigate
those patients found to be positive for tS+ expression by
IELs, CIA pattern, etc; probably in connection with the
study of other genetic markers associated with the HLA-DQ
locus. Second, the selection of patients who need to
undergo a trial of GFD will require a complete re-think,
with the consequent revision of the diagnostic criteria
of the disease. Patients positive for at least two
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markers and the expression of the HLA-DQa/B heterodimer,
should be followed up. The diagnosis of latent coeliac
disease would be confirmed earlier by a clinical trial of
gluten sensitivity in order to introduce a GFD in
sensitized patients.
Further elucidation of the relationships between these
immunological phenomena and the clinical entity of
coeliac disease will require not only direct, in vivo
investigations of gluten sensitivity in potential coeliac
patients, but also characterization of the genetic make¬
up of both coeliac and non-coeliac patients, who do or do
not have the immune abnormalities described above.
CONCLUSIONS
1. Untreated coeliacs have high levels of IgA and IgM
antibodies in intestinal secretions; the pattern is
characterized by a polyclonal increase of IgM antibodies.
2. This antibody pattern is maintained in coeliac
patients after treatment and healing of the intestinal
mucosa. DH patients without enteropathy also have a
similar pattern in jejunal fluid.
3. Some non-coeliac symptomatic patients referred for
222
diagnostic jejunal biopsy have a "coeliac-like intestinal
antibody" - CIA - pattern in jejunal fluid, and they may
be latent coeliacs.
4. These non-coeliac patients may express other putative
markers of latent coeliac disease, such as high total IEL
counts and a high proportion of TCRr<S+ IELs. Patients
positive for any of these markers should be described as
"potential coeliacs".
5. A positive CIA pattern is correlated with high numbers
of tS T cells in epithelium in non-coeliac patients.
6. Patients positive for 3 markers: the CIA pattern, high
counts of total IELs and tS+ IELs, may be latent
coeliacs; as has been shown in the case who later
developed an enteropathy after a trial of gluten loading.
7. Some of these symptomatic non-coeliac patients
responded clinically to the trial of a gluten-free diet.
8. Non-coeliac patients with morphologically normal
biopsy but a high IEL count more frequently expressed
HLA-DR antigens in jejunal crypt epithelium than those
patients with normal counts, suggesting the existence of
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We examined humoral immunity in coeliac
disease as expressed in serum (systemic
immunity), and in saliva, jejunal aspirate, and
whole gut lavage fluid (mucosal immunity).
The aims were to define features of the secre¬
tory immune response (IgA and IgM con¬
centrations and antibody values to gliadin and
other food proteins measured by enzyme
linked immunosorbent assay (ELISA)) in
active disease and remission, and to establish
whether secretions obtained by relatively non¬
invasive techniques (saliva and gut lavage
fluid) can be used for indirect measurements of
events in the jejunum. Serum, saliva, and
jejunal aspirate from 26 adults with untreated
coeliac disease, 22 treated patients, and 28
immunologically normal control subjects were
studied, together with intestinal secretions
obtained by gut lavage from 15 untreated and
19 treated patients with coeliac disease and 25
control subjects. Jejunal aspirate IgA and IgM
and gut lavage fluid IgM concentrations were
significantly raised in patients with untreated
coeliac disease; the lavage fluid IgM concen¬
tration remained higher in patients with treated
coeliac disease than in controls. Serum and
salivary immunoglobulin concentrations were
similar in the three groups. Patients with
untreated coeliac disease had higher values of
antibodies to gliadin compared with treated
patients and control subjects in all body fluids
tested; these were predominantly of IgA and
IgG classes in serum, and of IgA and IgM
classes in jejunal aspirate and gut lavage fluid.
Values of salivary IgA antibodies to gliadin
were significantly higher in untreated coeliacs,
though antibody values were generally low,
with a large overlap between coeliac disease
patients and control subjects. In treated
patients, with proved histological recovery on
gluten free diet, serum IgA antigliadin anti¬
body values fell to control values, though
serum IgG antigliadin antibody values
remained moderately raised. In contrast, there
was persistence of secretory antigliadin anti¬
bodies in treated patients (particularly IgM
antibody) in both jejunal aspirate and gut
lavage fluid. Antibody responses to belalacto-
globulin and ovalbumin were similar to those
for gliadin, including persistence of high intes¬
tinal antibody values in patients with treated
coeliac disease. There was a positive correla¬
tion between antibody values in jejunal
aspirate and gut lavage fluid, but not between
saliva and jejunal aspirate; thus salivary anti¬
bodies do not reflect intestinal humoral
immunity.
Systemic humoral immunity in coeliac disease
has been the subject of intensive investigation.
Numerous studies have established that patients
with untreated coeliac disease have high values of
circulating antibodies to wheat derived proteins
such as gliadin, and that antibody values fall after
a period of treatment with a gluten free diet.'"1
Estimation of serum IgA antigliadin antibody is
now routinely used both as a screening test for
coeliac disease and as a means of assessing dietary
compliance.
In contrast, information on mucosal immunity
in coeliac disease is patchy. There have been
many studies of mucosal lymphoid cells" and
there is circumstantial evidence of a local cell
mediated immune response to gluten." Several
studies have carefully mapped the numbers of Ig
producing plasma cells in the jejunal mucosa of
patients with untreated and treated coeliac
disease,'10 showing that untreated patients have
increased numbers of IgA and IgM (and to a
lesser extent, IgG) jejunal plasma cells. In the
1970s, the presence of intestinal antibodies to
food antigens was recognised by a relatively
insensitive precipitin technique," but there are
only two studies published," " both in children,
on the isotype of antibodies to dietary antigens in
intestinal secretions, and these give conflicting
results.
The general objectives of this study were
twofold. In relation to coeliac disease, our aim
was to characterise, in vivo, intestinal humoral
immunity. Total immunoglobulins and specific
antibodies to gliadin and to two antigens which
are not toxic in coeliacs were measured in three
different mucosal secretions. Untreated and
treated patients with coeliac disease were studied
to determine whether abnormalities of secretory
immunity are permanent and intrinsic to the
coeliac diathesis or are only present in active
disease. Separately, and of relevance to the
clinical investigation of mucosal immunity, we
studied the relations between systemic and intes¬
tinal antibodies, and we examined our data to
establish whether patterns of immunoglobulins
and antibodies in jejunal fluid are mirrored in
other secretions which can be obtained without
intubation. The salivary glands are considered
part of the common mucosal immune system,"
and we therefore studied pure parotid saliva. We
also used a whole gut lavage technique for the
non-invasive collection of intestinal secretions.'5
Methods
PATIENTS STUDIED AT THE TIME OF JEJUNAL
BIOPSY
Specimens of saliva, jejunal aspirate, and serum
were collected at the same time as jejunal biopsy
on 76 occasions in 69 patients. There were 41
patients with coeliac disease (seven studied
twice), (23 women and 18 men; median age 42
years, range 15-78) and 28 control patients (14
30 O'Mahony, Arranz, Barton, Ferguson
women, 14 men, median age 35 years, range
14-75). Control subjects had jejunal biopsy to
exclude cocliac disease - jejunal histology in
these patients was normal, no other significant
pathology was found, and a final diagnosis of
functional bowel disease was made. Twenty six
of the patients with coeliac disease were un¬
treated and histological examination of the
jejunal biopsy specimens showed subtotal or
severe partial villous atrophy. Seven of these and
a further 15 patients with treated coeliac disease
(all with previous diagnostic biopsy specimens)
underwent biopsy again while on a gluten free
diet. The median period on gluten free diet was
three years (range 3 months - 17 years). Eleven
had entirely normal jejunal histology (all of these
had been taking a gluten free diet for at least two
years), and 11 had minor histological changes -
for example increased intraepithelial lympho¬
cytes (most patients in this group had been
taking a gluten free diet for less than one year).
PATIENTS STUDIED BY WHOLE GUT LAVAGE
Gut lavage was carried out in 15 untreated coeliac
disease patients, 19 with treated disease, and 25
control patients. These included 10, eight, and
two patients respectively from each group who
had also had collection of jejunal aspirate. The
median period on a gluten free diet in patients
with treated cocliac disease undergoing gut
lavage was eight years (range 3 months - 19
years). Eleven of the patients on a gluten free diet
had in the past shown a clinical and histological
response to the diet, but did not undergo biopsy
again at the time of this study. Gut lavage was
carried out in 25 control patients (16 women and
nine men, median age 52, range 21-92 years).
These subjects were either healthy volunteers or
patients with functional bowel disorder.
SPECIMEN COLLECTION AND PROCESSING
Saliva: parotid salivary flow was stimulated with
5% citric acid sublingually in four 0- 5 ml aliquots
over five minutes, and collected via a Carlsson-
Crittenden cup placed over the parotid duct,
with gentle aspiration to maintain position and
suction. We collected stimulated saliva only.
Jejunal aspirate: samples were collected from a
point just distal to the duodcnal-jejunal junction,
through the tubing of the Crosby capsule, before
taking the biopsy specimen. The protease
inhibitor phenylmethyl sulphonylfluoride
(PMSF, Sigma) 100 mM in 95% alcohol (20 pi
per ml of aspirate) was added before aliquoting."
Serum was obtained from all patients.
Gut lavage: the lavage fluid used was a poly¬
ethylene glycol (PEG) based electrolyte lavage
solution (Golylely). After an overnight fast,
patients drank this solution at a rate of 250 ml
every 15 minutes for a period of four hours,
making the total volume consumed four litres.
Specimen collection began once the material
passed per rectum became liquid, clear, and free
of faecal material. Approximately 200 ml was
collected and filtered into 50 ml polypropylene
tubes; specimens were centrifuged and treated
with protease inhibitors as described by Gaspari
etal."
All the above specimens were aliquoted and
stored at -70"C.
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
Reference materials and reporting of results
For assays of immunoglobulins in the various
secretions, serial twofold dilutions of a standard
preparation were used to produce a standard
curve. For example, for IgA assays dilutions
ranging from 1250—19-35 ng'ml of a human
colostral IgA standard (Sigma) were used in each
test run. Serial dilutions of test samples (varying
in initial dilution depending on the type of
specimen) were also assayed. Only when the
optical density results of at least two of these
sample dilutions fell within the range of the
standard curve was the assay considered techni¬
cally satisfactory. The IgA content of the sample
was then determined by taking the mean IgA
content of these two sample dilutions. For total
IgM and IgG in secretions human reference
serum (Protein Reference Unit, Sheffield) was
used as a standard.
In the assays of specific antibodies, experi¬
ments were carried out to define optimal test
conditions for each antigen, isotyp>e, and secre¬
tion. Serum from a patient with untreated coeliac
disease, previously recognised as having high
litres of antibodies of all isotvpes to a wide
variety of dietary antigens, was used as a
reference standard. The reference specimen and
test specimens were studied at suitable dilutions,
varying for the different assays, and the plates
were read when the optical density for the
standard reached 10. Results for test specimens
are expressed as optical density readings, % of
this standard. Results are thus expressed as non-
parametric data; aniibody values are not directly
proportional to the antigen binding capacity of
the sample. This is a feature of all such assays.
Immunoglobulins (jejunal aspirate, gut lavage fluid,
and saliva)
Assays were performed in 96 well microtitre
ELISA plates (Dynatech). All reactants were
added in volumes of 0125 ml per well and all
washes were done three times using saline with
0 05% Twcen-80 added. For the assay of total
IgA, wells were coated with 100 ng/ml affinity
purified goat antihuman IgA (Northeast Labs) in
01 M carbonate buffer, pH 9 6, and incubated
overnight at 4°C and washed. After washing,
serial twofold dilutions of standard and samples
(initial sample dilution 1/100) were added to the
coated wells. Plates were incubated overnight at
4°C and washed. Goat antihuman IgA con¬
jugated with alkaline phosphatase (Northeast
Labs) diluted (in saline with 1% fetal calf serum
and 0 05% Tween-80) to a predetermined
optimal value was added and plates were in¬
cubated for three hours at 20°C. After washing,
paranitrophenylphosphate (PNPP, Sigma)
1 mg/ml in 10% diethanolamine (DEA) buffer,
pH 98, was added. Plates were read at optical
density 405 in an MR580 microELISA reader
(Dynatech). The IgA content of any given
sample was determined as described above.
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The method used to determine total IgM and
IgG in secretions was similar; initial sample
dilution was 1/25.
Serum immunoglobulins were measured by
autoanalyser using an immunoturbidimetric
method.
antigen and showing that the antibody was
specifically absorbed out. In a study of 20
samples, the within plate optical density coeffi¬
cient of variation was 7 3%, and the between
plate optical density variation was 111%. If the
optical densities of the duplicate sample dilu¬
tions varied by >15%, the assay was repeated.
Food antibodies
The assay was similar to that described above.
Immulon 2 (129B) ELISA plates (Dynatech)
were used. Wells were coated with antigen
(gliadin, betalactoglobulin and ovalbumin) at a
concentration of 5 pg/ml. Betalactoglobulin and
ovalbumin were supplied by Sigma; gliadin was
supplied by Dr Stefan Strobel. Reference stan¬
dard and samples were added in duplicate dilu¬
tions to the coated wells. The following sample
dilutions were used: serum: 1/100 (IgA and IgM)
and 1/200 (IgG); jejuna! aspirate: 1/10; gut lavage
fluid: 1/2; saliva: 1/2. An appropriate dilution of
standard was included in each assay; these
dilutions gave optimal optical density readings.
We established that these antibodies were
specific by incubating samples with the relevant
.ABLE I Immunoglobulin concentrations (median (range)) in serum (mg/ml), jejunal aspirate,
'lit lavage fluid, and saliva (pg/ml)
lg Untreated Treated Control
class coeliac patients coeliac patients subjects
Arum IgA 2-4(1-3—3-8) 2-0(0 7-3-3) 1-8(0 9-t-l)
IgM 1-1 (0 3-3-4) 0 9(0 3-3-1) 1-3(0-3-4-5)
IgG 10-5(5-6-15-7) 10 7 (5 4-20 1) 9 5 (7-3-15 9)
cjunat aspiralc IgA 290*(25-2282) 140-7(20-1558) 102 5(22 9-540 6)
IgM 29 8*t (1 9-357 9) 9 6 (0-174-4) 4 5(0-39-5)
IgG 23 9* (3-261 8) 11 8(0-3-271-4) 7 3 (1 2-29 3)
till lavage fluid IgA 146 2 (10 7—187-5) 90 8(8-8-621-8) 139-7(7 9-403)
IgM 17 5* (2 1-100 1) 25 7'(0-192-2) 5 3 (0-37)
IgG 2-7(0-1-34-9) 0 9(01-11-4) I 0 (0-12 2)
ialiva IgA 123-8(48-6-454) 1181(32-2-838-2) 165 8(66-5-606 9)
IgM 1 2 (0 1-138 9) 1 4 (0 1-12 4) 1 1 (0 1-3 6)
IgG 1 3(0-251) 0 9(01-10-6) 0-5(0-34-3)
Immunoglobulin concentration significantly higher (p<0 05) than in control subjects.
Immunoglobulin concentration significantly higher (p<0 05) than in treated coeliac disease patients.











iliadin IgA 43 7't (4 6-150) 5 8 (0 3—41 9} 5-3 (0—44-5)
IgM 43 0(19 3-95 4) 38 6(10-5-87-6) 47 9(16 1-108 8)
IgG 82 4*t (9 8-137-4) 41 6* (6 8-107-4) 21 (0-105-2)
31.G IgA 14 7*t(L4-150) 6 6* (2 1-87-5) 3 3 (0 2-36 4)
IgM 33-6(9-125-5) 38-7(11 3-94 6) 27 4 (3 5-82-2)
IgG 94-7* (5-150) 70 2(8 6-150) 30 9(0-131-8)
)VA IgA 18 8* (2 6-150) 14 8(4 8-60 6) 11 4 (0 9-35 9)
IgM 31-1(4-87) 37 8(9 5-123 4) 30 0(5 7-102 6)
IgG 64-4(2 6-150) 63 4' (8-4-150) 27-6(3-6-150)
AntiNxiy values significantly higher (p<0 05) than in control subjects.
Antibody values significantly higher (p<0 05) than in treated cocliac disease patients.
IL(» - betalactoglobulin; OVA = ovalbumin.
ARI.F. HI Jejunal aspirate antibody
Untreated Treated Control
h cocbac patients cocltac patients subjects
Irmgrrf class (n = 26) (n = 22) (n = 28)
Iliadin IgA 26 5*| {0 7-134 5) 4 0* (0 3-34-2) 1 1(0-13 3)
IgM 80 5*1 (0-1-150) 19 6* (2-1-114 4) 1-9(0-11-7)
IgG 1 8*1(0-23-4) 10* (0-4-8) 0 2(0-2-2)
11.(5 IgA 25 3* (0 6-150) 9 2 (1 1-110 9) 5 0(0 1-60 8)
IgM 16 4*(0-150) 9 2* (1 1-78 3) 1 6(0-11-7)
IgG 4 5* (0 104) 1 6(0-351) 1 0(0-7-7)
>VA IgA 15 8*(4-150) 19 6* (1 5-66 5) 4 2 (0-100 5)
IgM 18-7*(0-97) 8 4*(0 1-52.5) 1 1(0-17-7)
IgG 1-3* (0-26-2) 1-1 (0-11-7) 0 5(0-26-5)
STATISTICAL METHODS
Differences in antibody values and immuno¬
globulin content were analysed using the Mann-
Whitney U test. For correlations, Spearman's
test was used.
Results
IMMUNOGLOBULIN CONCENTRATIONS (TABLE I)
Serum
No significant differences were observed.
Jejunal aspirate
Untreated coeliac disease patients had signifi¬
cantly higher jejunal aspirate concentrations of
IgA, IgM, and IgG compared with controls, and
higher IgM compared with patients with treated
coeliac disease. Values for treated coeliac disease
patients were not significantly different from
those of control subjects.
Gut lavage fluid
IgM content was significantly higher in both
untreated and treated coeliac disease patients
than in control subjects .
Saliva
No significant differences were observed.
ANTIBODIES TO FOOD PROTEINS
Serum (Table II)
Untreated coeliac disease patients had high
values of serum IgA antigliadin antibody, with
values for treated coeliac disease patients similar
to control values. High values of serum IgG
antigliadin antibody were found in both un¬
treated and treated coeliac disease patients, with
significantly higher values in the untreated
patients. There were no significant differences
between patient groups in values of serum IgM
antibodies. Patterns of serum antibodies to OVA
and betalactoglobulin were generally similar to
those for antigliadin antibody, as detailed, with
statistical information in Table II. Untreated
patients had high values for IgA and IgG anti-
betalactoglobulin antibody and IgA anti-
ovalbumin antibody. Serum IgA anti-bctalacto-
globulin and IgG antiovalbumin antibody values
were higher in treated patients than in control
subjects.
Antibody values significantly higher(p<0 05) than in control subjects.
Antibody values significantly higher (p<0 05) than in treated coeliac disease patients.
1!.(»- hctalactoglobulin; OVA = ovalbumin.
Jejunal aspirate (Table III)
There was very little antibody detected in jejunal
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;gurc I: Jejunal aspirate
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itibody values. (Median
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Figure 2: Cut lavage fluid IgA and IgM antigliadin antibody
values. (Median antibody levels shown as horizontal bars.)
aspirates from control subjects, but as detailed in
Table III, for all three isolypes and all three
antigens studied, antibody values were signifi¬
cantly higher in jejunal aspirates from untreated
patients than from control subjects (p values all
<0 02). For antigliadin antibodies, values in
treated cocliac patients were intermediate
between untreated coeliac disease patients and
control subjects and significantly different from
both. When antibody values in the 11 treated
patients with entirely normal jejunal histology
were compared with those in control subjects,
IgA antigliadin antibody values were not signifi¬
cantly higher. Conversely, IgM antigliadin anti¬
body values remained significantly raised
(p<0 005) in this group. Antibodies to betalacto-
globulin and ovalbumin showed a greater over-
RI F. IV Gut lavage fluid antibody values
Untreated Treated Control
h coehac patients coeliac patients subjects
tigen class (* = IS) (n=!9) (* = 25)
indin IgA 53 6*t (2-2-137 8) 9-2* (0-4-72-9) 2 2(0-57-9)
Ig.M 56 9*t (8-150) 17 9* (0 2-150) 3 1 (0-88-7)
IgG 0 4* (0 2-19) 0 6(0-3) 0 2(0-6-5)
.G IgA 7 9*(I 8-85-5) 8 4 (0 6-76 5) 3 5 (0 1-712)
Ig.M 5 6* (0-14-5) 5-3* (0-53) 0 1 (0-22-6)
IgG 0-7(0-21) 0 4(0-8-1) 0 4(0-4-4)
A IgA 15 0* (3-7-39 3) 14-7* (0 5 -46-8) 4 8(0-76)
IgM 6 6' (0 8 33 3) 3 6* (0—46 3) 0 9(0-20 6)
IgG 0 3* (0-13) 0-0 (0-61-2) 0 0(0-3-6)
miNxjv values significantly higher (p<0 05) than in control subjects.
ntihody values significantly higher (p<0 05) than in treated coeliac disease patients.
RI F v Salivary antibody values
Untreated Treated Control
lg coehac patients coeliac patients subjects
it/ten class (* = 26) (*=22) (•> = 28)
ndin IgA 5-l't(0-1-29-6) 4 2(0-12-5) 3 0 (0-117)
IgM 5 I(0-150) 5 4(0-35-9) 2 4(0-15-5)
IgG 0 3*(0-17 9) 00(0-4-6) 0 0(0-7-6)
.G IgA 8-3* (1-9-53-7) 8 3* (0-46-5) 5 3(0-29-8)
IgM 1-0(0-28-3) 1 2(0-14 4) 0 8(0-11-9)
IgG 0 4(0-5 8) 0 0(0-18 8) 0 0(0-2 9)
A IgA 15 8 (1 9-92 9) 13 2 (0 6-34) 14 3 (3 4-30 2)
IgM 1-2(0-34 1) 1 4(0-16-7) 1-3(0-13-3)
IgG 0 0(0-13) 0 0(0-3 I) 0 0(0-1-7)
nlihody values significantly higher (p<0 05) than in control subjects.
ntihody values significantly higher (p<0 05) than in treated cocliac disease patients.
.(»- bctalactoglobulin; OVA =• ovalbumin.
lap between values in coeliac disease patients and
control subjects, but again high IgM antibody
values persisted in the treated patients.
Jejunal aspirate IgA and IgM antigliadin
antibody values are shown in Figure 1.
Gut lavage fluid (Table IV)
As in jejunal aspirate, high values of IgA and
IgM antibodies to gliadin were found in both
untreated and treated coeliac disease patients
compared with control subjects, with signifi¬
cantly higher antibody values in the untreated
compared with the treated patients. High values
of IgA and IgM antibodies to betalactoglobulin
and ovalbumin were found in untreated patients;
high values of IgA and IgM anti-ovalbumin and
IgM anti-betalactoglobulin antibodies persisted
in the treated coeliac disease patients.
Gut lavage fluid IgA and IgM antigliadin
antibody values are shown in Figure 2.
Saliva (Table V)
Salivary antibody values were generally low,
with large overlaps beween patient groups. Un¬
treated coeliac disease patients had higher values
of IgA and IgG antigliadin antibodies compared
with control subjects; only IgA antigliadin anti¬
body values were higher than in the treated
patients. Higher values of IgA anti-betalacto-
globin antibody were found in both untreated
and treated coeliac disease patients compared
with control subjects.
SERIAL STUDIES IN COELIAC DISEASE PATIENTS
Seven cocliac disease patients who had a clinical
and histological response to a gluten free diet
were studied before and after treatment. Serial
changes in serum IgA antigliadin antibody and
jejunal aspirate IgA and IgM antigliadin anti¬
bodies are shown in Figure 3. Whereas serum
antibody values fell significantly (p<0 05) with
treatment, there was no significant change in the
values of intestinal antibody despite histological
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recovery on a gluten free diet. There was, in fact,
a trend towards higher values of IgM antibody
after treatment. It should be noted that these
seven patients had been taking a gluten free diet
for six months or less, which may account for the
fact that they behaved differently from the
treated coeliac disease patients as a whole, who
had significantly lower jejunal aspirate antibody
values compared with untreated coeliac disease
patients.
CORRELATIONS BETWEEN ANTIBODY VALUES IN
JEJUNAL ASPIRATE, GUT LAVAGE FLUID, SERUM,
AND SALIVA (TABLE Vl)
IgA antigliadin antibody values were compared
in the various body fluids tested. In the untreated
coeliac disease patients, we found a positive
correlation between antibody values in serum
and jejunal aspirate (r = 0'68, p<0 0001) but in
the treated coeliac disease patients this correla¬
tion was not maintained as they had high values
of jejunal aspirate antibody, whereas serum
antibody values were low or absent. In the
control group, there was a positive correlation
(r=0 59, p<0'001) between antibody values in
serum and saliva. No correlation was found
between salivary and jejunal aspirate antibody
values in any of the three groups.
Both jejunal aspirate and gut lavage fluid had
been collected from 20 patients (from all three
patient groups). A positive correlation (r=0 79,
p<001) was found between antibody values in
jejunal aspirate and gut lavage fluid.
ment with a gluten free diet. It is possible that the
intestinal IgA antigliadin antibody and minor
histological changes could both be due to con¬
tinued ingestion of small amounts of gluten.
Conversely, intestinal IgM antibody values
remained higher than in control subjects, even in
patients with completely normal jejunal mucosa
who had been taking a gluten free diet for some
years. It is likely that minute amounts of gluten
(complete compliance to a gluten free diet is
difficult to achieve in adults) maintains a local
immune response rather than a systemic one.
Our finding of a persistent IgM antibody res¬
ponse parallels the finding of a relatively high
fraction of IgM plasma cells in treated coeliac
disease patients.'
We found high values of serum IgA and IgG
antigliadin antibody in untreated coeliac disease
patients. In the treated patients, serum IgA
antigliadin antibody values were similar to those
in controls but serum IgG antigliadin antibody
values, though significantly lower than in the
untreated coeliac disease patients, remained
significantly higher than in control subjects.
These findings agree with those of other
reports." "
Concentrations of IgA, IgM, and IgG were all
high in jejunal aspirates from untreated coeliac
disease patients. Counts of jejunal plasma cells
and in vitro immunoglobulin production in
coeliac disease are higher than in control subjects
for all isotypes,10 supporting the view that the
immunoglobulins (at least IgA and IgM) in
coeliac intestinal secretions are produced locally.
Discussion
Intestinal antigliadin antibodies in coeliac
disease patients were mainly in the IgA and IgM
classes, and significant amounts of IgM antibody
persisted in the secretions of treated coeliac
disease patients with entirely normal jejunal
histology. Secreted IgA antibody was detected
only in the subgroup of treated coeliac disease
patients with minor histological abnormalities,
most of whom had had less than a year's treat¬
TABLE VI Correlation between IgA anli^liadin antibody
values in serum, jejunal aspirate, and saliva
Scrum and Scrum and Saliva and
Group saliva aspirate aspirate
Untreated coetiac disease r=0 02I r=0 6l r=0 293
(n = 26) (NS) (p<0-0001) (NS)
Treated coeliac disease r=0 392 r=0 04 r=0 323
(n = 22) (NS) (NS) (NS)
Control subjects r = 0 593 r=-0 193 r=0 071
(n = 28) (p<0 001) (NS) (NS)
NS = no( significant.
Serum IgA anti - gliadin
GFD
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It is likely that most of the jejunal IgG is plasma
derived as the numbers of IgG secreting plasma
cells are low even in untreated coeliac disease.'
We should point out that immunoglobulin
measured in jejunal aspirate was total immuno¬
globulin and not specific secretory IgA and IgM.
It is possible that at least some of the jejunal IgA
and IgM is serum derived (coeliac disease is a
protein losing disorder). We are currently
characterising jejunal immunoglobulins and
antibody in terms of molecular weight and
percentage of total Ig which contains a secretory
component. An increase in the intestinal fluid
immunoglobulin content was not accompanied
by equivalent changes in serum immuno¬
globulins; in fact, the serum IgM content was
noticeably low in some untreated coeliac disease
patients.
We have not yet assessed the contribution of
specific antigliadin antibody to the increase in
intestinal immunoglobulin content in coeliac
disease. Falchuk and Strober," using an affinity
chromatography technique, reported that
approximately half of the net increase in IgA and
IgM synthesis (in an in vitro model of gluten
challenge) was due to synthesis of antigliadin
antibody. Conversely, in a more recent report of
in vitro secretion of antigliadin antibody by
coeliac jejunal mucosal biopsy specimens,20
Ciclitera et alcalculated that antigliadin antibody
accounted for 2-1%, 121%, and 41% of the total
concentrations of IgA, IgM, and IgG
respectively.
In any event, enhanced intestinal antibody
production in coeliac disease is not limited to
gluten derived proteins: we found high values of
intestinal antibody to betalactoglobulin and oval¬
bumin in untreated coeliac disease patients, with
persistence of IgM antibody to these proteins in
treated patients. Antibodies to these food pro¬
teins were less specific to coeliac disease than
antigliadin antibodies. It has been suggested that
high values of serum antibody to these proteins
in untreated coeliac disease is simply the result of
increased intestinal permeability to antigens.
Although ELISA is now accepted as the
standard assay technique for measuring anti¬
bodies to food proteins in coeliac disease, several
different ELISA methods have been described,
and different reference preparations are used by
each group of investigators. The method we used
is essentially similar to that of Savilahti et al,' and
we used crude gliadin as antigen for the ELISA
(rather than say, alphagliadin), as Skerrit et al"
have shown that sera and intestinal aspirates
from coeliac patients contain antibodies which
bind to several different gliadin subunits. We
have not ascribed levels of 'positivity' or 'nega¬
tivity' to antibody values; such arbitrary designa¬
tions are of some value in screening tests used in
clinical practice but not in prospective research
investigations.
Although untreated coeliac disease patients
had statistically higher values of salivary IgA and
IgG antigliadin antibodies compared with con¬
trols, salivary antibodies were generally low with
a large overlap between patients and controls.
Furthermore, there was no correlation between
jejunal aspirate and salivary antibody values.
Our results do not suggest that antibody tests on
saliva have any diagnostic or screening potential.
On the other hand, gut lavage offers a
relatively non-invasive alternative to intubation
for the collection of intestinal secretions for
immunoglobulin and antibody studies. Anti¬
body findings in gut lavage fluid were broadly
similar to those in jejunal aspirate, with a positive
correlation for IgA antigliadin antibody values in
those patients studied by both techniques.
Immunoglobulin concentrations, however,
differed considerably in jejunal aspirate and gut
lavage fluid; all three immunoglobulin isotypes
were raised in jejunal aspirate in the untreated
coeliac disease patients, whereas only IgM was
significantly raised in gut lavage fluid. Gut lavage
fluid is likely to contain secretions from not only
the small bowel but also gastric juice, bile,
pancreatic secretions, and colonic secretions. In
this respect, it is not a homogeneous fluid, unlike
jejunal aspirate, which reflects events in the
jejunum only, and is thus more likely to
represent accurately local immune phenomena
in coeliac disease. Fluid flow rate is another
factor that may influence Ig values in exocrine
secretions; this may partly account for dif¬
ferences in findings in jejunal aspirate and gut
lavage fluid.
The relevance of gluten reactive intestinal
B cells and antibodies to the pathogenesis of
coeliac disease is uncertain; the presence of
antibodies to gluten derived proteins in patients
with coeliac disease may be merely an epiphe-
nomenon in the context of a T cell mediated
enteropathy with expansion of the relevant
populations of T helper as well as effector cells."
It is certainly possible that mucosal IgM anti¬
body is immunopathogenic, for example by
fixing complement in the immediate vicinity of
enterocytes.
This study shows the dissociation of systemic
and intestinal humoral immune responses in
patients with coeliac disease, and is evidence that
for the study of immunopathology of intestinal
disease, direct investigation of the gut is
mandatory.
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Heterogeneity of Coeliac Disease
Within the framework of the current definition (a permanent gluten-
sensitive enteropathy), clinical, pathological, epidemiological and immuno¬
logical approaches are revealing several forms of coeliac disease. In so-called
active coeliac disease, malabsorption and nutritional deficiencies range from
profound to minimal; clinically silent coeliac disease is being increasingly
recognised, for example in family studies. Pathologically, there is also a
degree of heterogeneity. Descriptive terms such as 'flat mucosa', or 'subtotal
villus atrophy', are the pathologist's shorthand for a cluster of features (villus,
crypt sizes, epithelial cell damage, intraepithelial and lamina propria lym¬
phoid cell infiltrates) which together characterise the enteropathy of coeliac
disease. Quantitative histology and computerised image analysis have shown
that these features occur in a continuum, with the flat lesion at one end of the
spectrum and at the other end a mucosa with normal villus and crypt
architecture, but an abnormally high density or count of villus intra-epithe-
lial lymphocytes (IEL) [1,2]. The latter would be reported as normal by most
clinical pathologists.
This fact is important when one reviews the evidence for the existence of
latent coeliac disease. This term should only be applied to patients who fulfil
the following conditions: (i) have a normal jejunal biopsy while taking a
normal diet, and (ii) at some other time, before or since, have had a flat
jejunal biopsy which recovers on a gluten-free diet.
The suggestion that there might be a 'pre-coeliac' state was first made by
Weinstein [3] who described 2 patients with dermatitis herpetiformis (DH)
and normal jejunal biopsies in whom typical coeliac-like enteropathy devel¬
oped some weeks after 20 g of gluten was added to their already gluten-
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containing diet. Two studies from the UK confirmed this observation [4, 5]
and the concept is supported by case reports of coeliac patients in whom, by
chance, a jejunal biopsy has previously been taken and reported as normal
[6-8],
If full morphometric analysis were to show changes at the mild end of the
spectrum of coeliac-like enteropathy in the original biopsies (as has been
reported in 2 such patients [8]), this would require that the descriptive term
be revised from latent to a more general term such as low grade or mild
enteropathy.
Approaches to the Recognition ofLatent or Low-Grade Coeliac Disease
Coeliacs whose intestinal lesions have resolved on GFD and whose
jejunal biopsies are classified as 'normal' for diagnostic purposes may still
express subtle pathological or immunological abnormalities similar to those
of untreated coeliacs. These abnormalities include a high count of villus IEL
[9]; increased gamma/delta T cell receptor expression by IEL [10]; abnormal
jejunal permeability [11]; and high levels of IgM antigliadin antibody, other
IgM class antibodies, and IgA antigliadin antibody, in specimens of jejunal
fluid and whole gut lavage fluid, as described below [12],
Thus, one approach to the recognition of potential latent or low-grade
coeliacs may be by studies of IEL T cells expressing gamma/delta receptors.
This presents logistic problems, as the relevant immunohistochemical
studies must be performed on frozen sections. Positive results have been
reported in a single case of latent coeliac disease detected during family
studies in Finland [7]. We recently reported that there is a characteristic
pattern of intestinal fluid antibodies in untreated and treated coeliac disease,
which also occurs in DH patients without enteropathy [13]. Studies of
intestinal antibodies might facilitate the detection of latent coeliac disease in
other situations.
Features of the Coeliac-Like Intestinal Antibody Pattern
It is generally agreed that the intestinal fluid in untreated coeliac disease
contains high levels both of IgA and IgM anti-GLI antibody, and that in
contrast to serum antibodies, levels of intestinal antibodies remain high after
healing of enteropathy in GFD-treated coeliacs [12, 14-16]. In a definitive
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study of humoral immunity in coeliac disease, we studied levels of antibodies
to three dietary proteins in serum, saliva, jejunal fluid and intestinal secre¬
tions obtained by whole gut lavage, from untreated and treated coeliacs, and
controls [12],
Concentrations of IgA and IgM were high in jejunal fluid of untreated
coeliacs, as was gut lavage fluid IgM concentration. Lavage fluid IgM
concentration remained higher than controls in treated coeliacs. Untreated
coeliacs had high levels of antigliadin antibodies in all body fluids tested;
these were predominantly of IgA and IgG classes in serum, and of IgA and
IgM classes in jejunal fluid and gut lavage fluid. In treated coeliacs, with
proven histological recovery on a gluten-free diet, serum levels of IgA
antigliadin antibody fell to control levels. In contrast, there was a persistence
of secretory antigliadin antibodies in treated coeliacs (particularly IgM
antibody) in both jejunal fluid and gut lavage fluid. Antibody responses to
beta-lactoglobulin and ovalbumin were similar to those for gliadin, including
persistence of high intestinal antibody levels in treated coeliacs. Key data are
presented in tables 1 and 2.
Thus, we can define a 'coeliac-like intestinal antibody' (CIA) pattern as
the presence in jejunal fluid of IgM anti-GLI together with at least two of the
three other characteristic antibodies, IgA anti-GLI, IgM anti-OVA and IgM
anti-BLG. The significance of a high level of IgM anti-GLI as an isolated
finding, remains to be determined.
It is now clear that CIA+ specimens also contain high concentrations of
total IgM. Indeed, there is considerable evidence in the literature of over-
expression of IgM generally in the intestinal mucosa of coeliacs. Further¬
more. in a recent investigation of intestinal immune responses to an enteric
vaccine, coeliacs generated high levels of intestinal IgM antibodies to a
bacterial antigen, cholera toxin B subunit [unpubl.].
Studies in Dermatitis herpetiformis
We then examined intestinal humoral immunity in 8 patients with DH
who had normal jejunal histology (as determined by quantitative morpho¬
metry) on a gluten-containing diet, to determine whether such patients,
despite the absence of enteropathy, have abnormalities of secretory immu¬
nity similar to those encountered in patients with coeliac disease [13]. As a
group, the DH cases resembled classical untreated coeliacs in their pattern of
secretory immunity with higher than normal concentrations of IgA. IgM and
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Table I. Levels of antibody to gliadin. beta-lactoglobulin and ovalbumin in jejunal fluid,
assayed by ELISA (results are expressed as optical density readings. % of standard
reference preparation, median and range)
Antigen Ig class Untreated coeliac Treated coeliac Controls
(n-26) (n-22) (n = 28)
Gliadin IgA 26.5+'* 4.0* 1.1
(0.7-134.5) (0.3-34.2) (0-13.3)
IgM 80.5+t* 19.6* 1.9
(0.1-150) (2.1-114.4) (0-11.7)
IgG 1.8+'* 1.0* 0.2
(0-23.4) (0-4.8) (0-2.2)
BLG IgA 25.3* 9.2 5.0
(0.6-150) (1.1-110.9) (0.1-60.8)
IgM 16.4* 9 2* 1.6
(0-150) (1.1-78.3) (0-11.7)
IgG 4.5* 1.6 1.0
(0-104) (0-35.1) (0-7.7)
OVA IgA 15.8* 19.6* 4.2
(4-150) (1.5-66.5) (0-100.5)
IgM 18.7* 8.4* 1.1
(0-97) (0.1-52.5) (0-17.7)
IgG 1.3* 1.1 0.5
(0-26.2) (0-11.7) (0-26.5)
*
p < 0.05 vs. control; + p < 0.05 vs. treated coeliacs.
IgG, and high levels of specific antibodies (IgA and IgM) to the 3 food
proteins. Levels of serum IgA antigliadin antibody in the DH patients were
low.
Our finding of a coeliac-like pattern of secretory immunity in DH
patients without enteropathy suggested that investigation of gut humoral
immunity may provide a diagnostic index of latent coeliac disease.
Two-Stage Model of Coeliac Disease
Considerable effort Las been directed towards the development of an
animal model of gluten-sensitive enteropathy. Our studies with mice [17]
showed that immunological sensitisation to gliadin does not trigger the
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Table 2. Levels of antibody to gliadin, beta-lactoglobulin and ovalbumin in whole gut
lavage fluid, assayed by ELISA (results are expressed as optical density readings. % of
standard reference preparation, median and range)
Antigen Ig class Untreated coeliac Treated coeliac Controls
(n = 15) (n = 19) (n = 25)
Gliadin IgA 53.6* 9.2* 2.2
(2.2-137.8) (0.4-72.9) (0-57.9)
IgM 56.9*'+ 17.9* 3.1
(8-150) (0.2-150) (0-88.7)
IgG 0.4* 0.6 0.2
(0.2-19) (0-3) (0-6.5)
BLG IgA 7.9* 8.4 3.5
(1.8-85.5) (0.6-76.5) (0.1-71.2)
IgM 5.6* 5.3* 0.1
(0-14.5) (0-53) (0-22.6)
IgG 0.7 0.4 0.4
(0-21) (0-8.1) (0-4.4)
OVA IgA 15.0* 14.7* 4.8
(3.7-39.3) (0.5-46.8) (0-76)
IgM 6.6* 3.6* 0.9
(0.8-33.3) (0-46.3) (0-20.6)
IgG 0.3 0.0 0.0
(0-1.3) (0-61.2) (0-3.6)
* p<0.05 vs. control; 'p<0.05 vs. treated coeliacs.
development of a T cell-mediated lesion of the intestine when the diet
contains gluten. Additional factors, such as those occurring during intestinal
anaphylaxis or a graft-versus-host reaction, were necessary. Enhanced anti¬
gen presentation, recruitment of specific T cells in the mucosa, up-regulation
of the expression of class II antigens and failure of suppression, are all
candidate mechanisms for the effects observed.
The proposed two-stage model of coeliac disease [13] derives from the
confluence of several lines of clinical and experimental work and can be
stated as follows:
Inappropriate immunity to gliadin is a relatively frequent ocurrence; it is
genetically restricted, and may be expressed not only in gut and skin, but also
in the mouth (recurrent aphthae), kidneys (IgA nephropathy) and joints
(some arthritides). Expression of T cell-mediated immunity to gliadin in the
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gut occurs across a spectrum of histological and functional abnormalities.
The minimal lesion may appear histologically normal, or as a virtually
normal biopsy with a high count of villus IEL; the fully expressed lesion is a
flat mucosa with crypt hyperplasia, typical of coeliac disease.
Mucosal immunological sensitisation is an invariable feature of coeliac
disease but is not the precipitating factor for the expression of the full
intestinal lesion; a second factor drives the enteropathy from minimal
(latent) to overt, either by immunological mechanisms or by direct ancillary
effects on enterocytes. Candidate factors include an episode of hyperpcrmea-
bility, nutrient deficiency, increased dietary gluten, impaired intraluminal
digestion of ingested gluten, adjuvant effects of intestinal infection and a
non-HLA-associated gene. There may be a complementation of these with a
multifactorial trigger mechanism.
Frequency ofPatients with the CIA Pattern in a
Cohort Referred for Jejunal Biopsy
During the last year we assessed the frequency of the CIA pattern in a
prospective study of 140 patients who attended for diagnostic small bowel
biopsy [18]. Forty-two were biopsies in coeliac or DH patients, including 14
newly presenting coeliacs; in the 98 non-coeliac cases, studies ofjejunal fluid
revealed the CIA pattern in 16 cases.
Patients referred to us for jejunal biopsy usually have symptoms sugges¬
tive of coeliac disease, and this was the case for the 16 non-coeliac patients
with a positive CIA pattern. Diarrhoea was the main complaint in 11,
abdominal pain or discomfort in 3 and the other 2 had unexplained and
relatively asymptomatic anaemia. The final diagnoses for patients in the
group of CIA-positive cases were similar to those in the group who were CIA
negative.
Jejunal biopsy histology was reported by a consultant pathologist as
normal in 14, mildly abnormal in two. The lactulose/rhamnose permeability
test was positive in only 4 cases including the 2 with mild pathological
changes; brush-border enzyme assays had been performed in 12 and were
entirely normal in 10 cases. Levels of serum IgG antigliadin antibodies (anti-
GLI) were normal in 9 cases and of IgA anti-GLI in 10.
However, when formal counts of IEL were performed these were found
to be abnormally high in 6 of these 16 patients, 5 with absolutely normal villi
and 1 with minor villus blunting.
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Objective assessment of gluten sensitivity by treatment with a gluten-
free diet will only be possible in those patients who have minor biopsy
abnormalities. Three of the 16 CIA+ patients (2 with high 1EL count, 1 with
mild enteropathy and normal IEL count) have had a trial of gluten restric¬
tion; in 2 there was a rapid resolution of watery diarrhoea and in both of
these a high IEL count was present in the original biopsy and has fallen to
normal after gluten restriction. There was no clinical or pathological effect of
6 months' gluten-free diet in the third patient. A further such patient seen
recently has been found to have a high count of gamma/delta IEL, as well as a
high total IEL count and a positive CIA pattern.
This work may have considerable therapeutic implications. Sixteen of 98
non-coeliac patients were CIA positive. This is similar to the number of new
patients with coeliac disease (14) diagnosed in the course of the study. If
further research confirms that many CI.A+ patients are gluten-sensitive, then
by implication, the previous definition of coeliac disease will have excluded
up to half of the symptomatic patients, referred for jejunal biopsy, who
would benefit clinically from a gluten-free diet.
Theoretical Aspects
We have not yet established the immunopathogenesis of the CIA pat¬
tern. Up-regulation of the IgM component of intestinal immunity could
reflect a primary disorder of B cells, aberrant function of immunoregulatory
T cells, or the existence of an unusual immunostimulant operating in the gut
mucosa. An abnormality of trans-epithelial immunoglobulin transport
mechanisms may also operate.
Further work will show the interrelationships between high total 1EL
count, high gamma/delta 1EL counts, and the presence of the CIA pattern in
patients with normal biopsy architecture. Either these will turn out to be very
sensitive indices of mucosal DTH expression, and all associated with produc¬
tion of IL2 and interferon-y, or their patterns of occurrence may vary in
individual patients, perhaps genetically determined, and relevant to the
induction of a state of aberrant immunity to gluten.
Conclusion
Subtle aberrations from normal occur in the small bowel of most patients
with so-called 'latent' coeliac disease, and comprise a high count of villus
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Table 3. Proposed nomenclature of forms of coeliac disease and associated conditions











normal or high 1EL count
high IEL count
normal or high IEL count
IEL, increased gamma/delta T cell receptor utilisation by IEL, up-regulation
of mucosal IgM responses. One or more of these may be related to the
fundamental immunopathogenesis of the disease, i.e. is the factor which
leads to induction of abnormal mucosal immunity to gliadin; alternatively,
their presence may signal low-grade expression of hypersensitivity. Since
clinical gluten sensitivity exists in a proportion of patients with these biopsy
features, the present pathological description of coeliac disease should be
revised. Treatment with a gluten-free diet (carefully monitored) should be
offered to symptomatic patients with these minor forms of enteropathy.
It is likely that all patients with DH have latent or fully expressed gluten-
sensitive enteropathy. However, only rarely, and usually by chance (e.g.
previous biopsy in a research investigation), do other patients fulfil criteria
for latent coeliac disease. For prospective studies ofcandidate latent coeliacs,
such as those with high IEL count, positive CIA pattern, high gamma/delta
expression of IEL, relatives of coeliacs, IgA-deficient individuals, a more
generally applicable expression is needed. The term potential coeliac disease
(table 3) is proposed.
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Leading article
Clinical and pathological spectrum of coeliac disease - active,
silent, latent, potential
Currently recognised forms of gluten sensitive
mteropathy
\Vithin the framework of the current definition (a permanent
;luten sensitive enteropathy), clinical, pathological,
tpidemiological, and immunological approaches are reveal-
ng several forms of coeliac disease. In so called active coeliac
disease, malabsorption, and nutritional deficiencies range
rom profound to minimal; clinically silent coeliac disease is
reing increasingly recognised - for example, in family
studies. Pathologically there is also a degree of heterogeneity.
Descriptive terms such as 'flat mucosa', or 'subtotal villus
ltrophy', are the pathologist's shorthand for a cluster of
eatures (villus, crypt sizes, epithelial cell damage, intra-
tpithelial and lamina propria lymphoid cell infiltrates) which
ogether characterise the enteropathy of cocliac disease.
Quantitative histology and computerised image analysis have
;hown that these features occur in a continuum, with the flat
esion at one end of the spectrum and a mucosa with normal
.'illus and crypt architecture, but an abnormally high density
rr count of villus intraepithelial lymphocytes, at the other.17
The latter would be reported as normal by most clinical
pathologists. This fact is important when the evidence for the
existence of latent coeliac disease is reviewed. This term
should only be applied to patients who fulfil the following
tonditions: (i) have a normal jejunal biopsy while taking a
tormal diet; (ii) at some other time, before or since, have had
i flat jejunal biopsy which recovers on a gluten free diet.
The suggestion that there might be a 'precoeliac' state was
irst made by Weinstein who described two patients with
fermatitis herpetiformis and normal jejunal biopsies in
A'hom typical coeliac like enteropathy developed some weeks
ifter 20 g gluten was added to their already gluten contain-
ng diet.' Two studies from the United Kingdom have con¬
firmed this observation4' and the concept is supported by
:ase reports of coeliac patients in whom, by chance, a
ejunal biopsy has previously been taken and reported as
lormal."4
Subtle pathological and immunological abnormalities in
iome latent coeliacs
f full morphometric analysis were to show changes at the
nild end of the spectrum of cocliac like enteropathy in the
original biopsies (as has been reported in two such patients)5,
his would require that the descriptive term in these cases be
evised from latent to low grade or mild gluten sensitive
mteropathy. Furthermore, it would greatly facilitate research
tnd clinical management of such patients if there was a means
if identifying them, more widely available and less technically
iemanding than computerised image analysis.
Coeliacs whose intestinal lesions have resolved on a gluten
ree diet and whose jejunal biopsies are classified as 'normal'
or diagnostic purposes may still express subtle pathological
ir immunological abnormalities similar to those of untreated
:oeliacs. These abnormalities include a high count of villus
1EL"; increased gamma/delta T cell receptor expression by
ntraepithelial lymphocytes'"; abnormal jejunal perme-
tbility"; and high concentrations of IgM antigliadin antibody,
nther IgM class antibodies, and IgA antigliadin antibody (the
'coeliac like intestinal antibody' pattern) in specimens of
jejunal fluid and whole gut lavage fluid.1
One approach to the recognition of potential latent or low
grade coeliacs is by studies of intraepithelial lymphocyte T
cells expressing gamma/delta receptors. This presents
logistic problems, as the relevant immunohistochemical
studies must be done on frozen sections, but positive results
have been reported in a single case of latent coeliac disease
detected during family studies in Finland.7
We recently reported that the characteristic coeliac like
intestinal antibody pattern of intestinal fluid antibodies also
occurs in dermatitis herpetiformis patients without entero¬
pathy, a group of patients in whom it is likely that all or most
are in fact latent coeliacs." Similar studies of intestinal
antibodies might facilitate the detection of latent coeliac
disease in other situations.
Two stage model of coeliac disease
We have proposed a two stage model of gluten sensitive
enteropathy, latent and fully expressed." This derived from
the confluence of several lines of clinical and experimental
work and can be stated as follows: induction of a state of
inappropriate immunity (hypersensitivity) to gliadin is a
relatively frequent occurrence, genetically restricted. The
effects of abnormal interaction between the immune system
and gluten may be expressed not only in gut (coeliac disease
and skin (dermatitis herpetiformis), but also in the mouth
(recurrent aphthae), kidneys (IgA nephropathy) and joints
(some arthritides). Within the intestinal mucosa, expression
of T cell mediated immunity to gliadin in the gut occurs
across a spectrum of histological and functional abnormali¬
ties. The minimal lesion may appear histologically normal, or
as a virtually normal biopsy with a high count of villus
intraepithelial lymphocytes; the fully expressed lesion is a flat
mucosa with crypt hyperplasia, typical of coeliac disease.
Studies in mice14 showed that immunological sensitisation
to gliadin does not trigger the development of a T cell
mediated lesion of the intestine when the diet contains
gluten. Additional factors, such as those occurring during
intestinal anaphylaxis or a graft-r>mi«-host reaction, were
necessary. Enhanced antigen presentation, recruitment of
specific T cells in the mucosa, up-regulation of the expression
of class II antigens and failure of suppression, are all
candidate mechanisms for the effects observed.
By analogy, although mucosal immunological sensitisation
is an invariable feature of coeliac disease, it is not the
precipitating factor lor the expression of the full intestinal
lesion; a second factor drives the enteropathy from minimal
(latent) to overt, either by immunological mechanisms or by
direct ancillary effects on enterocytes. Candidate factors
include an episode of hyperpermeability, nutrient deficiency,
increased dietary gluten, impaired intraluminal digestion of
ingested gluten, adjuvant effects of intestinal infection and a
non-HLA associated gene.
Significance of a high count of intraepithelial lymphocytes
In animal work on delayed type hypersensitivity in rodent
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tesiine, a rise in the count of villus intraepithelial lvmpho-
'tes was a sensitive and early feature of the expression of
ucosal delayed type hypersensitivity1' and is induced by
gnals from activated lamina propria CD4 T cells.1" By
lalogy, in clinical practice a high count of intraepithelial
mphocytes in an architecturally normal small bowel biopsy
ill also imply a state of T cell activation, either antigen
iven - for example, by gluten, giardia, histocompatibility
ttigens - or as a result of aberrant mucosal immunoregula-
an (as in some theories of the pathogenesis of inflammatory
rtwel disease).
There is now a substantial body of evidence that the
ipression of gluten hypersensitivity as enteropathy may
; minimal, measurable only if a count of intraepithelial
mphocytes is performed. An accepted name for this type of
athologv is needed, such as 'high density intraepithelial
mphocyte enteropathy'. This must be clearly differentiated
om various other forms of non-coeliac enteropathy, such as
tat of HIV infection.17 Further work will show how a high
turn of intraepithelial lymphocytes relates to gamma delta
itraepithelial lymphocyte counts, and whether these are
lerely sensitive indices of mucosal delayed type hyper-
■nsitivity expression, and all associated with production of
-2 and gamma interferon, or whether high density of
itraepithelial lymphocytes, the unusual up regulation of
;M and/or gamma delta T cell numbers are independent
etors, perhaps genetically determined, relevant to the
iduction of a state of aberrant immunity to gluten, and thus
irectly to the pathogenesis of coeliac disease.
linical importance of an extension of the pathological
riteria for coeliac disease
7e have recently assessed the frequency of the coeliac like
itestinal antibody pattern, a candidate marker of latent
teliac disease, in patients referred for diagnostic small bowel
iopsy. Studies of jejunal fluid revealed the coeliac like
itestinal antibody pattern in 16 of 98 non-coeliac cases, of
hom six also had a high count of intraepithelial lymphocytes
^rranz and Ferguson, submitted). If further research shows
tat some of these patients are clinically gluten sensitive (and
e already have some evidence to support this), then by
nplication, the previous definition of coeliac disease (a flat
tucosa) may have excluded up to half of symptomatic
atients, referred for jejunal biopsy, who would benefit
inically from a gluten free diet. The present pathological
escription of coeliac disease may need to be revised and
eatment with a gluten free diet (carefully monitored)
offered to symptomatic patients with minor forms of
enteropathy.
Only rarely, and usually by chance - for example, previous
biopsy in a research investigation - does a patient fulfil
criteria for latent coeliac disease. A more generally applicable
expression is needed to describe people who should have the
diagnosis of latent or low grade coeliac disease considered -
such as those with high intraepithelial lymphocyte count,
positive coeliac like intestinal antibody pattern, high gamma
delta expression of intraepithelial lymphocytes, relatives of
coeliacs, IgA deficient individuals. The term 'potential
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Intestinal Antibody Pattern of Celiac Disease: Occurrence in
Patients With Normal Jejunal Biopsy Histology
EDUARDO ARRANZ and ANNE FERGUSON
Gastrointestinal Unit, University of Edinburgh and Western General Hospital, Edinburgh, Scotland
Background: Patients with celiac disease have immu¬
noglobulin (Ig) M antibodies and IgA antigliadin anti¬
body in gut secretions; this pattern of intestinal immu¬
nity may be a marker of latent celiac disease. Its
frequency in patients referred for jejunal biopsy has
been examined. Methods: Serum IgG and IgA antiglia¬
din antibody, jejunal fluid IgA and IgM antibodies to
gliadin, ovalbumin and p lactoglobulin, and jejunal fluid
IgA and IgM concentrations were measured by en¬
zyme-linked immunosorbent assay. Results: Seven¬
teen of 19 celiac patients on normal diet and 16 of 23
on gluten-free diet had the celiaclike antibody pattern,
as did 41 of 217 other patients. Jejunal biopsy histol¬
ogy had been classified as normal in 38 of these, with
minor abnormalities in 3; however, intraepithelial lym¬
phocyte (IEL) counts were high in 13 cases. Trial of a
gluten-free diet produced clinical improvement in 6 of
7 antibody-positive patients. After extra dietary gluten,
one developed subtotal villous atrophy. Conclusions:
The celiaclike intestinal antibody pattern and a high IEL
count may be markers of latent gluten-sensitive enter¬
opathy; some of these patients are clinically gluten
sensitive in the absence of enteropathy.
Celiac disease is currently defined as a permanentntolerance of the smal bowel mucosa to gluten.1
Because there is great variability of malabsorption and
heterogeneity of clinical presentation, the diagnosis is
based on the presence of a characteristically abnormal
jejunal biopsy (total or partial villus atrophy with crypt
hyperplasia) while the patient is taking a normal diet,
with improvement in histological appearances after
treatment with a gluten-free diet (GFD).
This definition is being challenged by the emerging
evidence that latent celiac disease2 is not particularly-
rare. Latent celiacs are patients who eat a normal diet
and have apparently normal jejunal histology but who
at some other time before or since have a gluten-sensi¬
tive enteropathy. The concept was first derived from a
gluten supplementation experiment in two patients
with dermatitis herpetiformis (DH),2 and patients
with DH, together with relatives of celiacs, have been
the most frequently studied.3'4
Celiacs whose intestinal lesions have resolved on
GFD and whose jejunal biopsy samples are classified as
"normal" for diagnostic purposes may still express sub¬
tle pathological or immunological abnormalities simi¬
lar to those of untreated celiacs. These include a high
count of villus intraepithelial lymphocyte (IEL),5 in¬
creased y/8 T-cell receptor expression by IEL,6 abnor¬
mal jejunal permeability,7 and high levels of immuno¬
globulin (Ig) M antigliadin antibody, other IgM class
antibodies, and IgA antigliadin antibody in specimens
of jejunal fluid and whole-gut lavage fluid.8
We recently reported that this celiaclike abnormal¬
ity of intestinal antibodies also occurs in DH patients
without enteropathy (the celiaclike intestinal antibody
[CIA] pattern) and suggested that studies of intestinal
antibodies might facilitate the detection of latent celiac
disease in other situations.9 Therefore, we have as¬
sessed the frequency of the CIA pattern in a prospec¬
tive study of 259 patients who attended for diagnostic
small bowel biopsy, and we considered the potential
clinical significance of our findings.
Materials and Methods
Patients
This Gastrointestinal Unit provides a regional ser¬
vice for the clinical investigation of gastrointestinal func¬
tion. During a 16-month period, a total of 151 patients
attended for peroral jejunal biopsy, and jejunal fluid was
collected at the same time. Samples of jejunal fluid and small
bowel mucosa adequate for analysis were obtained from 140
patients (49 male, 91 female) (series A) ranging in age from
Abbreviations used in this paper: BLG, p lactoglobulin; CIA, celiac¬
like intestinal antibody; DH, dermatitis herpetiformis; ELISA, en¬
zyme-linked immunosorbent assay; GFD, gluten-free diet; GLI, glia¬
din; IEL, intraepithelial lymphocyte; OTH, patients with other
diagnoses (nonceliac/DH); OVA, ovalbumin; PVA, severe partial vil¬
lus atrophy; TVA, total villus atrophy.
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) 83 years (mean age, 37.2 years). Serum samples were
:cted from 13" of these patients. Twenty-two of the
s were celiac patients undergoing follow-up biopsies to
iS response to GFD; a decision as to the final diagnosis
he remaining 118 cases was made 2-3 months after the
sy from examination of the case records and without
A'ledge of the results of antibody tests on serum or secre-
>. Similar studies were performed in a further cohort of
nonceliac patients (series B).
Specimen Collection and Processing
After an overnight fast, the patient swallowed a
son biopsy capsule together with 15 rng of Metoclopra-
; (Beecham; Welwyn Garden City, England). When the
ule had passed to the first loop of jejunum (assessed by
tgraph screening), 1-2 mL intestinal fluid was drained
•avity through the tubing. The protease inhibitor phen-
■thylsulfonyl fluoride, 20 (il/mL at a concentration of
nol/L, was immediately added. The capsule was then
to obtain a jejunal mucosal biopsy. Jejunal fluid was
Terred on ice to the laboratory and stored at —70°C
in 10 minutes of collection. Venous blood samples were
taken and the serum separated, aliquotted, and stored at
°C.
junal mucosal biopsy specimens were formalin-fixed
sent to the diagnostic pathology laboratory for examina-
by a consultant pathologist who reported both in a
led textual description and made the following classifi-
ins: (1) total villus atrophy (TVA), (2) severe partial
s atrophy with crypt hyperplasia (PVA), (3) minor non-
ific abnormalities (these included villus shortening
out crypt hyperplasia and general increase in inflamma-
cell infiltrate), and (4) morphologically normal,
the specimen was large enough, a separate piece of
e was taken for assays of disaccharidases (lactase, su-
•, maltase, and trehalase).10 In some patients, a lactu-
Thamnose test of jejunal permeability was also per-
ied.n
Immunoglobulin and Antibody Assays
In specimens of jejunal fluid, concentrations of im-
oglobulin Ig A and IgM and levels of IgA and Ig.M
todies to gliadin (GLI) (gift from Dr. H. Weiser), oval-
in (OVA), and P lactoglobulin (BLG; Sigma Chemical
Poole, Dorset, England) were assayed by enzyme-
:d immunosorbent assays (ELISA) previously de¬
ed.8 Levels of IgA and IgG anti-GLI in serum were also
ured by ELISA.
)r assays of Igs in jejunal fluid, serial twofold dilutions
reference preparation were used to produce a standard
e. Serial dilutions of test samples were also assayed,
s were read in an MR500 Automatic microplate reader
tatech, Billingshurst, Sussex, England) and set at a wave
-h of 405 jimol/L (optical density [OD]405). Only when
esults of at least two of the sample dilutions fell within
ange of the standard curve was the assay considered
lically satisfactory and the Ig content of the sample
determined as the mean for these two sample dilutions. Hu¬
man colostral IgA (Sigma Chemical Co.) was used as a stan¬
dard for IgA and human reference serum (Protein Reference
Unit, Sheffield, England) was used as a standard for Ig.M.
In the assays of specific antibodies, prior experiments
were done to determine optimum test conditions for each
antigen, isotvpe, and fluid. Serum from an untreated celiac
patient, previously recognized as having high levels of anti¬
bodies of IgG, IgA, and IgM isotypes to GLI, OVA, and
BLG, was used as a reference standard. The reference speci¬
men and test specimens were studied in duplicate at a prede¬
termined dilution, varying for the different assays, and the
plates read when the OD for the standard reached 1.0. If the
duplicates varied by more than 10%, the result was dis¬
carded. Antibody levels were expressed as percentages of the
OD of the standard. Results are thus obtained and presented
as nonparametric data; antibody levels are not directly pro¬
portional to the antigen-binding capacity of the sample.
This is a feature of all such assays.
Care was taken to ensure that the results were not merely
due to nonspecific binding of IgM, a matter of particular
concern in assays of anti-GLI. All plates were preincubated
with 1% bovine serum albumin in buffered saline with 0.5%
Tween 20, pH 7.4, before addition of the samples. To con¬
firm antigen specificity of the assays, samples of jejunal fluid
were tested for IgM anti-GLI and IgM anti-OVA before and
after incubation for 1 hour in GLI-coated microtiter wells.
There was 50%-70% reduction of the OD reading for anti-
GLI but there was no change in anti-OVA. Similar, anti¬
gen-specific reduction in activity was found after incubation
in OVA-coated wells and after testing for IgM anti-OVA
and IgM anti-GLI.
Classification of Antibody Data
"Normal" values for the various antibody assays
were based on results in 28 immunologically normal individ¬
uals previously studied8; as explained above, units of mea¬
surement were OD for test specimen expressed as percent¬
age of the OD of the standard. For serum, normal values
were taken as <20 for IgA anti-GLI and <40 for IgG
anti-GLI; for all IgA and IgM antibodies in jejunal fluid,
values <15 were considered normal.
When jejunal fluid antibody studies showed a high value
for IgM anti-GLI, together with high levels of at least two
other intestinal antibodies characteristic of celiac disease
(IgA anti-GLI, IgM anti-OVA, IgM anti-BLG), the speci¬
men was designated as "celiaclike intestinal antibody" posi¬
tive (CIA+) and all other specimens were considered CIA—
(negative).
Counts of Intraepithelial Lymphocytes
IEL counts were performed in 94 biopsies, all with
essentially normal mucosal architecture (7 celiacs on a
GFD, 4 patients with DH, 44 nonceliacs from series A, 39
nonceliacs from series B). In total, there were 41 CIA+
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nonceliac cases and 42 patients with a similar range of diag¬
noses but normal intestinal antibody patterns.
A differential count of cells was performed within the
villus or surface epithelium with a Leitz microscope and
XI00 immersion lens (Leica, Milton Keynes, England). At
least 1000 enterocytes per biopsy were counted, and the
results were expressed as numbers of lymphocytes per 100
villus enterocytes.5
Statistical Methods
The Student's t test and the Mann-Whitney U test
were used for comparing Ig and antibody levels, respec¬
tively, between groups; and the Spearman's test for compari¬
sons of serum and jejunal fluid anti-GLI antibody levels. P
values < 0.05 were considered significant.
Jesuits
Series A: Diagnostic Groups and Pathology
Details of the patients, their diets, final diag¬
noses, and biopsy histological classification are given
in Table 1.
Celiac disease and DH. Thirty-six of the biopsy
samples were taken from 33 patients with celiac dis¬
ease (3 patients underwent biopsy twice). There were
14 new cases of celiac disease and 22 biopsy samples
from GFD-treated celiacs, the majority in the early
stages of treatment (<1 year), with improved but still
unequivocally abnormal histology. Five of the 6 DH
patients were newly diagnosed and 1 was on a GFD.
Not celiac. There were 3 patients in whom a
diagnosis of celiac disease had previously been made
on inadequate criteria (no biopsy or normal biopsy); in
the final analysis they have all been classified as
healthv.
Inflammatory bowel disease. Four patients had
Crohn's disease and 3 had ulcerative colitis.
Idiopathic diarrhea. These 23 patients had
chronic, watery diarrhea, and no firm diagnosis was
made even after full investigation by a consultant gas-
troenterologist. One was also IgA deficient.
Oral ulceration. These were patients with se¬
vere aphthous ulceration or oral candidiasis (HIV neg¬
ative) referred for malabsorption work-up by dental
surgeons and in whom no evidence of intestinal dis¬
ease emerged.
Miscellaneous disease. There were 23 patients
with various significant organic gastrointestinal dis¬
eases including diverticular disease, small bowel bacte¬
rial colonization, colonic polyps, giardiasis, colorectal
cancers, radiation enterocolitis, drug-induced diar¬
rhea, and alcoholic cirrhosis.
Nutritional deficiencies. Seven patients had pre¬
sented with anemia or weight loss ultimately attributed
to poor diet.
Irritable bowel syndrome. These were patients
with abdominal pain, bloating, and variable bowel
habit with no identifiable organic cause.
No abnormality detected. There were a few pa¬
tients who had trivial symptoms or psychiatric disease
or had constitutional short stature.
Of the 98 patients with a final diagnosis other than
celiac disease or DH, 93 were reported to have a histo¬
logically normal jejunal biopsy and 5 had minor histo-
Table 1. Final Classification of Patients by Diagnosis and by Jejunal Biopsy Histology
Histology
No. of Age Minor
Final diagnosis Diet patients (median [range]) SVA/PVA changes Normal
Celiac disease ND 14 39 (19-82) 14
GFD 22 39(14-82) 16 2 4
DH ND 5 44 (30-60) 2 2 1
GFD 1 20 1
Not celiac ND 1 34 1
GFD 2 26 (14-38) 2
Inflammatory bowel disease ND 7 29 (18-41) 2 5
Idiopathic diarrhea ND 23 36(15-67) 23
Oral ulceration ND 6 37 (19-80) 6
Miscellaneous gastrointestinal
disease ND 23 46 (16-76) 23
Nutritional deficiencies ND 8 49 (23-69) 1 7
Irritable bowel syndrome ND 13 35 (20-45) 1 12
No abnormality detected ND 15 34 (13-57) 1 14
NOTE. For details of diagnostic categories see text.
GFD, gluten-free diet; ND, normal diet; SVA, severe villus atrophy.
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ical abnormalities (short villi in 2, excess inflamma-
f cells in 3).
Classification by Intestinal Antibody Pattern
The 140 patients were also subdivided by intes-
il antibody findings into four groups: celiac/CIA+
i celiac/CIA—, celiacs and DH patients who did (33
:s) or did not (9 cases) express the CIA pattern;
ients with other diagnoses (nonceliac/DH)
H/CIA + and OTH/CIA —, patients with other
gnoses who did (16 cases) or did not (82 cases) ex-
ss the CIA pattern.
Antigliadin Antibodies in Serum
Serum samples, collected at the time of jejunal
psy, were available for 137 of the 140 cases studied,
■els of serum IgA and IgG anti-GLI antibodies are
wn in Figures 1 and 2. Twelve of the 14 untreated
acs had high levels of serum IgA anti-GLI as did 9
he 21 celiacs on GFD. Of the 5 new DH cases, 2
! high serum IgA anti-GLI and one had high serum
> anti-GLI. Fourteen of the 96 nonceliac, non-DH
:s also had IgA anti-GLI values above 0.20, but, as
strated, in only 1, a man with alcoholic cirrhosis,
, the level particularly high. In contrast, detectable
1m IgG anti-GLI was present in the majority of
ients, and although a high value was found in 10 of
untreated celiacs, high values were also present in
of 96 nonceliac, non-DH cases.
Antibodies to Foods in Intestinal Secretions
The CIA pattern was present in 13 of 14 newly
senting celiacs and in 4 of the 5 new DH patients.
Diagnostic groups
re 1. Serum IgA antigliadin antibody levels in patients grouped




Figure 2. Serum IgG antigliadin antibody levels in patients grouped
by final diagnosis (normal range is shaded). 9. ND patients; O, GFD
patients.
Clinical, biopsy, and immunological information on
the two who were CIA— are presented in Table 2;
there were no unusual clinical features, but it is of
interest that the celiac patient, who had classical enter¬
opathy, also had a classical celiac HLA phenotype,
whereas this was not the case for the DH patient,
whose jejunal mucosa was normal. Of the 22 celiacs
and 1 DH patient on GFD, the frequency of the CIA+
pattern was 69.5% and 16 of the 98 nonceliac patients
(16.3%) were CIA+.
Results of assays of intestinal fluid IgA and IgM
anti-GLI are presented in Figures 3 and 4.
Ig Concentrations in Jejunal Fluid
As shown in Table 3, concentrations of IgA and
IgM in jejuna] fluid were generally higher in celiac and
DH patients on a normal diet than in other diagnostic
groups. When the patients were subdivided according
to intestinal antibody patterns, it emerged that the two
subsets with positive CIA patterns, COE/CIA+ and
OTH/CIA+, had significantly higher concentrations
of IgM than the CIA negative cases, irrespective of
diagnosis. Total IgA concentrations were higher in the
OTH/CIA+ group than in the other subsets.
Serum Anti-GLI Antibodies in Relation to
Intestinal Antibody Patterns
There were no differences in the levels of serum
antibodies between the CIA+ and CIA— nonceliac
groups. In other words, high levels of serum anti-GLI
correlated with the presence or absence of gluten-sen¬
sitive enteropathy but not with intestinal antibody lev¬
els.
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Table 2. Clinical, Pathological, and Immunological Details of
Two Patients (Celiac and DH) on Normal Diet
Negative for the CIA Pattern
Patient 1 Patient 2
Diagnosis Celiac DH
Diet Normal GFD Normal (low residue)
Age 44 49
Indication for Diarrhea DH
jejunal biopsy Iron-deficient Variable bowel habit,
anemia asthma,
eczema
Biopsy histology TVA PVA Normal
Disaccharidases Normal
IEL count/(100 35 40 32
enterocytes)





IgA-AGA 25.8a 8.7 4.8
IgG-AGA 51,0a 35.0 23.1
Jejunal fluid
T. IgA (pg/mL) 1 1.5 19.1 32.7
T. IgM (jjg/mL) 1.4 1.5 0.7
IgA-AGA 2.2 3.9 6.4
IgM-AGA 6.1 7.8 8.2
Other Abs Low Low Low
HLA Type A1,1 1;B8 ,57;BW4/6 A1,2; B44.35; BW4/6
DR3.7; DRW52/53; DR2.4; DRW53;
DQw2 DQW1,3,7




Clinical Details of CIA Positive Nonceliac
Cases (Series A)
Details of diagnosis, reason for the biopsy, and
other studies performed in the group of 16 nonceliac,
non-DH cases in series A, positive for the intestinal
antibody pattern, are presented in Table 4. In 6 cases
the intraepithelial lymphocyte (IEL) count was high;
other features of the biopsy samples were normal in 5
of these; 1 man had minor, nonspecific abnormalities
with short villi. Minor abnormalities of the mucosa
were also present in two cases with normal IEL
counts. The sugar permeability test was abnormal in
only 5 cases, including the 3 with minor histological
abnormalities.
Intestinal Antibody Patterns in Series B
Jejunal fluid antibody levels were measured in
an additional 119 nonceliac patients with normal je¬
junal biopsy histology. Positive CIA patterns were pres¬
ent in 2 of 8 "nonceliacs," 2 of 14 patients with IBD, 4
of 12 with idiopathic diarrhea, 3 of 12 with mouth
INTESTINAL ANTIBODIES IN POTENTIAL CELIACS 1267
Diagnostic groups
Figure 3. Jejunal fluid IgA antigliadin antibody levels in patients
grouped by final diagnosis (Normal range is shaded). ®, ND patients;
O, GFD patients.
ulcers, 7 of 34 with various other diagnoses, 3 of 7 with
nutrient deficiencies, 1 of 18 with irritable bowel syn¬
drome, and 3 of 14 with no abnormality detected.
Intraepithelial Lymphocyte Counts
\X ith the technique used, the normal range is
10-40 IEL per 100 villus enterocytes, and virtually all
untreated celiacs have abnormally high counts within
the flat surface epithelium (e.g., results in our studies
of four separate groups of patients have ranged from
44 to 180 IEL per 100 enterocytes).5'12"14 Results for
biopsies from patients in series A and B are shown in
Figure 5. Abnormally high counts were present in one
(CIA+) of 7 GFD-treated celiacs, in 3 of the 4 DH
patients (all 3 were CIAT), and in 14 patients with
Diagnostic groups
• Patients on normal diet
o Pabents on gluten free diet
Figure 4. Jejunal fluid IgM antigliadin antibody levels in patients
grouped by final diagnosis (normal range is shaded). ®, ND patients:
O, GFD patients.
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)le 3. Ig Concentrations in Jejunal Fluid
Total IgA Total IgM
ac
'D 224.5 ± 244.7 25.8 + 29.6
>FD 118.6 ± 134.4 18.8 + 49.6





ammatory bowel disease 213.4 ± 191.7 9.4 12
pathic diarrhea 153.6 ± 286.4 7.6 + 18.9
1 ulceration 43.9 ± 50.4 3.3 + 4
cellaneous 137.4 ± 128.9 5.4 + 6.9
ritional deficiencies 260 ± 348 24.7 + 41.7
able bowel syndrome 102.3 ± 161.9 1.9 + 1.5
abnormality detected 181.8 ± 206 2.9 + 3.6
ac/DH 167.5 ± 194 21.5 + 42
IA+ 189.3 ± 208 19.2 + 24.6
IA- 78.3 ± 86 2.3 + 1.8
er diagnosis
IA+ 426.6 ± 335.7 25.4 33
IA- 101.6 ± 136.7 3.2 ± 4.5
fE. Data represent mean ± SD in pg/mL.
ler diagnoses. Thirteen of these were CIA+ cases;
L count was high in only one CIA— nonceliac pa¬
nt (a woman with colonic Crohn's disease).
Clinical Effects of GFD or Gluten Loading
Eight CIA+ nonceliac, non-DH cases and one
A— patient have had clinical trials of gluten restric¬
tion. Details are presented in Table 5. Five CIA+ pa¬
tients with chronic high-volume diarrhea had com¬
plete resolution of diarrhea within 1-2 weeks of
starting a gluten-free (or, in one case, low-gluten) diet;
in four of these, the IEL count in the initial biopsy was
high. Interestingly, a GFD did not markedly influence
the severe watery diarrhea of a woman with collage¬
nous colitis (CIA—) whose identical twin is a celiac.
The GFD had no effect in two CIA+ patients with
inflammatory bowel disease and intractable diarrhea.
A 41-year-old CIA+ woman with recurrent severe
aphthous ulceration when eating a diet with 24 g glu¬
ten daily was prescribed a GFD; she noticed some im¬
provement but found the diet inconvenient and took it
for only 5 weeks. Several months later, studies of y/5
1EL in a stored biopsy specimen were performed and
counts were found to be high. She then agreed to take
10 g additional gluten daily for a month and had an¬
other jejunal biopsy. Pathological examination re¬
vealed subtotal villus atrophy.
Discussion
Within the framework of the current definition
(a permanent gluten-sensitive enteropathy), clinical,
pathological, epidemiological, and immunological ap¬
proaches are revealing several forms of celiac disease.
In so-called active celiac disease, malabsorption and
nutritional deficiencies range from profound to mini¬
mal; indeed around 50% of newly diagnosed adult ce-
>le 4. Demographic Data of Patients Positive for the Coeliaclike Antibody Pattern in Jejunal Fluid
e Indication for Biopsy Tissue IEL Lactulose/rhamnose
Age Sex jejunal biopsy Final diagnosis histology disaccharidases count" permeability ratio"
20 F Diarrhea Crohn's disease Minor Not done 27 0.134
changes
24 F Diarrhea, abdominal pain Ulcerative colitis Minor Low (L. S) 15 0.240
Sclerosing cholangitis changes
67 M Diarrhea Idiopathic diarrhea Normal Normal 21 Not done
19 F Diarrhea, weight loss Idiopathic diarrhea Normal Not done 80 0.012
28 F Diarrhea, weight loss Idiopathic diarrhea Normal Normal 27 0.01 1
56 M Diarrhea, IgA deficiency Idiopathic diarrhea Normal Normal 35 0.033
54 F Diarrhea Microscopic colitis Normal Normal 46 0.032
43 M Diarrhea Colonic polyps Normal Normal 22 0.020
32 F Diarrhea, anemia Pernicious anemia Normal Normal 53 0.054
35 F Anemia Iron deficiency Normal Normal 43 0.022
23 M Anemia Iron deficiency Normal Normal 27 0.022
44 M Diarrhea, fatigue Poor diet, somatisation Minor Low (L) 73 0.032
disorder changes
29 F Diarrhea, abd dis/t Irritable bowel syndrome Normal Not done 22 0.008
19 F Bloating, abd dis/t NAD Normal Normal 47 0.050
57 F Bloating, abd dis/t NAD Normal Not done 20 0.045
25 F Abdominal discomfort NAD Normal Normal 18 0.036
dis, abdominal distension; NAD, no abnormality detected; L, lactase; S, sucrase.
rmal; 10-40 per 100 enterocytes.
rmal; <0.04.










Coeliacs DH Not IBO Idio. Mouth Misc. Nut. de(. IBS NAD
(GFD) coeliac diarrhoea ulcers
Diagnostic groups
Figure 5. Intraepithelial lymphocyte counts in jejunal biopsies from
94 patients reported as normal or with minor histological changes
(normal range, 10-40 lymphocytes per 100 villus enterocytes).
O, Patients positive for CIA pattern; 9, patients negative for CIA pat¬
tern.
liacs have no symptoms referable to the gut.13,16 Clini¬
cally silent celiac disease is being increasingly recog¬
nized (eg., in family studies where an abnormal
mucosa is found in 10% of completely healthy relatives
of celiacs).17,18 Pathologically, there is also a degree of
heterogeneity. Descriptive terms such as "flat mucosa"
or "total villus atrophy" are the pathologist's short¬
hand for a cluster of features that together characterize
the enteropathy of celiac disease. Quantitative histol¬
ogy19 and computerized image analysis20 of biopsy sam¬
ples taken during gluten withdrawal and challenge
have shown that all of these features occur in a contin¬
uum with a flat, avillus lesion at one end of the spec¬
trum and at the other end a mucosa with normal villus
and crypt architecture but an abnormally high density
or count of IEL. The latter would be reported as nor¬
mal by most clinical pathologists.
This fact is important when one reviews the evi¬
dence for the existence of latent celiac disease and the¬
ories as to whether such patients are merely at one end
of a spectrum of the pathology of enteropathy20-22 or
whether celiac disease develops in a one- or two-stage
process, latent and fully expressed.9 There are a few
reports of normal jejunal biopsies previously being ob¬
tained from newly diagnosed celiacs.23"25 Morphomet¬
ry analysis showed changes at the mild end of the
spectrum of enteropathy in the original biopsies of two
such patients,25 but there are also reports of formal
histological measurements showing that the original
biopsy specimens were completely normal.23,24
Clearly there is a need for some means other than
pathological to identify the state of latent celiac dis¬
ease. One approach may be by studies of IEL T cells
expressing y/8 receptors6; positive results have been
reported in a single case detected during family studies
in Finland.24 We are following another potential line,
based on our observation that the intestinal antibodv
pattern of celiac disease also occurs in Dll patients
without enteropathy, and thus may provide a diagnos¬
tic test of latent celiac disease in other situations.9
It is generally agreed that the intestinal fluid in un¬
treated celiac disease contains high levels of both IgA
and IgM anti-GLI antibody and that, in contrast to
serum antibodies, levels of intestinal antibodies re¬
main high after healing of enteropathy in GFD-treated
celiacs.8,26-28 In a definitive study of humoral immu¬
nity in celiac disease, we found that, in celiacs, secre¬
tions contained high levels of IgM antibodies to two
other dietary proteins studied in addition to anti-GLI.8
Thus, we defined the CIA pattern as the presence in
jejunal fluid ot IgM anti-GLI together with at least two
of the three other characteristic antibodies, IgA anti-
GLI, IgM anti-OVA, and IgM anti-BLG.
It is now clear (Table 3) that CIA+ specimens also
contain high concentrations of total IgM, in keeping
with over-expression of IgM generally in the intestinal
mucosa of celiacs,28-36 and this is not limited to food
protein antibodies. In a recent investigation of intes¬
tinal immune responses to an enteric vaccine, celiacs
generated high levels of intestinal IgM antibodies to a
bacterial antigen, cholera toxin B subunit.37
Although it was not a primary aim of the present
study to assess the CIA status of celiacs, it is of interest
that 1 ot 14 newly presenting celiacs was CIA negative.
Two of the 8 cases of DH without enteropathy previ¬
ously studied by us were also CIA negative9 as was one
DH patient without enteropathy in the present series.
The fact that she lacked the characteristic HLA haplo-
type of celiac disease (although was DR4 positive as
are other such atypical celiacs)38 may be important and
highlights the possibility that differences between pa¬
tients in their intestinal expression of gluten sensitivitv
or in their mucosal immune responses may have a ge¬
netic basis. W e have suggested that there may be sepa¬
rate genetic factors that regulate the capacity for gluten
sensitization on the one hand and a susceptibility to
develop severe enteropathy in the expression of muco¬
sal T-cell-mediated immunity on the other.39
We have not yet established the immunopathogene-
sis of the CIA pattern. Because this persists during
strict gluten exclusion, the theory that it reflects a poly¬
clonal response to lectinlike stimulation by gliadin
cannot be sustained. Mucosal immunity is character¬
ized by an overall downregulation of isotypes other
than IgA.40 The general increase in the IgM compo¬
nent of intestinal immunity, which we have described,
could reflect either a primary disorder of B cells (i.e.,
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le 5. Details of Patients Treated With Gluten-Free Diet
Jejunal biopsy on normal diet Jejunal biopsy on gluten-free diet
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lestyramine; Bristol-Myers, Hounslow, England.
abundance of "polyreactive" B cells, CD5+);
rrant function of the T-cell subsets that control the
y stages of B cell development (ie., suppressor T-
dysfunction41'42 or overactivity of local helper T
s39); or the existence of an unusual immunostimu-
operating in the gut mucosa. Antigen-related ter-
lal differentiation and expansion of IgM and IgA B
s appear normal. Transepithelial immunoglobulin
isport is also normal,36 and indeed the production
ecretory component by epithelial cells is increased
reliac disease.43 An abnormally high capacity for
isport of IgM and IgA across the epithelium might
duce the CIA pattern. However, we have examined
molecular forms of jejuna) fluid IgA (with and
hout secretory component) and find no differences
between CIA+ and CIA— specimens (unpublished ob¬
servations). It has been suggested that IgM has much
higher affinitv for the secretory component than di-
meric IgA. Thus, overproduction of IgM in the lamina
propria may partially obstruct transepithelial IgA
transport — an explanation for the presence of dimeric
IgA in the serum in celiac disease.39
Normal biopsy DH patients provide the only well-
defined group of patients in whom in vivo dietary ma¬
nipulations (the current gold standard) reveal latent
gluten-sensitive enteropathy in many cases. We found
that the CIA pattern was positive in 6 of 8 such pa¬
tients,9 suggesting that non-DH latent celiacs are also
very likely to be CIA positive. In the present study, 41
of 217 nonceliac patients were CIA positive; 13 of
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these also had high counts of IEL and thus clearly have
intestinal pathology at the mild end of the spectrum of
gluten-sensitive enteropathy.21,22 However, in contrast
to DH latent celiacs, most of these patients had symp¬
toms suggestive of small bowel disease. Thus, quite
apart from the theoretical interest in such patients,
there is an important practical issue as to whether their
diagnoses and management should be revised and
GFD prescribed.
Although clinical effects of treatment are important
to the patient, objective measures of the effects of GFD
in celiac disease are mandatory to clinicians and inves¬
tigators. Thus, histopathological improvement forms
part of the definition of the disease. Objective assess¬
ment of a response to a GFD in the present series of
patients will only be possible in those patients who
have minor biopsy abnormalities. Eight of the 41
CIA+ patients (5 with high IEL count, 1 with mild
enteropathy and normal IEL count, and 2 with en¬
tirely normal biopsy samples) have had a trial of gluten
restriction; in 5 there was a rapid resolution of watery
diarrhea and in the 4 cases in whom repeat biopsy has
been performed, a high IEL count decreased to normal
in 3 and there was no change in the (previously nor¬
mal) IEL count in 1 case. There has been a previous
report of gluten-sensitive diarrhea describing benefit
from a GFD in 9 of 17 patients suffering from chronic
diarrhea.44 A CIA+ patient with aphthous ulceration
took additional dietary gluten for 1 month and devel¬
oped a classical celiaclike enteropathy.
The present work, together with in vivo gluten
challenge studies in celiac patients, indicates that the
expression of gluten hypersensitivity as enteropathy,
measurable only if a count of IEL is performed, may be
minimal. An accepted name for this type of pathology
is needed, such as "high IEL mild enteropathy." This
must be clearly differentiated from low-grade or other
forms of nonceliac enteropathy. Further work will
show how this relates to y/8 IEL counts and whether
the presence of the CIA pattern is an even more sensi¬
tive index of mucosal DTH expression than is 1EL
count or whether the unusual upward regulation of
IgM is an independent factor, perhaps genetically de¬
termined, relevant to the induction of a state of
aberrant immunity to gluten.
We suggest that some of the cases in the literature,
conforming to the present definition of latent celiac
disease, will, on review of biopsy pathology, be found
to show high IEL mild enteropathy, thus falling
within the "continuum" concept of gluten-sensitive
enteropathy.22 However, there are already published
and unpublished cases in whom the IEL count in the
original biopsy was normal. Not all such patients are
asymptomatic; therefore the word "latent" may in any
event be inappropriate in relation to the full clinical
expression of gluten sensitivity. For prospective stud¬
ies of candidate-latent celiacs, such as those with high
IEL count, positive CIA pattern, high y/8 expression
of IEL, relatives of celiac patients, and IgA deficiency,
a more generally applicable expression is needed. The
term potential celiacs has recently been accepted by
delegates at a workshop of the European Society for
Paediatric Gastroenterology and Nutrition.45
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ABSTRACT
Patients with coeliac disease have IgM antibodies and IgA anti-
gliadin antibody in gut secretions, and also high counts of IEL
which express the t/6 T cell receptor. These features of
intestinal immunity may be markers of latent coeliac disease. We
have examined their occurrence in 77 patients referred for
jejunal biopsy, in whom biopsy histology was normal, to
establish to what extent these, and other candidate markers,
(high total IEL count, serum IgA anti-gliadin antibody (AGA),
increased permeability) co-exist in the same patient. Twelve
patients had high serum AGA and 9 increased permeability. The
count of t/6 IEL was high (>5.5 per mm villus epithelium) in 9
patients, intestinal antibody pattern was positive in 21, and
total IEL count high (>40 per 100 enterocytes) in 13. Overall
there were 31 patients with positive indices, but in 19 only a
single test was abnormal. High t/6 IEL counts were found in 6 of
the 21 intestinal antibody positive patients, but only in 2 of 56
who were intestinal antibody negative (p<0.001); there were no
other significant associations. Clinical tests of gluten
sensitivity will be required to establish the prevalence of
latent gluten-sensitive enteropathy in the 40% of patients
referred for jejunal biopsy in whom one or more of the
immunological indices of potential coeliac disease is present.
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INTRODUCTION
Coeliac disease, defined as a permanent intolerance of the small
bowel mucosa to gluten, is heterogeneous in clinical presentation
and pathological expression. There are also patients with
"latent coeliac disease", who have a normal jejunal biopsy when
eating a normal diet but at some other time, before or since,
have been shown to have typical, severe gluten-sensitive
enteropathy (1). Diagnostic criteria of latent coeliac disease
are stringent, and the diagnosis is usually made in retrospect or
by chance. Thus we have suggested that the term "potential
coeliac disease" may be more appropriate in clinical practice, to
be used while dietary manipulations are being undertaken in
patients suspected to be latent coeliacs (2). If the findings are
positive, the diagnosis of low-grade pathology coeliac disease is
then confirmed.
Recent studies have revealed a number of intestinal immune
features as candidate markers of latent or potential coeliac
disease: high counts of T cell receptor (TCR) r/5 intra¬
epithelial lymphocytes (IEL) have been shown in dermatitis
herpetiformis (DH) and in a case of latent coeliac disease (3,4);
a coeliac-like intestinal antibody (CIA) pattern occurs in DH
patients with normal biopsy histology (5); the total count of IEL
may be high as a subtle feature of enteropathy in some coeliac
patients (6); anti-reticulin and antiendomysium antibodies are
present in some healthy relatives of coeliac (7); intestinal
permeability changes have also been reported in first degree
relatives of coeliacs (8).
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We recently reported that 19% of 217 non-coeliac patients
referred for jejunal biopsy had a positive CIA pattern, and that
a proportion of these (6 of the 9 patients who had a trial of
gluton-free diet) were clinically gluten sensitive, particularly
when the total IEL count was high (9). We have now undertaken a
comprehensive evaluation of non-coeliac patients to establish the
associations (or lack of associations) between the CIA pattern
and high r/S IEL counts, high total IEL counts, serum IgA anti-
gliadin antibody (AGA) and intestinal permeability to the probe
sugars lactulose and rhamnose. We have not attempted to include
systematic clinical investigations of gluten sensitivity in this
series.
METHODS
Specimen collection and processing
This Gastro-Intestinal Unit provides a regional service for the
clinical investigation of gastro-intestina1 function. In
patients referred for per-oral jejunal biopsy, the following
protocol was used:
After an overnight fast, the patient swallowed a Watson biopsy
capsule together with 15 mg of Metoclopramide. When the capsule
had passed to the first loop of jejunum, (assessed by X-ray
screening), 1-2 ml intestinal fluid were drained by gravity
through the tubing. The protease inhibitor phenylmethyl sulphonyl
fluoride (PMSF), 20 ul/ml at a concentration of 0.1M, was
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immediately added. The capsule was then fired to obtain a jejunal
mucosal biopsy. Jejunal fluid was transferred on ice to the
laboratory and stored at -70°C within 10 minutes of collection.
Venous blood samples were also taken, serum separated, aliquotted
and stored at -70°C. A 1actu1ose/rhamnose test of jejunal
permeability was also performed (10).
Jejunal mucosal biopsies were orientated with the aid of a
dissecting microscope and divided into two pieces. One was
formalin-fixed and sent to the diagnostic pathology laboratory
for subjective examination by a consultant pathologist. The other
piece was embedded in OCT compound, frozen, and stored at -70°C.
Reference values for CD3 and r/5 IEL counts were obtained from
results in a subset of jejunal biopsy patients, finally
considered immunologically normal. Since all of these patients
had been suspected to have coeliac disease, we validated this
reference range by studying small bowel (duodenal) biopsies from
further 26 patients, none of whom had symptoms of small bowel
disease. Biopsies from the distal second part of the duodenum
were collected at upper GI endoscopy, embedded in OCT compound
and frozen.
Clinical diagnosis
Some of the series were coeliac patients having follow-up
biopsies to assess response to GFD; a decision as to the final
diagnosis for the remaining patients was made 2-3 months after
the biopsy procedure, from examination of the case records, and
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without knowledge of the results of immunological investigations.
These non-coeliacs were grouped as follows:
Not coeliac (NOT COE) - patients in whom a diagnosis of coeliac
disease had previously been made on inadequate criteria (no
biopsy or normal biopsy); in the final analysis they have all
been classified as healthy.
Farai iy members (FH) - first degree relatives of coeliacs,
subsequently shown to be normal.
Inflammatory bowel disease (IBD) - Crohn's disease or ulcerative
colitis.
Idiopathic diarrhoea (IDIO DIA) - chronic, watery diarrhoea; no
firm diagnosis made after full investigation by a consultant
gastro-enterologist.
Oral ulceration (ORAL ULC) - severe aphthous ulceration (HIV
negative), referred for malabsorption work-up by Dental surgeons
but no intestinal disease present after full investigation.
Miscellaneous (MISC) - patients with various significant organic
diseases, including small bowel bacterial colonisation,
colorectal cancer, radiation entero-co1itis, drug-induced
diarrhoea, collagenous collitis, eczema.
Nutritional deficiencies (NUT DEF) - anaemia or weight loss,
ultimately attributed to poor diet.
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Irritable bowel syndrome (IBS) - symptoms of abdominal pain,
bloating and variable bowel habit with no identifiable organic
cause.
No abnormality detected (NAD) - a few patients with trivial
symptoms, psychiatric disease, or constitutional short stature.
Duodenal biopsy patients studied
Duodenal biopsies were collected from 26 patients (17 female, 9
male; age range 16-87, mean 63.7) without small bowel disease,
who had diagnostic upper GI endoscopy. Diagnoses were duodenal
ulcer (4), gastric ulcer (4), hiatus hernia (3), oesophagitis
(4), other GI disease (3), no abnormality detected (8).
Counts of Total Intra-Epithelial Lymphocytes
A differential count was performed of cells within the villus
epithelium with a Leitz microscope and X100 immersion lens. At
least 1000 enterocytes per biopsy were counted and the results
were expressed as numbers of lymphocytes per 100 villus
enterocytes (6). Normal values are 10-40 I EL per 100 villus
enterocytes. Formal counts were performed in all 77 non-coeliac
patients, and in the 5 treated coeliac biopsies with normal
villous architecture.
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Counts of CD3 positive and of r/<S I EL
Serial 7 - um cryostat sections mounted on poly-l-lysine (Sigma,
Poole, Dorset) coated slides, were dried, and then fixed in fresh
acetone for 30 minutes at room temperature. The staining
technique was as follows. After being rehydrated in Tris
buffered saline (TBS, pH 7.6) and blocked with rabbit serum
(SAPU, Carluke, Scotland) in TBS, monoclonal antibodies were then
applied for 60 minutes: TCR-61 (T Cell Sciences, Cambridge, MA)
at dilution 1/80, or CD3 (Scottish antibody production Unit,
SAPU) at dilution 1/20; foilowed by Biotinylated rabbit anti-
mouse IgG (DAKO, High Wycombe, UK) at dilution 1/400, for 60
minutes. The sections were treated with StrepABComplex (DAKO) for
60 minutes, and the reaction was visualised using
diaminobenz i dine (DAB) as a substrate. Sections were
counterstained with Gills number 1 haematoxylin. The appearances
of a typical biopsy with a high count of r/S IEL are
illustrated in Figure 1.
A Leitz-TAS plus computerised image analysis system (with a TASIC
software operating system) was used for cell counts in frozen
sections, and the results expressed as total cell count per mm of
villous epithelium. Only those specimens in which at least 5 mm
of epithelium could be counted, were considered technically
acceptable; with duplicate counts by separate observers, mean
difference in cell count was 17%, range 3-32%. Details of how
the reference range was derived are presented below.
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Immunoglobulin and antibody assays
In specimens of jejunal fluid, concentrations of IgA and IgM, and
levels of IgA and IgM antibodies to gliadin (GLI) (gift from Dr
H. Weiser), ovalbumin (OVA) and beta-lactoglobulin (BLG) (Sigma
Chemical Co. Poole, Dorset, UK) were assayed by enzyme-linked
immunosorbent assays (ELISA) previously described (11). Levels
of IgA and IgG anti-GLI in serum were also measured by ELISA.
Classification of antibody data
"Normal" values for the various antibody assays were based on
results in 28 immunologically normal individuals previously
studied (11). When jejunal fluid antibody studies showed a high
value for IgM anti-GLI, together with high levels of at least two
other intestinal antibodies characteristic of coeliac disease,
IgA anti-GLI, IgM anti-OVA, IgM anti-BLG, the specimen was
designated as "coeliac-like intestinal antibody" positive (CIA+),
and all other specimens were considered CIA negative (CIA-).
Sugar permeability test
Concentrations of lactulose and rhamnose in urine were assayed by
High Pressure Liquid Chromatography and the percentage of
lactulose and rhamnose excreted was expressed as the L/R ratio.
Normal values are < 0.040.
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Statistical methods
Differences in cell counts between groups were assessed by the
two-tailed Mann-Whitney U test. Comparisons of frequency tables
of positivity for candidate markers was by the Chi square test
with Yates' correction.
RESULTS
Jejunal biopsy patients studied
Material suitable for the full range of immunological
investigations was obtained from 77 non-coeliac patients (49
female, 28 male; age range 17-77, mean 37.3). Details of the
patients, their diets, final diagnoses, biopsy histological
classification and sugar permeability test results are given in
Table 1.
As part of the technical appraisal of CD3 and t/6 cell counts,
frozen sections of jejunal biopsies from a group of coeliac
patients (predicted to have high t/6 IEL counts) was also
examined. Fifteen jejunal biopsies were collected from 14 coeliac
patients (11 female, 3 male; age range 16-86, mean 42.7).
Thirteen were already diagnosed, attending for follow-up biopsies
(one of these had two biopsies, on a gluten-free diet and during
a gluten challenge); only one was a newly presenting patient.
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Reference values for r/5 IEL, and expression of results (Table 2)
A subset of 34 jejunal biopsy patients, considered at final
assessment to be immunologically entirely normal, was used to
establish interim reference ranges for jejunal CD3 IEL cells and
t/<S IEL counts (per mm epithelium). There were 16 with IBS, 14
with trivial or transient disorders and 4 in whom no abnormality
had been detected. Reference values for the upper limit of
normal (mean + 2 SD) thus obtained were 67.5 CD3 IEL per mm
epithelium and 5.5 t/6 IEL per mm epithelium, respectively.
We considered whether to express results for t/6 IEL as a
percentage of the total number of CD3+ IEL, as has been the
practice of some other groups. However this produced spuriously
high, abnormal values in a few cases with very low total CD3
counts (presumable with deficiency of a/r IEL rather than excess
of t/6 cells). We have therefore presented data for t/6 IEL only
as the unmodified count per unit length of villus or surface
epithelium, taking values >5.5 cells/mm epithelium as abnormally
high.
Fourteen of the biopsies from coeliacs had abnormally high t/6
IEL counts. The remaining patient (normal mucosa, on a gluten-
free diet, with no unusual clinical features) had a normal count;
his data is presented separately from the other cases.
As shown in Table 2, there were significant differences between
the reference values obtained for CD3 cells in duodenal and
jejunal specimens, with values for duodenum (mean 19.4 CD3+ IEL
per mm epithelium, SD 11.4) significantly lower (p<0.001) than
for jejunum. This may reflect a true difference between these
tissues, but alternatively may be explained by the fact that
patients having duodenal biopsies were significantly older than
the reference jejunal biopsy group (we have previously reported
low IEL counts as a feature of human immunosenescence, (12)).
However t/S cell counts (per mm) were similar in the two sites.
There was one endoscopy patient (a woman with an uncomplicated
gastric ulcer) who had a strikingly high t/S count at 24 per mm;
in other respects her duodenal biopsy histology was entirely
normal.
Comparison of CD3 and Total IEL counts
In much of the published work on latent coeliac disease, and on
the spectrum of pathological expression of gluten sensitivity,
IEL counts have been performed in H&E stained sections, using a
conventional light microscope, with results expressed as IEL per
100 enterocytes. In the future, if frozen sections and image
analysis are necessary to count t/S IEL, it may be preferable to
count CD3 + cells per mm as an alternative to total IEL per 100
enterocytes. The material examined in the present series allows
a direct comparison of these two techniques. As shown in Figure
2, there was a highly significant correlation between IEL counts
in paraffin sections and CD3 + cell counts in frozen sections
(r=0.765, p<0.001) . All cases with high CD3 + cell counts had
high IELs, but there were 7 cases with high IEL count, normal CD3
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cell count, suggesting that an non-T subset of lymphocytes may be
present in the epithelium of these patients.
Positive results for candidate markers of latent coeliac disease
in 77 non-coeliac patients
These are summarised in Table 3, with patients subdivided into
diagnostic groups.
The CIA pattern of jejunal fluid antibodies was present in 21
patients. There were nine patients with high counts of r/5 IEL in
the villus epithelium, and conventional IEL counts were high in
13 cases. High titres of serum IgA antigliadin antibodies were
present in 12 patients, with no obvious relationship with
diagnostic groups or the other markers. The sugar permeability
test was abnormal in 9 cases, mainly those with mild
abnormalities of jejunal pathology or with IBD.
Associations between the CIA pattern, high t/S counts and high
total IEL counts are illustrated diagrammatically in Figure 3.
High r/6 IEL counts were found in 6 of the 21 CIA positive
patients, but only in 2 of 56 CIA negative (pcO.OOl); there were
no significant associations in any other marker combinations. A
high total IEL count was more frequent in CIA positive patients
(5 of 21), than in patients negative for the CIA pattern (8 of
56) , but the difference was not significant.
There were 31 patients with one or more positive result, but in
19 only a single test was abnormal. Of particular interest are
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patients with three parameters positive - CIA pattern, t/S IEL
count, total IEL count. Two of the three have been shown to be
gluten-sensitive (9). A woman with chronic high volume diarrhoea
had complete resolution of diarrhoea within 2 weeks of starting a
gluten free diet, and IEL count was normal in a biopsy taken 2
months later. Another woman with recurrent severe aphthous
ulceration had a trial of gluten free diet; she noticed some
improvement but found the diet inconvenient and took it for only
five weeks. Several months later, when studies of r / <5 IEL in a
stored biopsy specimen were performed and counts were found to be
high, she agreed to take 10 g additional gluten daily for a month
and had another jejunal biopsy. Pathological examination
revealed subtotal villus atrophy.
DISCUSSION
The existence of latent coeliac disease implies that the finding
of a normal jejunal biopsy does not completely exclude gluten
sensitivity. As discussed above, there is some evidence that
certain minor immunological abnormalities (which persist in
treated coeliac and DH patients after healing of enteropathy) may
identify latent coeliacs. One of these changes, the coeliac-like
intestinal antibody, or "CIA" pattern, polyclonal up-regulation
of mucosal IgM responses, occurs in 20-30% of patients referred
for diagnostic jejunal biopsy. We have shown that the symptoms of
some CIA+ patients respond to treatment with a gluten-free diet
(9) •
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In the present prospective study we have combined assessment of
the CIA pattern with studies of another candidate marker of
latent coeliac disease, a high count of r/6 IEL, together with
several other immunological and functional tests. It is important
to emphasise that there is a conceptual difference between the
finding of a high total IEL count and the other aspects studied.
It is now generally accepted that a high density of villus IEL
(e.g. as assessed by differential counts in the present study)
may be the only pathological expression of gluten sensitivity in
coeliac patients (13), allowing the diagnosis of a mild but
significant enteropathy. However the pathophysiological,
diagnostic and clinical significance of positive findings for the
other parameters examined are still uncertain.
We have found a statistically significant association between a
positive CIA pattern and a high density of r/S IELs. The CIA
pattern was also correlated (but not significantly) with a high
total IEL count. We have also confirmed our previous findings
that patients with subtle immune changes in gut humoral immunity
have entirely normal levels of serum IgA anti-gliadin antibody
(9,11). A positive sugar permeability test is independent of the
other features, mainly abnormal in patients with inflammatory
bowel disease and alcohol- or NSAID-related problems.
Around 40% of patients referred for diagnostic jejunal biopsy,
and in whom routine biopsy pathology was normal, had positive
results for one or more of the tests that have been proposed as
indices of latent coeliac disease. Although we have obtained
evidence of clinical and mucosal gluten sensitivity in a few of
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these patients (9), this has been on an opportunistic basis,
unsystematic and uncontrolled. Induction of severe enteropathy by
extra dietary gluten would be unequivocal proof of gluten
sensitivity, but this raises ethical issues and may be clinically
unacceptable to symptomatic patients. Acute enteral or rectal
gluten challenge, monitored by multiple biopsies, should be more
practicable. However since the histopathologica1 effects of
dietary gluten in clinically gluten-sensitive/normal jejunal
biopsy patients are strikingly different from those in classical
coeliacs, it is entirely possible that the pathological changes
produced by acute gluten challenge in the jejunum or rectum will
be equally different in latent/potential coeliacs and classical
coeliacs.
With the currently available range of tests, studies of a single
putative marker cannot be expected to identify all cases of
latent coeliac disease. The two best indices are likely to be a
positive CIA pattern and high t/S count. However these are not
present even in all classical coeliacs. We found one of 14
untreated coeliacs and one of 6 DH patients were CIA negative
(9), and one otherwise completely typical coeliac man in the
present series (who also has insulin-dependent diabetes) had no
t/S IEL. Although logistically difficult, the identification of
potential coeliacs still reqires studies of several candidate
markers, using jejunal fluid for ELISA studies, and frozen
sections of a mucosal biopsy for T cell receptor staining.
A high total IEL count, in an H&E stained section, may be due to
expansion of one or more of the three main subsets of lymphocytes
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within the villus epithelium of the small intestine: (i) CD3
positive (T cells) IEL which utilise the a/B T cell receptor;
numbers of these rise and fall in coeliac patients with gluten
ingestion and exclusion; (ii) CD3 positive (T cells) IEL which
utilise the t/6 T cell receptor; generally, counts of these cells
are high in coeliac patients, irrespective of diet; (iii) a small
proportion of IEL are CD3 negative cells, with no T cell
receptors; their nature, in man, is uncertain. In a few patients
in the present study, total IEL count was high with CD3 cell
count normal, suggesting that expansion of the atypical, non-T
IEL subset may occasionally occur; further patients will need to
be studied in order to establish the clinical significance of
this finding.
The CIA pattern and a high t/6 IEL count occur independently in
some non-coe1iacs, but also co-exist more frequently than
expected by chance. These phenomena may be due to separate,
intrinsic, genetically determined aberrations of the constituent
lymphocyte populations of the mucosal immune system, which happen
to occur together in most coeliacs. Alternatively, the posession
of both aberrations may increase the likelihood of full
expression of enteropathy in an individual who is genetically
predisposed by virtue of an independent gene for gluten-
sensitivity. These aberrations may be constitutively expressed,
or may be detectable only in situations of mucosal immune
activation. Whatever the underlying mechanism, it is clear that
the repertoire selected from the full range of potential immune
cells and molecules includes intestinal IgM antibodies and t/6
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IEL in coeliacs, whereas these are not utilised in most non-
coeliacs.
We have discussed elsewhere (9) the range of possible mechanisms
of the CIA pattern, including a primary defect of maturation or
IgA-IgM switch of B cells, and immunoregu1atory T cell
dysfunction. An expanded r/S IEL population may be genetically
determined (3,4). High counts of t/S IEL, but not of a/R IEL,
were found in healthy relatives of coeliac patients who possessed
the extended haplotype of coeliac disease (14). Alternatively,
t/S IEL may represent an expanded population controlled by local
regulatory factors, perhaps triggered by gluten (15,16). However
t/S IEL have very limited diversity (and thus limited capacity
for antigen recognition) (17) and they are not gluten-specific
(18) . The fact that a high density of t/S IELs was found in a
latent coeliac patient years before the development of
enteropathy (3), and our finding of high t/S IEL counts in
several non-coeliac patients argue against their involvement in
mucosal damage.
Further elucidation of the relationships between the
immunological phenomena described, and the clinical entity of
coeliac disease, will require not only direct, in vivo
investigations of gluten sensitivity in potential coeliac
patients, but also characterization of the genetic make-up of
both coeliac and non-coeliac patients, who do or do not have the
various immune abnormalities described above.
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TABLE 1. Patients studied, classified by final diagnosis and
biopsy histology.
Diagnosis (n) Age Sex Diet
mean f/m N GFD
(range)
Histology Permeability
N M.Ch PTVA N Abn
NOT COE 4 30.6 2/2 2 2 3 1 4
(17-64)
FH 4 26.8 4/" 3 1 4 4
(17-44)
IBD 6 38.5 3/3 6 5 1 2 4
(23-65)
DIA IDIO 14 32 . 6 6/8 13 1 12 2 13 1
(21-70)
ORAL ULC 4 27 3/1 4 3 1 3 1
(19-52)
MISC 19 42.6 13/6 19 18 1 17 2
(19-77)
NUT DEF 4 35 4/~ 3 1 4 4
(30-46)
IBS 16 38 10/6 16 16 15 1
(21-71)
NAD 6 30 4/2 6 6 6
(21-52)
COELIAC 15* 42.7 12/3 2 13 5 2 8 7 8
(16-86)





M.Ch= minor non-specific histological abnormalities
PTVA= severe partial, or total villus atrophy
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TABLE 2. Reference values for cell counts in villous epithelium



































TABLE 3. Diagnostic groups: numbers of cases positive for
candidate markers of latent coeliac disease.
Final (n) CIA+ high t/S high IEL Abn.L/R high serum
Diagnosis cases counts counts test AGA levels
NOT COE 4 2 1 1
FH 4 1 1
IBD 6 2 1 4 2
DIA IDIO 14 4 3 4 1 2
ORAL ULC 4 2 1 2 1 1
MISC 19 4 2 2 3
NUT DEF 4 2 1 1
IBS 16 3 2 1 2
NAD 6 1 3 1
COE. N diet 1 1 1 not done 1 1
Glu Ch 1 1 1 not done 1 1




Serial cryostat sections of jejunum from a non-coeliac patient
with high total IEL count. Immunoperoxidase staining of intra¬
epithelial lymphocytes with antibodies to CD3 (Figure la) and to
TCR 61 (Figure lb).
Figure 2.
Intra-epithelial lymphocyte counts in 77 pairs of jejunal biopsy
specimens. Total IEL counts in paraffin sections are expressed as
IEL per 100 villus enterocytes; CD3+ cell counts in frozen
sections are expressed as cells per mm length of villus
epithelium.
Figure 3.
Associations between the CIA pattern, high r/6 counts and high
total IEL counts in 77 non-coeliac patients.
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